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2Abstract
Background
The recommended treatment for pregnant  drug misusing women is maintenance methadone.
This  is  of  proven  benefit  in  terms  of  improving  maternal  well-being,  but  is  commonly
associated with neonatal abstinence syndrome (NAS). NAS reflects withdrawal at birth from in
utero exposure to licit (including maintenance methadone prescribed to reduce illicit drug use)
or illicit opioids (heroin). Symptoms include diarrhoea, extreme irritability, feeding problems,
jitteriness  and sleep  disturbance  and  in  some cases  seizures.  These  signs  suggest  impaired
regulation of homoeostatic processes, postulated to be due to dysfunctional vagal regulation. At
present  NAS cannot  be  predicted  in  individual  cases,  therefore  management  must  include
prolonged hospital stay to monitor for symptoms, and pre-emptive treatment is not feasible.
Resting  heart  rate  variability  (HRV)  is  a  well-established  measure  of  the  parasympathetic
autonomic nervous system, reflective of cardiac vagal tone (CVT). The purpose of this study
was to develop a better understanding of the electrophysiology of methadone-exposed neonates
using EEG, ECG and CVT, with the aim of improving short and longer term management of the
in utero drug exposed infant.
Materials and Methods
Twenty six methadone-exposed infants and thirty controls matched for gestation, birth weight,
and postcode of residence underwent a one hour sleep polysomnogram (PSG) incorporating an
electroencephalogram (EEG) and electrocardiogram (ECG), recorded within the first 48 hours
of life (preceding onset of any NAS). In utero drug exposure was described by a combination of
maternal drug and alcohol history and urinalysis, and infant meconium and urine toxicology.
PSGs were scored for sleep state (quiet; intermediate; active), and artefact-free epochs extracted
by an experienced paediatric neurologist. EEG spectral analysis was performed and HRV used
to estimate CVT.
Results
PSGs from 45 infants (80% of those tested), including 20 methadone-exposed infants,  were
deemed suitable for a sleep study analysis. For the 20 methadone-exposed infants, additional
drug  exposure  was  as  follows:  opioids  12/20  (60%):  benzodiazepines  11/20  (55%):
amphetamines 7/20 (35%): cocaine 4/20 (20%) and cannabis 13/20 (65%). Three of these 20
infants developed significant NAS requiring treatment. The EEG analysis showed cases tended
to have increased EEG power and lower spectral edge frequencies but no group differences
reached significance. The ECG analysis showed higher power amongst cases for many of the
HRV parameters, but none reached  significance between groups. However, control infants had
lower CVT for all sleep states than methadone-exposed infants: active sleep CVT 1.9 vs 3.5
(p=0.002),  indeterminate  sleep  CVT 2.4  vs  3.7  (p=0.033)  and quiet  sleep  CVT 3.2  vs  4.6
(p=0.362). 
Conclusion
Newly  born  infants  of  opioid-dependent  mothers  prescribed  maintenance  methadone  have
increased  CVT consistent  with  impaired  homeostatic  regulation  of  the  autonomic  nervous
system.  Although CVT did not  predict  NAS for  the  small  number  of  infants  who required
treatment, CVT may have potential as a predictor of NAS in conjunction with other neonatal
and maternal parameters.
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Preface
During the early 2000s an increase in the number of children referred to Opthalmology
at  the  Royal  Hospital  for  Sick  Children  in  Glasgow  with  nystagmus  and  possible
delayed visual maturation was observed. Dr Ruth Hamilton and Prof. Gordon Dutton  of
the departments of Clinical Physics and Ophthalmology recognised that many of these
children had a history of in utero exposure to methadone and/or illicit drugs (Hamilton
et al., 2010). It was also noted that there had been a contemporaneous increase in the
number of drug-misusing mothers prescribed methadone within Greater Glasgow and
Clyde.
The  author  of  this  thesis  contributed  to  a  subsequent  pilot  study undertaken  at  the
Princess Royal Maternity (McGlone et al., 2008). Visual evoked potentials (VEPs) were
recorded within three days of birth from 21 term infants of opioid-dependent woman
prescribed  methadone in  pregnancy  and from 20 controls.  VEPs from drug-exposed
infants were less likely to be of typical waveform and more likely to be immature or
non-detectable  (p<0.01)  than  those  of  control  infants.  VEPs  were  also  smaller  in
amplitude (median 11 vs 24 µV, p<0.001). VEPs of drug-exposed infants had matured
after 1 week but remained of lower amplitude than VEPs of newborn controls (p<0.01)
and continued to be non-detectable in 15%. This pilot study indicated that further study
was required to address the specific effects of maternal  methadone  and/or other illicit
drug misuse upon infant VEPs, as well as possible associations between in utero drug
exposure and subsequent visual and general neurological development.  
This led to the ‘Vision in Drug-Exposed Infants’ (VIDI) study (McGlone et al., 2014,
2013), funded by Yorkhill Children’s Charity and TENOVUS Scotland. The VIDI study
obtained uniquely comprehensive toxicology information, identifying the extent of  in
utero drug exposure for a cohort of 100 infants and related this to newborn VEPs as
well as visual and general neurological development at six months of age. Dr Laura
McGlone, a paediatric trainee, recruited all the infants for the VIDI study and undertook
the  assessments.  In  a  nested  study,  the  author  investigated  the  effects  of  in  utero
exposure to methadone and other illicit drugs on neonatal sleep states and cardiac vagal
tone (CVT),  by means of  polysomnography and calculation of heart  rate  variability
(HRV). The nested study is described in this thesis.
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Abbreviation Description
ANS Autonomic nervous system
AS Active sleep
BPM Beats per minute
CFM Cerebral function monitor
CIPA Cardiac parasympathetic activity
CVT Cardiac vagal tone
DFT Discrete Fourier Transform
ECG Electrocardiogram
EEG Electroencephalogram
EMG Electromyogram
FFT Fast Fourier transformation
FIR Finite impulse response
GA Gestational age
HF High frequency
HRV Heart rate variability
IUGR Intrauterine growth restriction
IIR Infinite impulse response
IS Indeterminate sleep
LF Low frequency (HRV)
MF Mid frequency (HRV)
NAS Neonatal abstinence syndrome
NICU Neonatal intensive care unit
NREM Non-rapid eye movement
PSD Power spectral density
PSG Polysomnogram
QS Quiet sleep
REM Rapid eye movement
RMSSD Root mean square of successive differences
RR RR interval
SDNN Standard deviation of the RR intervals
SUDI Sudden Unexpected Death in Infancy
STFT Short time Fourier transform
VLF Very low frequency (HRV)
31
1 Clinical Background
1.1 Treatment for Opioid Dependency 
Standard  treatment  for  the  pregnant  opioid-dependent  woman  in  the  UK  involves
prescription  of  methadone,  a  synthetic  opioid  (Ajayi,  2008;  Mattick  et  al.,  2003).
Methadone is used as an analgesic as well  as for maintenance treatment of patients
using illicit opioids. Methadone acts on the opioid receptors, producing many of the
same effects as illicit opioids. It is useful in treatment of opioid dependence because it
can be given orally and its long duration of effect helps to stop cravings associated with
opioid withdrawal. 
Higher doses of methadone can block the euphoric effects  of heroin, morphine,  and
similar drugs. The hope is that with properly prescribed methadone patients can reduce
or stop altogether their use of illicit opioids.
Methadone maintenance was first used in the US in the 1950's and a large evidence base
now exists. In pregnant opioid-dependent women, methadone reduces the likelihood of
preterm  birth  and  intrauterine  growth  restriction  (IUGR)  as  well  as  risk  taking
behaviours (Burns et al., 2007; Mattick et al., 2003).
The main problem with methadone maintenance treatment during pregnancy is the high
incidence of neonatal abstinence syndrome (NAS) relating to infant opioid withdrawal,
variably reported between 19% and 80% (Baar et al., 1989; Dashe, 2002; Dryden et al.,
2009;  Fajemirokun-Odudeyi  et  al.,  2006;  McCarthy  et  al.,  2005). The variability  in
incidence is due at least in part to different methods of assessing the severity of NAS.
Although higher prescribed maternal methadone doses increase the likelihood of the
infant  requiring  treatment  for  NAS  (Dryden  et  al.,  2009),  the  relationship  between
maternal drug use and NAS is complex and NAS cannot be predicted in individual cases
(Mactier, 2011).
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Buprenorphine is a synthetic opioid, and like methadone can help stabilise lifestyle and
reduce illicit drug use. Studies by Fischer et al., (2006) and Jones et al., (2005) suggest
that  when  compared  with  methadone,  in  utero buprenorphine  exposed  infants  have
reduced  length  of  hospital  stay  and  reduced  severity  of  symptoms.  Retention  to
treatment was however poorer with the buprenorphine group. Currently both drugs are
used in clinical practice in the UK, but methadone is still the predominant treatment in
Scotland.
1.2 Neonatal Abstinence Syndrome
NAS is a group of signs and symptoms occurring in a newborn infant as a result of
withdrawal from physically addictive substances taken by the mother during pregnancy. 
These substances can include opiates (derivatives of the opium poppy), or synthetic
opioid substances including methadone or buprenorphine used to treat opioid addiction.
Other substances causing NAS include benzodiazepines, cocaine and amphetamines as
well as caffeine, nicotine and some antidepressant agents such as selective serotonin re-
uptake inhibitors (Castellanos and Rapoport, 2002). This thesis will consider primarily
the effects of opioid use in pregnancy. For clarity the term opioid will be used to include
both synthetic and natural substances with opioid activity.
1.2.1 Pathophysiology
All  opioid  substances  are  physically  addictive,  meaning  that  the  individual  patient
develops tolerance, requiring increasingly larger doses to achieve the same effect. Drug
addiction is a complex interaction of physical and psychological dependence, and does
not occur in every subject who takes opioids. During pregnancy, opioids and other drugs
of misuse cross the placental barrier; this occurs in varying degrees, depending on the
pharmaco-kinetic properties of the individual drugs. Once drugs cross the placenta, they
tend to accumulate in the foetus because of the immaturity of the foetal renal system
and enzymes used to  metabolise  opioids.  Abrupt disruption of the passage of  drugs
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when the umbilical cord is clamped at birth results in the infant going “cold turkey” and
(depending upon how much drug is in the foetal system, and how quickly this residual
drug is metabolised) sometimes also results in NAS.
Aside from withdrawal symptoms in the first week or two of life, common findings in
infants exposed to opioids include low birth weight, prematurity and IUGR. 
1.2.2 Diagnosis
Signs  of  NAS  fall  under  three  main  categories;  neurological,  cardiorespiratory  and
gastrointestinal.  These  signs  can  include  trembling,  irritability  and excessive crying,
disordered sleep, increased muscle tone, rapid breathing (tachypnoea), sweating, fever
and unstable temperature, poor feeding and incoordinate sucking, vomiting, diarrhoea
and dehydration. Seizures may also occur in infants suffering from NAS but are rare.
The  pattern  and  timing  of  neonatal  abstinence  reflect  the  pharmacology  of  the
substance(s)  from which  the  infant  is  withdrawing,  including  drug  half-life  and  its
distribution in bodily fat or fluids. The half-life of a particular drug is dependent upon
its metabolism, which in turn may be influenced by genetic variation between subjects
(Eap et al., 2002). For example, withdrawal from heroin, which has a very short half-life
of 3 minutes  (Inturrisi et al., 1984), occurs within the first 24 - 48 hours, whereas the
onset of withdrawal from methadone, which has a very variable half-life of between 12
and 60 hours (Eap et al., 2002), is typically delayed until day 3 to 5 . Withdrawal from
benzodiazepines may be delayed for up to two weeks.
The severity of NAS is commonly assessed using either the Lipsitz or Finnegan scoring
tools  (Finnegan et al., 1974; Lipsitz, 1975) which each produce a cumulative score of
the various signs of NAS. The scoring system currently used in the Glasgow neonatal
units is a modification of the Lipsitz scoring system. NAS is the likely diagnosis if an
infant presents with the signs described above, when its mother is known to have used
addictive substances during pregnancy, but caution must be exercised in the diagnosis as
other conditions (such as intracerebral bleeds, hypocalcaemia and thyrotoxicosis) may
mimic NAS. 
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1.2.3 Management
Standard management for an infant at  risk of developing NAS generally involves a
prolonged  postnatal  stay  in  hospital  where  the  infant  can  be  closely  supervised.  In
Glasgow, the median postnatal stay for healthy maternal drug-exposed infants who do
not require pharmacological treatment for NAS is three times longer than the median
stay  for  healthy  non-maternal  drug exposed infants  (Dryden et  al.,  2009). Although
NAS is more common in infants born to women prescribed higher doses of methadone,
NAS cannot  be  predicted  in  individual  cases,  hence  the  prolonged  hospital  stay  is
applied to all infants of drug-misusing women. Being able to predict which infants will
develop NAS would allow for early discharge of unaffected infants, which is likely to
not only cause less distress to both mother and infant (and almost certainly less adverse
effects on parenting), but also produce significant cost savings to the NHS. The ability
to predict NAS would also allow trials of pre-emptive medication (shown to be useful in
adults).
The majority of infants with NAS in Glasgow are withdrawing from opioids (Dryden et
al., 2009; Jackson et al., 2004), with or without additional benzodiazepines. Almost all
pregnant  opioid-dependent  women smoke in  pregnancy;  it  is  not  known how much
nicotine withdrawal contributes to NAS. Simple measures including nursing, swaddling,
pacifiers and demand feeding are used to control mild NAS, and the infant is kept with
mother  whenever  possible.  NHS  Greater  Glasgow  and  Clyde  neonatal  network
guidelines indicate that pharmacological treatment should be started if the Lipsitz score
is  ≥ 5  on  two  occasions  12  hours  apart,  despite  efforts  to  console  the  infant  by
nursing/carrying.  Pharmaceutical treatment is based on the mother's drug use during
pregnancy; if, as is usually the case, the newborn has been exposed to opioids in utero,
oral morphine solution is prescribed to the infant at a starting dose of 60 micrograms/kg
four hourly, otherwise oral phenobarbital is used  (Jackson et al., 2004; Osborn et al.,
2010). For  infants  with  the  most  severe  NAS  whose  signs  and  symptoms  are  not
controlled by oral morphine replacement, phenobarbital is added as second line therapy.
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1.2.4 Extent
In  Scotland,  the  estimated  number  of  illicit  drug  users  in  2009/10  was  59,600  (CI
58,300  –  61,000)  of  which  17,300  (30%)  were  female  (Team,  2013).  In  England
approximately  46,500  female  addicted  to  heroin  are  receiving  treatment,  the  vast
majority of whom are of child bearing age (Health and Social Care Information Centre,
2012).  The true extent of drug misuse in pregnancy has not been properly described,
although accurate records of women prescribed methadone do exist. 
1.3 Effects of Maternal Opioid 
Dependence on the Foetus and Child
1.3.1 Growth
Intrauterine growth restriction (IUGR) refers to the poor growth of an unborn infant
during pregnancy. Specifically, it means that the developing infant has not achieved its
genetic  growth  potential  and  is  commonly  defined  as  weighing  <10th centile  for
gestational age. IUGR is due to dysfunction of the placenta and is a risk factor for an
impaired neuro-developmental outcome (Allen, 1984; Teberg et al., 1988).
The growth of infants born to opioid dependent mothers is poor in the neonatal period
and longitudinal  growth is  compromised for  at  least  the  first  3  years  of  life.  Head
growth and weight do however tend to catch up over the first 18 months  (Hunt et al.,
2008;  Lifschitz  et  al.,  1985;  Ornoy  et  al.,  2001,  1996). One  author  has  reported
continued poor head growth in children exposed to heroin in utero (Wilson et al., 1979).
In humans, reduced  in utero head growth in infants of drug exposed mothers and is
relatively greater than reduction in birth weight (Dryden et al., 2009; Hunt et al., 2008;
Jones et al., 2005; McGlone et al.,  2014; Rosen and Johnson, 1982; Whitham et al.,
2007). Head growth is a proxy for brain growth and may be more impaired in infants
exposed  to  methadone  compared  with  buprenorphine  (Fajemirokun-Odudeyi  et  al.,
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2006).
1.3.2 Development of the Brain
In animal studies, mice exposed to heroin in utero showed behavioural deficits (Vatury
et al., 2004) and in rats, opioid exposure reduced mu-opioid receptor binding affinity
and  concentration  of  neurotransmitters  (Darmani  et  al.,  1992;  Robinson  and
Smotherman,  1997). Further  animal  evidence  indicates  that  in  utero exposure  to
buprenorphine adversely affects brain myelination (Sanchez et al., 2008). 
Foetal neurobehaviour serves as a window to the developing nervous system (Nijhuis,
2003)  and it is likely that disruption to foetal neurobehaviour reflects adverse effects
upon the neuro-development of the foetus. 
As  in  animal  studies  preliminary  MRI  findings  in  methadone-exposed  infants  and
children  suggest  possible  alterations  in  mylinations.  Walhovd  et  al.,  (2012) used
diffusion tensor imaging to compare the early cerebral connective tract development of
infants  born  to  methadone  with  comparison  infants.  They  showed  that  methadone-
exposed  infants  exhibited  higher  mean  diffusivity,  suggesting  altered  maturation  of
connective tracts.
Hunt  et  al.,  (2008) reviewed  fourteen  studies  examining  the  neuro-developmental
outcomes of infants exposed to opioids  in utero. A variety of psychological tests were
employed for the assessment of outcomes. He concluded that “opioid-exposed infants
had significantly lower scores with all assessment tools used except for the psycho-
motor  development  index of  the Bayley Scales  of  Infant  Development.”  These data
were  shown  to  be  most  significant  at  the  18  month  stage.  Differences  in  neuro-
developmental  outcome  remained  at  the  three  year  assessment.  A weakness  of  the
studies  was  that  male  infants  were  over-represented  in  the  opioid  exposed  group.
Further studies examining the role of social deprivation at three years  (Ornoy et al.,
1996) and at eight years of age  (Ornoy et al., 2001) showed that children of heroin-
addicted mothers who had been adopted performed better at psychometric testing than
the children who remained with their natural parents. There is a likely interplay between
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genetic potential,  in utero environment and upbringing which makes interpretation of
follow up studies very difficult. 
1.3.3 Visual Development
The  first  reports  of  abnormal  visual  findings  in  children  of  methadone-maintained
mothers were published over 30 years ago  (Rosen and Johnson, 1982). Abnormalities
include  strabismus  (misaligned  eyes),  nystagmus  (involuntary  eye  movements),
refractive errors and delayed visual maturation. Visual evoked potentials (VEPs) can be
used as an objective measure of the maturity and integrity of the visual pathway. VEPs
in prenatally exposed rats at birth and at six months  (Pinto et al., 1986) and in adult
humans  (Bauer, 1998) with a history of chronic methadone exposure show a tendency
to be smaller and delayed in onset. In the early newborn period, McGlone et al., (2013,
2014)  demonstrated immature VEPs and subsequently impaired vision at 6 month in
infants of opioid-dependent women prescribed maintenance methadone in pregnancy. A
non-randomised study by  Whitham et  al.,  (2010) showed that,  at  4  months  of  age,
infants exposed to methadone in utero had relatively delayed VEPs when compared to
controls and to infants exposed to buprenorphine.
1.4 Electrophysiology of Opioid Exposure
1.4.1 Electroencephalography (EEG) and 
Polysomnography (PSG)
EEG is a non-invasive tool that can be used to measure cortical activity both in adults
and infants. PSG is a technique including EEG and other physiological measurements
such as ECG and respiratory rate used for monitoring sleep activity. 
In adults, differences based on EEG spectral analysis (a lower frequency alpha peak)
were  present  in  the  EEG  of  chronic  methadone  subjects  compared  with  abstinent
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controls. Such differences appeared to be dose related  (Gritz et al., 1975), consistent
with methadone dose related changes in EEG found in the rat model (Mitra et al., 1981).
Much of the research that has been undertaken in adults focuses on understanding the
long term effects of these drugs on the adult brain. The subject often has a long term
history of drug exposure and may or may not be undergoing a period of abstinence. 
By contrast,  EEG work carried out  on the neonate is  directed by a clinical  need to
understand the effects of in utero drug exposure, and the effects of NAS. The agitated
nature of infants diagnosed with NAS suggests abnormal cortical function which must
be important as the neonatal period is a time of crucial neurological development. As a
neonate spends much of its time asleep, it is important to study EEG patterns in the
various sleep states. 
One of the earliest studies was performed by  Schulman, (1969), who compared sleep
states of three groups using PSG. The control group was healthy neonates, whilst the
other groups were either infants at risk of central nervous system (CNS) impairment or
infants born to opioid addicted mothers. The study found that the infants born to opioid
addicted mothers contained no identifiable quiet sleep (Non REM) components, and an
excess of motor activity during REM sleep.
Sisson et al., (1974) examined sleep patterns of ten fullterm newonates whose mothers
had been exposed to either heroin or a combination of heroin and methadone. They
found that such in utero drug exposure dramatically altered the sleep patterns, with both
heroin and methadone suppressing REM (rapid eye movement) sleep and reducing the
amount of quiet sleep. A later study by Dinges et al., (1980) of 58 fullterm neonates (28
exposed to methadone and/or heroin, and 30 unexposed) showed the opposite effect,
with an increase in REM sleep in drug-exposed infants. The authors did however note a
similar  reduction  in  quiet  sleep  in  drug-exposed  infants.  Manfredi  et  al.,  (1983)
compared PSG, at 10, 20 and 30 days after birth, from 31 fullterm neonates  of “drug
addict  mothers"  (predominately opioid exposure) with these  of  10 control  neonates.
They showed that although the signs of NAS had diminished within the first ten days of
life, sleep patterns at both 10 and 20 days still showed significant differences from the
control group. Specifically, the drug-exposed infants went into REM sleep more quickly
that the controls, but showed a decreased duration of REM periods. By 30 days of life,
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there  were  no  significant  differences between  the  exposed  and  unexposed  groups,
suggesting that the effects of in utero drug exposure on sleep patterns may have passed
after the first month of life. 
Pinto et al., (1988) monitored PSG activity at 2 and at 4-5 weeks of life in a group of 13
infants whose  mothers  were chronically  addicted to  heroin with at  least  a  one year
history of drug abuse. Of these 13, only one showed no signs  of NAS, and did not
require any treatment. The authors found that amounts of quiet and active sleep were
reduced, and sleep pattern changes increased, with a general lack of sleep wave cycling
between sleep states.
A PSG study by O’Brien and Jeffery, (2002), compared 21 neonates aged between two
and  10 days  and exposed to  opioids  during  pregnancy  with  a  group of  15  healthy
controls.  Both  treated  and non-treated  opioid-exposed groups had reduced levels  of
quiet sleep, and the treated group also showed higher levels of intermediate sleep and
arousals.
Sarfi  et  al.,  (2009) measured  the  patterns  of  sleep-wakefulness  in  three  month  old
infants  exposed  to  either  methadone  or  buprenorphine.  Parents  were  instructed  to
complete a 24 hour chart indicating their infant's state of awareness i.e. awake, agitated,
asleep and crying.  The study population was 71 infants,  of  whom 36 were born to
mothers in  a  high-dose maintenance treatment  (either  methadone or buprenorphine).
They concluded that the in utero  drug-exposed group did not differ in terms of sleep-
wakefulness from an unexposed control group at three months of age. These findings
are consistent with the conclusions of Manfredi et al., (1983), that the effects of in utero
drug exposure on sleep decline by three months of age.
A  normal  phenomenon  called  benign  neonatal  sleep  myoclonus  (BNSM)  can  be
observed in neonates during all stages of sleep. BNSM presents clinically as myoclonic
jerks, which are more frequent and prominent during phases of quiet sleep. Held-Egli et
al.,  (2009) investigated the incidence, duration and risk factors of BNSM for infants
treated for NAS. By performing PSG investigations on 78 term and nearly term in utero
drug-exposed neonates, they diagnosed BNSM in 68% of the infants with NAS. In all of
these infants, both cranial ultrasound, and neurological investigations were normal. By
comparison, only 2.6% of the control infants demonstrated BNSM. 
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Seizures  are  a  further  cause  for  concern  in  NAS.  A study  involving  302  neonates
exposed  in utero  to narcotics was published by Herzlinger et al., (1977). They found
that 18 neonates (6%) had seizures attributable to NAS, of whom 10 (56%) had been
exposed to methadone. Only one of 83 (1.2%) neonates exposed exclusively to heroin
went on to develop seizures.
Published studies of in utero opioid exposure and sleep studies have been summarised
in Table 1.
We are aware that:
 Sleep patterns are dramatically altered in infants exposed to opioids  in utero
during the first days of life (Dinges et al., 1980; Manfredi et al., 1983; Sisson et
al., 1974).
 Methadone  exposure  may  be  related  to  a  greater  level  of  seizure  activity
compared  to  “passively  addicted  to  narcotics”  neonates  not  exposed  to
methadone (Herzlinger et al., 1977).
 In utero drug-exposed infants demonstrate lower levels of quiet sleep, but this is
not improved by treatment for NAS (O’Brien and Jeffery, 2002).
 Effects of  in utero  drug exposure on infant sleep are no longer apparent three
months after birth (Held-Egli et al., 2009; Manfredi et al., 1983).
 Both methadone and buprenorphine used as treatment for opioid dependence in
pregnancy may lead to NAS (Sarfi et al., 2009).
 Benign neonatal sleep myoclonus is more prevalent in neonates who show signs
of NAS (Held-Egli et al., 2009).
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Year Author Age-group and 
(age at test)
Test Exposure Conclusions
1969 Schulman Neonates PSG Heroin QS did not develop in these 
neonates, although there were 
cyclic changes in activity level as 
a function of changing EEG 
activity
1974 Sisson et al., Neonates PSG Heroin Minimal REM (AS)
1977 Herzlinger et al., Neonates EEG for 
seizures
Mixed 
including 
methadone
Methadone only group, highest 
level of seizures.
1980 Dinges et al., Neonates (2 to 
7 days of age)
PSG Heroin 
including 
methadone
Increased REM (AS), less QS and 
disorganised sleep states.
1983 Manfredi et al., Neonates – 
Infants at 10, 
20 and 30 days 
of life
PSG Mixed opioids Significant sleep pattern 
differences at 10 & 20 days. 
Exposed group entered REM 
quicker but had less episodes of 
REM.
1988 Pinto et al., Neonates and 
Infants (2nd and
4th or 5th week 
of life)
PSG Heroin QS reduced. AS – decrease in LVI,
while mixed frequencies 
(continuous irregular, low voltage)
increased in exposed group. High 
frequency of sleep pattern changes
in addicted infants, little tendency 
to normal sleep cycling.
2002 O'Brien and 
Jeffrey.
Neonates (2-10
days of life)
PSG Opioids In the treated group, increased 
wakefulness. Treated and non-
treated exposed groups had less 
QS. Treated showed more IS.
2009 Safri et al., Neonates Sleep / 
awake, 
no PSG.
Methadone or 
buprenorphine
No significant difference between 
the two groups.
2009 Held-Egli et al., Infants at 3 
months
PSG Opioids High incidence of jerky 
movements
Table 1: A summary of the studies involving neonates and infants who have been exposed in utero to
opioids and investigated using either EEG or PSG. QS: quiet sleep. AS: active sleep. LVI: low
voltage irregular.
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1.4.2 Electrocardiography (ECG), Respiratory 
Physiology and Vagal Tone
ECG is a non-invasive technique for measuring the electrical activity of the heart. The
mass cellular depolarization and repolarization of cardiac muscle tissue which causes
muscle contraction and relaxation creates an electrical signal that is recorded at the skin
surface as an ECG. Each heart contraction corresponds to a change in the ECG signal,
whose major component is the QRS complex. The dominant peak is the R wave. The
time between consecutive R waves is called the RR interval. Pulses that occur before
and after  the QRS complex are called the P and T waves  and are created by atrial
depolarization and ventricular repolarization respectively. The QT interval is therefore a
measure of the time for the ventricles to depolarize and repolarize. 
In adults, methadone exposure affects the ECG by increasing the QT interval (Stringer
et al., 2009).
Similar effects have been described in neonates. Parikh et al. (2011) examined the effect
of in utero methadone exposure on the neonate ECG at days 1, 2, 4 and 7 of life. In the
methadone-exposed group of 26 term infants, the QT interval was prolonged on day 1:
methadone group 435ms vs control 401ms, p<0.001, day 2: 433ms vs 390ms, p<0.001),
although this effect was gone by day 7.  Jansson et al. (2005) and Parikh et al. (2011)
investigated the effects of maternal methadone use on foetal and maternal RR interval,
heart rate variability (HRV), respiration rate, and respiratory sinus arrhythmia (RSA);
heart rate variability during breathing is also an indicator of parasympathetic activity. At
peak methadone dosage, foetal heart rate was slower, less variable, and displayed fewer
accelerations. Foetuses were less active, and the normal integration between heart rate
and motor activity (whereby heart rate increases with increased foetal movement) was
attenuated.  Maternal  heart  rate  was  unchanged,  but  methadone  administration  was
associated with lower maternal  respiratory rate  and RSA. Thus maternal  methadone
administration had significant effects on foetal physiology.
These findings  may be  of  relevance to  the relationship  between maternal  substance
misuse and sudden unexplained death in infancy (SUDI), as documented by Kandall et
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al., (1993).  Infants exposed to methadone, heroin, or a combination of methadone and
heroin, had a higher risk (odds ratios of 3.6, 2.3 and 3.2 respectively) than unexposed
infants of developing SUDI. 
Vagal tone (an indicator of the parasympathetic activity of the 10th cranial nerve) can be
inferred from the ECG (this is discussed in greater detail in section 3.6). Jansson et al.,
(2007) examined vagal tone in 50 methadone-maintained pregnant women at 36 weeks’
gestation using HRV from the ECG. After birth, infants showing signs of NAS were
more likely to have mothers with changes in vagal tone in response to methadone. The
authors concluded that infant vagal tone might be a useful marker for predisposition to
NAS because  NAS is  “essentially  attributable  to  disruption  or  dysregulation  of  the
autonomic nervous system”. 
A summary of findings from studies of foetal and neonatal ECG in infants exposed in
utero to opioids is presented below:
 Measurement of maternal ECG late in pregnancy is partially predictive of the
severity of NAS in the infant (Jansson et al., 2007).
 Neonates exposed to methadone in utero show prolonged QT intervals in days 1
and 2 of life, but by day 4 this effect has gone (Parikh et al., 2011).
1.4.3 Visual Electrophysiology (VEP)
Pinto et al. (1988) investigated the effect of methadone on the developing foetal visual
system by giving methadone to female rats throughout the duration of pregnancy, then
performing visual evoked potentials (VEPs), on the neonatal rats. The neonatal rats had
delayed  flash  VEPs,  and  smaller  flicker  VEPs  compared  to  a  non-exposed  control
group, although no long term effect (up to 90 days) was shown.
A more  recent  study  performed  by  Whitham et  al.  (2010) examined  the  effects  of
prenatal exposure to buprenorphine or methadone on 4 month old infant VEPs. Infants
prenatally exposed to methadone had prolonged VEP latencies compared with either the
control group or the buprenorphine group.
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In a  prospective cohort  study by  McGlone et  al.  (2013), flash VEPs were recorded
within 72 hours of birth for 100 healthy infants and 50 matched comparison infants that
been exposed to methadone in utero. The drug exposed group was more likely to have
smaller  amplitude  (VEPs  median  27  V  vs  39  V  p<0.001)  and  more  immature
waveforms  (p<0.001).  Following  up  the  same  cohort  of  infants  after  6  months,
McGlone et  al.  (2014) showed that  40% of  the  drug-exposed cohort  failed  clinical
visual assessment: the relative risk of abnormal assessment was 5.1 (95% CI 1.3 to 20;
p=0.02).  Additionally,  drug-exposed  infants’  pattern  onset  VEPs  when  present  -
demonstrated smaller (C2 15' check size 10 V vs 17 V p=0.003) and slower (C2 15'
check size 128ms vs 108 ms p<0.001) peaks than those of the comparison infants. It
was a subset of this study population that was investigated in this thesis.
1.5  Conclusion
The use of methadone to treat opioid dependency is standard practice around the world
with recognised benefits for the mother. Few studies have fully considered outcomes for
the  infant.  There  is  good  evidence  of  reduced  foetal  brain  growth and  increasing
evidence  of  adverse  effects  on  developing  visual  function  in  childhood  of  opioid
dependency in pregnancy although whether this is due to illicit drug use or prescribed
methadone (or indeed other factors) remains unclear.
This  chapter  has  also  covered  adverse  effects  on  neonatal  sleep  and  measurable
consequences on the infants autonomic nervous system patterns resulting from opioid
dependency in pregnancy.
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1.6 Hypothesis and Aims
The  purpose  of  this  study  was  to  develop  a  better  understanding  of  the
electrophysiology of methadone-exposed neonates, with the ultimate aim of improving
short  and longer term management of the  in utero drug exposed infant.  I  sought to
accomplish  this  by  recording  PSG in  infants  born  to  methadone  maintained  opioid
dependent  women  and  compare  the  results  with  data  obtained  from  healthy,  term
controls. This was a nested study within a larger study of drug-exposed infants called
the 'Vision in Drug-Exposed Infants study (Mactier et al., 2012; McGlone et al., 2014,
2013) which afforded a unique opportunity for comprehensive toxicology to identify the
extent of in utero drug exposure.
Overall Aim: 
• To investigate the effects of in utero methadone exposure on sleep states and
vagal  tone  using  polysomnography  and  heart  rate  variability  in  the  neonatal
period. 
• To develop software to undertake customised analysis of electrophysiological
data.
Hypothesis 1: That opioid exposed infants differ from controls with regards to EEG
parameters recorded during PSG.
Hypothesis 2: That exposed infants differ from controls in ECG parameters measured
during  PSG  and  analysed  using  time  domain,  frequency  domain  and/or  non-linear
methods.
Hypothesis 3: That exposed infants differ from controls in autonomic nervous system
function, as represented by CVT derived from ECG recorded during PSG.
Hypothesis 4: That at least one of these electrophysiological measures is predictive of
NAS.
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2 Electroencephalography 
This chapter describes electroencephalography (EEG) and its role in monitoring sleep
patterns in the neonate. EEG is the recording of electrical activity resulting from ionic
current flow within the brain cells (neurones); in the clinical setting this is generally
achieved by measuring electrical activity over a period of time from multiple electrodes
placed on the scalp.
The  chapter  is  divided  into  three  sections,  including  an  overview  of  relevant
neuroanatomy and neurophysiology: techniques of EEG - international standards and
clinical  interpretation:  and  sleep,  its  importance  to  the  neonate,  and  the  use  of
polysomnography to study activity during sleep. The first section, an overview of the
anatomy and physiology of the brain, has been drawn from the following references:
(Kandel et al., 2000; Marieb and Hoehn, 2007; Nokes et al., 1995; Novák et al., 2004;
Nunez and Srinivasan, 2005; Sanei and Chambers, 2007; Teplan, 2002). 
2.1 Anatomy and Physiology
2.1.1 The Nervous System
The  nervous  system is  the  network  of  specialised  nerve  cells  that  relays  messages
between the brain and different parts of the body, ultimately controlling almost all of the
body functions. 
The central nervous system (CNS) consists of the brain and the spinal cord, which are
protected  by  bony  structures  including  the  skull  and  spinal  column,  by  membrane
tissues known as the meninges, and by cerebrospinal fluid. 
The peripheral nervous system (PNS) consists of nerves that extend beyond the CNS; its
main role is to connect the CNS to the limbs and organs of the body. The PNS is not
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protected by bone as  the CNS is,  leaving it  at  greater  risk of  damage.  The PNS is
subdivided into two further systems, the somatic and autonomic nervous systems. The
somatic nervous system (SNS) is responsible for voluntary control of movement via
skeletal muscles and includes both sensory (afferent) neurons which carry information
to the brain and spinal cord and motor (efferent) neurons which transmit information
from the CNS to the muscle fibres.  The autonomic nervous system (ANS) controls
involuntary functions including heart-rate, respiration and blood pressure and has a role
in emotional responses such as sweating and crying. The ANS is controlled from the
lower  brain  stem  and  has  both  sensory  and  motor  functions.  The  ANS  has  two
subsystems: 
 the sympathetic nervous system controls the body's response to “fight-or-flight”
situations  by  increasing  respiratory  rate,  slowing  or  stopping  digestion  and
releasing sweat to lower the body’s temperature
 the parasympathetic nervous system which restores equilibrium after a fight-or-
flight scenario has passed by governing the reduction of heart-rate and sweat
production. The parasympathetic nervous system also increases gut motility and
invokes pupillary constriction. 
The  brain  may  be  considered  as  having  three  main  sections:  the  cerebrum,  the
cerebellum and the brain stem.
The cerebrum is the largest part of the brain and consists of the cerebral cortex and
subcortical structures including the hippocampus, the basal ganglia and the olfactory
bulbs. It has two hemispheres divided by the central sulcus and is concerned with many
functions  including  movement,  sensory  processing,  olfaction,  communication  and
memory. 
The cerebral  cortex is  the outermost  layered structure of  neural  tissue consisting of
neuronal cell bodies and their supporting sections. The major part of the cortex is highly
organised with six layers numbered 1- 6 from the surface inwards; more primitive parts
of the brain such as the hippocampus have fewer layers. 
The cerebral cortex comprises four lobes:
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 The frontal  lobe deals  with cognitive  function  including reasoning and short
term memory. It contains most of the dopamine-sensitive neurons found in the
cerebral cortex. At the rear of the frontal lobe, close to the central sulcus, the
motor cortex processes information required for movement.
 The  parietal  lobe  integrates  sensory  information  including  pain,  touch  and
spatial awareness.
 The  temporal  lobe  is  responsible  for  interpreting  sound.  The  temporal  lobe
contains the hippocampus and also plays an important role in the formation of
long term memories and spatial awareness. 
 The occipital  lobe includes the primary visual cortex which integrates visual
information received via the retina, the photosensitive membrane at the back of
the eye.  
The cerebellum is located underneath and behind the cerebrum, and is responsible for
coordinating movement, balance and posture. 
The  brain  stem consists  of  the  midbrain,  the  medulla  oblongata  and the  pons.  The
cranial  nerves  whose  nuclei  lie  within  the  brainstem  provide  the  main  motor  and
sensory innervation to the face and neck. The brain stem also contains all the nerve
fibres  passing  to  the  spinal  cord  from  the  cerebellum  and  the  cerebrum.  Most
importantly, the brain stem regulates breathing and cardiac function and is essential in
maintaining consciousness and regulating the sleep cycle.
2.1.2 Neurons
The fundamental building block of the nervous system is the neuron (or nerve cell), of
which  there are  approximately  1x1011 in  the  brain of  a  newly  born fullterm  human
infant.  The  neuron is  a  highly  specialised  electrically  excitable  cell  capable  of
processing and transmitting information via electrical  and chemical signals. Neurons
can transmit signals to other neurons via neural networks, or convey signals to or from
other tissues, including muscles or receptor cells such as photoreceptors in the retina or
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auditory receptors in the cochlea.
Figure 1 shows the basic structure of a neuron. In common with all other cells, neurons
contain  a  nucleus  and  a  cell  body,  but  neurons  are  distinguished  by  two  types of
processes, axons and dendrites.  The axon is the neuron's longest process and its main
role is to carry outgoing signals from the cell body. Axons extend to the extremities via
the PNS. Dendrites deal with incoming signals, facilitated by the enormous surface area
created by their many processes.
Axons are coated with a segmented myelin sheath (a white, fatty protein-lipoid) which
acts as an insulator  of the electrical  impulse passing through the axon and helps  to
conduct  the  electrical  impulses  more  quickly.  Non-myelinated  fibres,  including  the
dendrites, conduct electrical impulses more slowly.  The myelin sheath is produced by
Schwann cells that surround the axon main body; gaps between these cells  occur at
points known as the nodes of Ranvier. These uninsulated nodes represent points on the
axon capable of generating electrical activity.
When a neuron is stimulated, an electrical impulse or action potential is generated along
the length of the axon,  transmitting information throughout the central and peripheral
Figure 1: A neuron and its processes showing dendrites. The left shows the main cell body  with
dendrites extending out. The centre shows an axon which is coated by Schwann cells, with gaps
called Nodes of Ranvier.
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nervous systems. 
2.1.3 Resting Membrane Potentials and Action 
Potentials
Communication  between  neurons  is  facilitated  by  both  chemical  and  electrical
processes. The key ions in the CNS are sodium (Na+), potassium (K+), calcium (Ca2+)
and chloride (Cl-), and there are also negatively charged protein molecules.
A neuron that is not transmitting an impulse is said to be at rest, and has a negative
internal charge relative to its exterior (Figure 2).  This creates a potential difference of
approximately  -70  mV,  known  as  the  resting  membrane  potential,  maintained  by
resistance to passage of ions and negatively charged protein molecules across the cell
membrane.
Figure 2: Measurement of resting membrane potential in nerve cells. By attaching a voltmeter across
the membrane, a potential difference of -70 mV can be measured.
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An action potential is triggered when the resting potential of the cell changes from -70
mV to  -55 mV. Once triggered, the action potiential always has the same magnitude, as
defined by the 'all or none' principle . The process lasts up to 2 ms and is illustrated in
Figure 3.
The  action  potential  occurs  because  of  the  exchange  of  ions  across  the  neuronal
membrane.  A  stimulus  triggers  opening  of  the  Na+ channels  and  due  to  the
transmembrane  concentration  gradient,  Na+  ions  enter  the  neuron.  The  neuron  then
become more positively charged, causing depolarisation and triggering of the action
potential. Repolarisation occurs after approximately 1 ms, when the K+ channels open
allowing K+ ions to leave the cell, and the Na+ channels start to close. Ion concentration
then returns to a state of equilibrium, restoring an internal potential of -70 mV.
2.1.4 Synapses
A synapse is a junction between two neurons. The neuron conducting impulses toward
Figure 3: The action potential process showing the change in membrane potential from the resting
state, depolarization, repolarisation and finally hyperpolarisation as the potential returns to -70 mV
and the resting state.
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the synapse is called the pre-synaptic neuron, and that conducting impulses away from
the neuron, the post-synaptic neuron. Synapses may be electrical or chemical:
An electrical synapse or gap junction allows positively charged ions to cross a gap of
approximately  3.5-4  nm,  depolarising  the  post-synaptic  cell.  Electrical  synapses  are
very  fast  (approximately  0.2  ms),  and  are  important  for  reflex  actions.  Electrical
synapses also allow for synchronised action, and have the capacity to transmit in both
directions, although the signal strength is dissipated as it travels. In embryonic nervous
tissue, electrical synapses permit guiding cues between neurons, and are important in
neuronal  development.  Over  time,  many  of  these  early  stage  electrical  neurons  are
replaced by chemical neurons.
The chemical synapse is  more complex and slower by approximately 2 ms than its
electrical equivalent, although it can transmit a signal with a constant strength that does
not dissipate over distance. The gap in a chemical synapse is larger at approximately 20-
40 nm (Hormuzdi et al., 2004). Release of neurotransmitter is triggerered by the arrival
of  a  nerve  impulse.  Chemical  synapses  are  much  more  common  than  electrical
synapses.
2.1.5 Neurotransmitters
As noted above, neurotransmitters are chemical compounds which mediate transmission
of  information  across  chemical  junctions  between  neurons.  Neurotransmitters  are
released from the axon terminal after an action potential has reached the end of the
axon: the neurotransmitter then crosses the synapse to the next neuron where it is taken
up in a process termed reuptake (Figure 4).
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As yet,  over  100  chemical  neurotransmitters  have  been  discovered;  these  chemical
compounds can be classified by their function:
 Excitatory neurotransmitters increase the likelihood that the receiving neuron
will fire an action potential and include epinephrine and norepinephrine. Both
of these “stress hormones” are involved in the regulation of heart rate, blood
vessel diameter and metabolism.
 Inhibitory neurotransmitters decrease the likelihood that an action potential
will be fired by the receiving neuron and include serotonin, which produces
feelings  of  well-being  and  helps  to  regulate  the  sleep  cycle,  and  γ-
aminobutyric acid which regulates muscle tone. 
 Both excitatory and inhibitory – Some neurotransmitters can both stimulate
and inhibit action potentials, the most common being dopamine. Dopamine
release is associated with motivation and pleasure as well as movement. 
Figure 4: Neurotransmitters crossing the gap junction.
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Body  functions  including  heart  rate  and  respiratory  rate  are  regulated  by
neurotransmitters, depletion of which may result in suboptimal physiological function.
Pharmaceutical  substances  commonly exert  their  effects  via  neurotransmitter  release
and/or reuptake.  Illicit  drugs including cocaine and amphetamines temporarily block
reuptake of dopamine, resulting in euphoria whereas cannabinoids and opioids bind to
neuron receptors and block the reuptake of dopamine. 
2.1.6 Development of the Human Nervous System
Electrical activity in the human brain starts to occur around the  17th to  23rd week of
gestation. By  term age (40 weeks’ gestation)  the brain contains approximately 1x1011
neurons and the average neuronal density is around 104 neurons per mm3 (Nunez and
Srinivasan, 2005). The number of synaptic connections increases until adulthood when
there is a complement of approximately 5x1014 synapses (Teplan, 2002). About 80% of
dendrites form after birth, a large number of them during the first three years of life.
Throughout the early years of life, synaptic pruning and synapses that are rarely used
are removed, thus reinforcing the role of more important synapses. 
As levels of stimuli  increase after birth,  more myelin is  produced, which speeds up
signal transmission within the central and peripheral nervous system.
2.2 The Electroencephalogram (EEG)
The electrical potentials generated by single neurons cannot be detected using surface
scalp  electrodes,  and  so  a  standard  EEG  as  measured  in  clinical  practice  is  the
summation of the synchronous activity of millions of neurons with a similar spatial
orientation. 
The EEG waveform generated depends on the orientation and distance of the firing
neurons in relation to the placement of the recording electrode.  In accordance with the
inverse  square  law,  the  generated  electric  field  drops  over  distance,  thus  electrical
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activity from deep sources is more difficult to detect than activity generated near the
scalp.  Although neurons in  deeper  brain  structures  do not  contribute directly  to  the
surface EEG recording, their signals still have a significant effect on the overall EEG.
For  example,  the  thalamo-cortical  connections  are  involved  in  synchronisation  of
synaptic activity, especially in the generation of sleep spindles.
The technical aspects of recording the EEG will be covered in the following sections,
with particular emphasis on recording the EEG in the neonatal period. 
2.2.1 International Standards
Guidelines for recording EEG in the neonate have been established by the American
Clinical Neurophysiology Society (ACNS) and the International Federation of Clinical
Neurophysiology (IFCN). 
Key American guidelines are as follows:
 ACNS Guideline  One:  Minimum technical  requirements  for  Performing Clinical
Electroencephalography (Epstein and others, 2006). 
 IFCN – Chapter 1-1: The ten-twenty electrode system of the IFCN  (Klem et al.,
1999).
 IFCN – Chapter 1-2: Instrumentation (Ebner et al., 1999).
 IFCN – Chapter 1-3: IFCN standards for digital recording of clinical EEG (Nuwer et
al., 1998).
 IFCN – Chapter 3-3: Neonatal EEG (De Weerd et al., 1999).
 ACNS Guideline  on  Continuous  EEG monitoring  in  Neonates  (Shellhaas  et  al.,
2011).
Following these best practice guidelines is important in order to ensure consistency in
EEG recordings. In the neonate this is of particular importance as the EEG varies with
increasing maturity, and so the age and maturity of the infant must be taken into account
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in interpretation of the final trace. 
2.2.2 Electrode Placement
Ag-AgCl scalp electrodes are most commonly used for EEG recording, and are attached
to the head with reference to the International 10/20 positioning system (Jasper, 1958),
devised to standardise the positions of electrodes (Figure 5).  Measurements from key
bony  landmarks  on  the  scalp  determine  the  correct  placement  of  electrodes.  These
landmarks are the nasion, the inion, and the left and right preauricular points above the
ear (A1 and A2 on Figure 5). The 10-20 system is based on the percentage of distance
between these landmarks e.g. 10% posteriorly of the total distance between nasion and
inion. Even numbered electrodes are placed on the right hand side of the head, and odd
numbered electrodes on the left. Midline electrodes are labelled ‘z' (Rennie et al., 2008).
The standard placements for a neonatal recording are Fp1, Fp2, T3, T4, C3, C4, O1, O2,
Oz, Cz, as well as the reference at the vertex, or Cz.  The ground electrode is often
placed on the forehead or on a bony mass near the ear (Shellhaas et al., 2011).
Figure 5: The 10-20 electrode placement system.
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2.2.3 Amplification 
The EEG signal requires to be amplified from the small signals (10-100 V) recorded
on the scalp. This is done using a differential amplifier.
A differential amplifier has two inputs; one from the active electrode and one from the
reference electrode. The amplifier subtracts the reference from the active input, so that
identical  signals  occurring  on  both  input  electrodes  are  cancelled  out  and  artefacts
common to  both  inputs  are  removed.  Only  the  difference  between  input  signals  is
amplified, i.e. if the two inputs change by the same amount with respect to ground, then
this change does not appear at the amplifiers output. Thus only the difference between
the two inputs is amplified (Figure 6). 
The  ability  of  a  differential  amplifier  to  reject  signals  common  to  both  inputs  is
governed by its common mode rejection ratio (CMRR), which under ideal situations is
at least 120dB. A typical common mode signal which requires to be rejected is 50Hz
mains interference, as this is likely to present approximately equally on both active and
reference electrodes (Rowan and Tolunsky, 2003). 
2.2.4 Montages
A montage describes the combination of electrodes used for each EEG channel. It is
Figure 6:  Illustration of a two channel recording system. The output signals (A and B) are the
amplified difference between the two inputs, 1 and 2 for output A, and 3 and 4 for output B.
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usual for montages to use equidistant pairs of electrodes running from the front to the
rear of the head with the same reference electrode used for all channels (Rennie et al.,
2008). The data may be viewed post-acquisition using different montages. For example,
if channel 1 montage is Oz-Fz, and channel 2 montage is Pz-Fz, then a new montage
can be created by subtracting channel 2 from channel 1:  (Oz-Fz)–(Pz-Fz) = Oz-Fz-
Pz+Fz = Oz-Pz.
Montages  can  be  referential  or  bipolar.  Referential  montages  (left  hand illustration,
Figure 7) use a common electrode as reference input for all channels. This common
reference point is usually placed along the midline of the head, such as at location Cz, to
avoid  hemispheric  bias  (Rennie  et  al.,  2008).  The  bipolar  montage  (right  hand
illustration in Figure 7) uses two electrodes per channel, as well as a ground. The two
electrodes are called electrode pairs.
Mizrahi et al., (2003) advise that a bipolar montage should be used for infant recordings
to give broad coverage of the entire scalp. This same recommendation is made in the
ACNS standards  (Shellhaas  et  al.,  2011).  Rennie et  al.,  (2008) recommend that  the
following regions should be covered: right and left frontal, temporal, occipital, central
(or parietal) and the mid central region. 
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2.2.5 Practical Considerations for Infant EEG
The EEG is often performed whilst the infant is asleep to ensure adequate artefact-free
data,  although twitches or jolts  may still  occur.  Care is  required to  place electrodes
without  waking  the  infant.  Electrodes  should  avoid  the  fontanelles  (fibrous  areas
between the bony plates of the skull) or any haematoma (Rennie et al., 2008). An awake
infant can pull at electrode leads which are easily dislodged.
An environment conducive to sleep (dim lighting,  warm and quiet)  is  helpful,  as is
recording after a feed when the infant is more likely to be settled. It is normal practice to
video  the  recording  session  and  to  make  contemporary  annotations  to  aid  in  later
interpretation of artefacts (Rennie et al., 2008). 
2.2.6 EEG Trace Characteristics
In order to interpret and describe an EEG recording the following nomenclature is used.
Frequency: The number of occurrences of an event within a certain length of time. The
frequency can be described in three ways:
Figure 7: Montage types : Referential on the left and bipolar on the right. A line joining two
electrodes indicates the pairing for the twin inputs to the amplifiers.
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1. Rhythmic - Events having a constant and regular frequency.
2. Arrhythmic - Events having no stable rhythm within the signal.
3. Dysrhythmic - An abnormality or event in an otherwise normal rhythm.
Voltage  (Amplitude):  Either  the average or  peak voltage  of  the signal  over  a  given
period of time.
 Attenuation - Also known as suppression or depression, the result of a
gradual reduction in the amplitude of the signal. 
 Hypersynchrony  -  Increase  in  voltage  and  regularity  of  rhythmic
activity. This implies that there is an increase in the amount of neural
activity contributing to the EEG rhythm.
 Paroxysmal  -  Sudden  and  abrupt  increase  in  activity  above  the
background level that can often involve much higher voltages, before
the level returns to the lower levels. This is typical of seizure activity.
Morphology: The morphology of an EEG trace refers to its wave shape. This is defined
by the frequencies that make up the waveform and their phase and voltage relationships.
Such patterns can be defined as follows:
 Monomorphic - EEG activity that appears to have one dominant factor or
source.
 Polymorphic - A complex EEG waveform that is composed of a number of
frequency components.
 Sinusoidal - A waveform that resembles a sine wave i.e. a certain type of
monomorphic wave.
 Transient - An isolated, sudden change in amplitude that is different from
the background. This may be either a ‘spike’, which is a transient peak with
a duration of 20 – 70 ms, or a ‘sharp wave’ that is a transient pointed peak
of 70-200 ms. 
Synchrony: This refers to the relationship between two events occurring simultaneously,
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but at different locations over the head. An example would be the phase relationship
between activity measured between the two hemispheres of the brain.
Periodicity: Is a reference to the distribution of patterns within the EEG trace over time
i.e. how regularly an event occurs; usually defined as generalised, focal or lateralised.
2.2.7 EEG Morphology
Traditional methods of EEG interpretation consist of visually identifying key factors
and attaching significance to this. Frequency content of the EEG for a neonate usually
lies between 0.5 and 40 Hz, with each frequency being categorised into four major
bands as shown in Figure 8.
Higher frequencies above 40 Hz constitute the gamma band; the exact width of this
band has still to be defined. Gamma activity is not usually included as part of a clinical
assessment  of the neonate as the EEG is  predominantly made up of  low frequency
activity in the 0.5 – 12 Hz range. Another consideration is that of recording EEG in an
electrically noisy clinical environment. Although not best practice, it may be necessary
Figure 8: Basic EEG frequency characteristics. Beta (β) 12-30 Hz; Alpha
(α) 8-12 Hz; Theta (θ) 4-8 Hz; Delta (δ) 0-4 Hz
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to employ band-pass filtering between 0.5 and 40 Hz to minimise the effect of mains 50
Hz interference.
2.2.8 Artefacts
Artefacts are unwanted signals that distort the original signal. They should be avoided
or  at  least  highlighted  to  avoid  misinterpretation.  Artefacts  are  generally  of  higher
amplitude,  and  have  a  different  wave  shape  in  comparison  to  the  signal  sequence
(Teplan, 2002). The source of the artefact may be either patient-related or technical.
Patient-related artefacts  are  often unwanted physiological  signals,  such as  coughing,
whilst technical artefacts may be reduced by improving electrode impedance or using
shorter wires to reduce conductive artefact.
The common artefacts found in EEG recordings are shown below (adapted from Teplan,
(2002)):
Patient-related (biological source)
• Body movements, muscle movements, heart-rate, eye movements such as blink
artefact, sweating and respiration.
Equipment related (non-biological source)
 Mains  interference  (50  Hz),  variations  in  impedance,  cable  movements,
broken wires and poor connections to pre-amplifier, poor contact with scalp
due to dried or excessive electrode paste.
During  sleep  monitoring,  recording  the  electrooculogram  (EOG)  (eye  movement),
electromyogram  (EMG)  (muscle  contraction)  and  electrocardiogram  (ECG)  aids
identification of artefact from the EEG signal. For example, a spike that appears on the
EEG  trace  may  confidently  be  interpreted  as  a  blink  artefact  using  video  if  the
corresponding EOG also shows the spike. 
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2.3 Sleep Monitoring
2.3.1 Polysomnography (PSG)
PSG is an comprehensive assessment of sleep, comprising multichannel EEG, EOG,
EMG, ECG & respiratory monitoring as well as real time video recording. The EEG
alone is insufficient to be conclusive regarding a neonates sleep state. 
EOG records  the potential  difference between the cornea and the retina (the cornea
being positively charged with respect to the retina) using electrodes placed 1 cm above
and below the outer canthi of the right and left eyes respectively. It is particularly useful
in recognising rapid eye movement (REM) during sleep. Although the importance of
REM sleep in the neonate is unclear, it is thought to play an important role in early
neurological development (Mirmiran, 1995).
The EMG records facial muscular activity and is measured using two electrodes placed
under the neonates chin, above and below the jaw line. EMG is an indicator of sleep
state because muscle tension is reduced as the infant becomes more relaxed and enters
deeper sleep states. The EMG is also important in identifying the onset of REM sleep as
muscle  activity  measured  below the  chin  is  an  indicator  of  active  sleep  and is  not
present during quiet sleep.
ECG measures  heart  activity  and uses two electrodes  placed under  the clavicles  on
either side of the chest to record the QRS complex and the T wave. Recording the ECG
enables removal of cardiac artefacts from the EEG trace.
Detailed annotations are also made during the recording highlighting information such
as the observed clinical state of the patient e.g. awake, asleep, movement etc, and the
time that these events occurred (De Weerd et al., 1999). Only by unifying all aspects of
the recording can an accurate interpretation be made. 
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2.3.2 Sleep Scoring in Adults
In adults there are five sleep stages, as established and standardised by Rechtschaffen
and  Kales,  (1968).  These  are  four  stages  of  progressively  deeper  non  rapid  eye
movement  (NREM) sleep  and  one  stage  of  REM sleep.  The  sleep  stages  are  only
applicable to adult recordings as the neonates sleep architecture differs from that of an
adult.
2.3.3 Neonatal Sleep Scoring
Sleep  scoring  in  neonate  is  a  more  complex  procedure  than  in  adults  due  to  the
immature  brain  and changing neural  development.  Numerous  protocols  for  defining
sleep stages in the neonate have been proposed  (Anders, 1982; Crowell  and Group,
2003;  Grigg-Damberger  et  al.,  2007;  Hoppenbrouwers  et  al.,  1978). Essentially  the
neonate can be categorised as being awake or in one of three sleep states: active sleep
(AS), quiet sleep (QS) and indeterminate sleep (IS) (De Weerd et al., 1999).
The awake stage can be subdivided into: crying, active awake or quiet awake. In quiet
sleep EEG may show either tracé alternant (TA) or high voltage slow (HVS) patterns. In
active sleep EEG may show either low voltage irregular (LVI) or mixed (M) patterns
(Grigg-Damberger et al., 2007). It should be noted that these criteria are for term infants
and should not be applied to preterm infants. 
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As previously noted, age and maturity are important factors in establishing the stage of
sleep since considerable neurological changes occur in late pregnancy and in the early
weeks of life. For a neonate, maturity can be defined in a number of different ways
(Table 2):
Gestational Age (weeks): time elapsed between the first day of the last menstrual period
and the date of delivery. 
Chronological Age (days, weeks, months, or years): time elapsed from birth.
Postmenstrual Age 
(PMA)
(weeks): gestational age plus chronological age. Note that in UK 
literature the term post conceptional age may be used synonymously 
(but erroneously). 
Corrected age (weeks or months): chronological age reduced by the number of weeks
born before 40 weeks of gestation; the term should be used only for 
children up to 3 years of age who were born preterm.
Conceptional Age 
(CA)
An historic term, used in early US literature (weeks): time elapsed 
between the date of conception and the date of delivery. This will be 
two weeks less than equivalent postmenstrual age.
Table 2: Neonatal age terminology as defined by Engle et al., (2004).
The most accurate term is postmenstrual age (PMA) – for a neonate, full term infant this
will be 40 weeks. However, although the American Academy of Pediatrics (AAP) has
recommended abandoning the term conceptional age (CA) due to the difficulty involved
in accurately establishing the day of conception, much of the existing EEG evidence
defines  age-appropriate  EEG  patterns  in  neonates  by  conceptional  age  (Grigg-
Damberger et al., 2007). One must therefore consider if a correction factor of two weeks
should be applied to conceptional age.
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2.3.4 Physical Observations in Neonatal Sleep 
Scoring
One of the more commonly used methods for physical observations was proposed by
(Prechtl, 1974) and is summarised in Table 3.
Stage Description
Stage 1: Quiet Sleep (QS) Closed eyes without rapid eye movement (REM). No body 
movements. Heart and breath rate regular. Very rarely micro-
awakening.
Stage 2: Active Sleep  
(AS)
Closed eyes with REM. Body movements, various motility types. 
Heart and breath rate irregular. Many micro-awakenings.
Stage 3: Quiet 
Wakefulness
Open eyes. Few body movements, harmonious. Heart and breath rate
regular.
Stage 4: Active 
Wakefulness
Open eyes. Generalised body and eye movements. Heart and breath 
rate irregular.
Stage 5: Crying Generalised body movements. Vocalisation and crying.
Table 3: Prechtl's criteria for sleep/awake state identification (Prechtl, 1974). 
The following generalised (table  3) is applicable for scoring PSG for subjects up to 6
months of age. Each epoch would fall into one of the following states.
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State EEG EOG EMG Respiratory & 
body 
movements
Active Sleep 
(AS) - REM
Amplitude
Low voltage irregular (LVI) 
14µV – 35 µV.
High Voltage Slow (HVS) - 
50µV – 150 µV. 
Mixed (M) – a mixture of the 
above.
Frequency
Fast theta activity (4 to 8 Hz) 
dominant with significant 
amounts of delta (1-5 Hz)
Positive for 
rapid eye 
movements 
(REM)
Low or 
suppressed.
Irregular.
Gross body 
movements, 
sucking, 
grimaces, 
smiles and 
vocalisations.
Quiet Sleep 
(QS) - NREM
High Voltage Slow (HSV)
tracé alternant (TA) – a 
mixture of high voltage slow 
waves (0.5-3Hz) with rapid 
low voltage superimposed 
and sharp waves of 2-4 Hz 
between slow waves.
Mixed (M).
Negative for 
REM
High Regular
Some mouth 
movements and 
occasional 
startling 
(myoclonus)
Intermediate 
(IS)
 Intermediate is defined when none of the above criteria is met for either 
active or quiet sleep.
Awake Active awake: Eyes open and gross body movements. Possible vocalisations 
without crying.
Quiet awake: relative inactivity with eyes open.
Crying: Vocalisations and vigorous activity, with eyes open or closed.
Table 4: Neonatal sleep scoring criteria, adapted from Lindquist, (2007).
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2.3.5 Active Sleep (REM Sleep)
The example below Figure 9 shows an epoch of active sleep. The EEG shows a mixture
of low voltage irregular patterns and high voltage slow waves. Faster theta activity is
also present, within segments of slow wave delta. The respiratory trace is irregular, and
the EOG (the bottom trace) shows some activity.
2.3.6 Quiet Sleep (Non REM Sleep)
The example below Figure 10 shows a tracé alternant pattern indicative of a quiet sleep
where the EEG is a mixture of low voltage signals followed by bursts of high voltage
slow waves, with a frequency of 2-4 Hz. The respiratory pattern is regular and smooth,
and there is no REM activity shown on the EOG.
Figure 9: Active sleep in a healthy term infant. The PSG includes multiple EEG channels, where the
dominant pattern indicates active sleep. The EEG consists of a mixture of low voltage irregular, and
high voltage slow waves. Faster theta activity can also be seen. An irregular breathing pattern is also
shown (Crowell and Group, 2003)
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2.3.7 Indeterminate Sleep
When an epoch has elements of both quiet and active sleep, or it does not contain more
than 50% of one type of sleep or the other, it is described as indeterminate sleep.
2.3.8 Hypnograms
Once the PSG has been interpreted by classifying each epoch as a type of sleep, it can
be summarised on a hypnogram, which is a graphical representation of sleep activity
either throughout one sleep cycle (1 hour), or as an all night recording. Although time
consuming to generate, a hypnogram gives a clear picture of whether the sleep patterns
are normal, and can highlight periods of abnormality. The task of classifying the sleep
stages is  generally  performed either  by a neurophysiology neurologist,  or a suitably
qualified PSG technologist.
Figure 11 shows an example of a hypnogram over a 40 minute period where the neonate
has had periods of active and intermediate sleep between being awake.
Figure 10: Quiet sleep in a healthy term infant. Here the PSG includes multiple EEG channels, where
the dominant pattern indicates quiet sleep. In the EEG, prolonged periods of low amplitude activity are
broken up by bursts of high voltage slow frequency waves. Regular, and cyclical breathing are also
shown on the respiratory channel (Crowell and Group, 2003).
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Descriptive statistics can be used to highlight patterns and trends between the stages.
This approach gives an overall picture of the sleep session and allows for comparison
between the sessions/subjects.
2.4 EEG and Quantitative 
Polysomnography
The  methods  described  above  are  commonly  used  for  interpreting  EEGs.  Since
interpretation  is  based  on  the  skill  and  experience  of  the  viewer,  its  accuracy  is
dependent upon availability of highly-trained neurologists, and a degree of subjectivity
cannot be eliminated. For this reason, more objective methods have been developed to
aid in interpretation of the EEG. These are covered in the chapter on signal processing
(Chapter 4).
Figure 11: A 40 minute segment of a neonatal hypnogram analysed in 2 minute segments. WK –
awake, AS - active Sleep, IS – indeterminate sleep and QS – quiet sleep
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3 Electrocardiography and Cardiac 
Vagal Tone
This  chapter  describes  the  techniques  of  recording  the  electrocardiogram  (ECG),
extracting the heart  rate  variability  data,  and analysing these data  in  both time and
frequency domains. The first sections are an overview of the anatomy and physiology of
the heart, and have been sourced from the following references:  (Marieb and Hoehn,
2007; Nokes et al., 1995).
3.1 Cardiac Anatomy
The  heart  is  one  of  the  principal  organs  of  the  cardiovascular  system.  In  the  most
general terms, its purpose is to receive oxygen-deficient blood from around the body,
send it to the lungs for oxygenation, and then pump oxygen-rich blood around the body.
In an adult, the heart is approximately the size of a clenched fist, weighs between 200
and 400 grams, and is located within the centre of the chest, with a third of its body to
the right of the midline. The heart pumps at a rate of approximately 60-100 times a
minute in a resting healthy adult, and the rate is expressed in beats per minute (bpm).
The heart consists of four main chambers, two atria, and two ventricles (Figure 12). The
upper chambers or atria collect blood from the body and from the lungs and the lower
chambers or ventricles prove the main pumping force to move blood throughout the
body. Consequently the ventricles are larger and are more muscular than the atria.
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Separating the chambers are the two atrioventricular (AV) valves (mitral and tricuspid). 
These prevent back flow from the ventricles into the atria. The two semilunar valves, 
aortic and pulmonary, control the flow of blood from the heart to the aorta and the 
pulmonary arteries respectively. The aorta is the main artery of the body while the 
pulmonary artery is responsible for carrying oxygenated blood from the heart (Figure 
12).
The sinoatrial (SA) node is a bundle of highly specialised neurons located in the right
atrium. Its role is to send out electrical signals to control the rate at which the heart beats
(sinus rhythm); the SA node is thus the heart's natural pacemaker. The electrical impulse
from the SA node fires a series of electrical events transmitted through a specialised
Figure 12: The major sections of the heart.
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conductivity system which controls contraction of the atria and ventricles.
Because the right atrium is closer to the SA node, the right atrium depolarises first, and
thus  the pumping action in  the right  atrium precedes  that  of  the left.  The electrical
impulse is  subsequently delayed at  the AV node, allowing the ventricles to fill  with
blood before a further impulse is sent via the Bundle of His and the Purkinje fibres,
triggering the muscle contraction required to send blood out of the heart. 
3.1.1 Cardiac Electrophysiology
The interior of a cardiac muscle cell is negatively charged in relation to the exterior (the
resting potential). When these muscle cells are electrically stimulated from the SA or AV
node, they depolarise, the resting potential  changes from negative to positive,  and a
contraction occurs. 
The three stages of cardiac action potential are as follows:
 Depolarisation due to an influx of Na+ ions into the cell, reversing the membrane
potential from negative (-70 mV) to positive (+20 mV).
 The plateau phase, due to the influx of Ca++ ions.
 Repolarisation  where  K+ ions  leave  the  cell  via  the  ion  channels,  and  the
membrane potential is returned to its resting potential.
The process is shown in Figure 13.
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As electrical impulses spread throughout the heart, the heart's electric field changes in
both  magnitude  and direction,  creating  the  electrical  output  of  the  cardiac  cycle  as
observed on an ECG. The cardiac cycle on an ECG has three major phases, namely P;
QRS; and T.
Normally the cardiac cycle originates in the SA node, sending a pulse across the atria
which initialises the atrial depolarisation and produces the P wave. This impulse then
activates the AV node before the impulse is carried over the entire endocardial surface,
travelling  in  multiple  directions  simultaneously.  This  stage  corresponds  to  the  QRS
complex. The final stage is where the ventricular repolarisation occurs, resulting in the
T wave.
3.1.2 Heart Rate
The heart rate is determined by the heart itself as well as by regulatory pathways from
the brain and hormonal signals from the adrenal gland. Cardiac output is a product of
heart rate and stroke volume and is normally dependent on physiological need. Exercise
and stress both require an increase in cardiac function, with a greater need for blood
Figure 13: Action potential of cardiac cells.
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borne nutrients such as glucose and oxygen. Conversely, sleep reduces the need for both
oxygen and nutrients. Increased or decreased demands for cardiac output are met in part
by  regulating  the  heart  rate,  mediated  via  the  autonomic  nervous  system,  both
sympathetic and parasympathetic. 
For  an  increase  in  heart  rate,  the  neurotransmitters  norepinephrine  and  epinephrine
(adrenaline) are released from the adrenal gland via the sympathetic nervous system,
whilst a reduction in heart rate is achieved by the neurotransmitter acetycholine, via the
vagus nerve and the parasympathetic nervous system.
Changes in the heart rate, also known as the analysis of the variation of the beat to beat
interval, is called heart rate variability (HRV). Using analytical techniques in the time
and  frequency  domain,  HRV can  be  used  to  separate  frequency  components.  High
frequency (HF) oscillations (0.15 – 0.40 Hz) are associated with heart rate and changes
in blood pressure, induced by respiratory activity, and are controlled by the vagal branch
of the autonomic nervous system. The low frequency (LF) component (0.04 – 0.15 Hz)
is related to the baroreflex (the process for maintaining blood pressure) and is associated
with sympathetic activity  (Villa et al., 2000).  Consequently, analysis of the frequency
components  of  heart  rate  can  be  used  to  understand  the  relative  inputs  of  the
sympathetic and parasympathetic at any point in time.
3.1.3 Respiratory Sinus Arrhythmia and Vagal Tone
Respiratory sinus arrhythmia (RSA) is a naturally occurring fluctuation in heart rate
associated with the breathing cycle. It is an indirect measure of the parasympathetic
nervous system (Katona and Jih, 1975). With each respiratory cycle, the heart rate rises
and falls; inspiration results in increased negative intrathoracic pressure and reduced
cardiac filling so the heart rate increases to maintain cardiac output. The opposite occurs
in expiration, with a consequent reduction in heart rate. 
Vagal tone is a measurement of the activity of the tenth cranial nerve, commonly known
as the vagal nerve. The vagus nerve is part of the peripheral nervous system and is
important in homoeostasis. There are no non-invasive methods of measuring vagal tone
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directly but other physiological mechanisms such as heart rate can give an indication of
vagal tone.
Vagal tone is temporarily suppressed during inspiration, resulting in  an increase in heart
rate. Exhalation is associated with resumption of vagal activity and a reduction in heart
rate.
3.2 Electrocardiology
Electrocardiology is the measurement of the potentials produced by the mass cellular
depolarization and repolarization of cardiac muscle tissue.  An ECG is performed by
attaching  surface  electrodes  to  the  patient,  and  recording  the  electrical  potentials
between these points; analysis of ECG signals gives a picture of cardiac electrical and
muscle function. 
3.2.1 ECG Equipment
A simple,  single channel ECG system is made up of three electrodes applied to the
chest,  an  amplifier  to  magnify  the  signals  (usually  measured  in  mV),  a  method  of
applying filters to minimise the effect of unwanted interference, a data storage facility,
and a method of representing the waveform either on screen or on paper. .
More comprehensive ECG investigations can be made using additional electrodes, i.e.
12 for the ‘12 lead’ (10 channel) ECG, but this is not necessary for simply monitoring
heart rate.
3.2.2 Electrode Positions
The propagation of impulses through the heart creates a vector whose orientation and
magnitude varies according to the location of electrodes on the chest. This vector also
changes  as  a  function of  time.  The differential  potential  is  measured  between three
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positions, the right arm (R), the left arm (L), and the left leg (F). Using the notation of
the International Electrotechnical Commission, this configuration gives three channels
of data, referred to as lead I (L–R), lead II (F–R) and lead III (F–L). The configuration
is called the  Einthoven triangle, after  Willem Einthoven who developed the ECG in
1901. Although the Einthoven triangle is the most basic form of ECG lead placement,
various features of the heart's depolarisation can be still established.
For a neonatal sleep study, a three electrode system is considered sufficient,   with the
electrode placement following the 'modified three electrode bipolar system'  (Crowell
and Group, 2003). Bipolar refers to the fact that the ECG is the differential between two
electrodes, with the third acting as the ground. This configuration produces maximal the
P-wave  height.  The  three  electrode  system detects  R  waves accurately  so  that  RR
investigations are possible.
The normal location of the electrodes for a modified three electrode bipolar recording
are the right arm (RA), the left arm (LA) and left leg (LL). This system shows the R
wave deflection in an upward direction (Crowell and Group, 2003). 
3.2.3 ECG Recording Standards
Different recording standards are recommended depending on the primary purpose of
the ECG . The European Society of Cardiology (ESC) developed guidelines for the
recording and interpretation of neonatal ECG  (Schwartz et al., 2002), and the use of
heart rate variability  (Force, 1996).  The task force report, entitled 'Guidelines for the
interpretation of the neonatal electrocardiogram', advises the use of a 12 lead ECG and
the American Heart Association (Bailey et al., 1990) recommends a 150 Hz minimum
high frequency cut  off  and 500 Hz as  a  minimum sampling  rate  for  detailed  ECG
analysis. However, these standards are for  the identification of cardiac abnormalities
using ECG.
The American Academy of Sleep Medicine (AASM) has more relaxed standards for
heart rate monitoring for the purpose of polysomnography. The AASM Manual for the
Scoring of Sleep and Associated Events (Iber, 2007), sets out  comprehensive guidelines
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for polysomnography, stating the following key recommendations:
 A 3 lead ECG recording.
 A sampling  frequency  of  500  Hz  is  desirable,  but  200  Hz  is  a  permissible
minimal frequency for recording, as long as complex waveform analysis is not
undertaken.
 Filter settings for ECG should be 0.3 Hz for low frequency (high pass filter) and
70 Hz for high frequency (low pass filter).
 There should be the capacity for 50/60Hz filter for each channel.
 The digital resolution should be equal to or greater than 12 bits per sample.
Since this study focussed on sleep architecture, as opposed to a complex ECG wave
form analysis, the AASM guidelines for recording ECG were used.
3.2.4 ECG Artefacts and Ectopy
An artefact is a distortion of a desired signal due to an unwanted external source. Such
artefacts  are  common  in  neonatal  ECG  recording  and  must  be  removed  from  any
analysis.  The  main  sources  of  artefacts  for  neonatal  ECG  are  electrical  noise
contamination, patient movement and muscle activity, and baseline drift. They are often
due to incorrect application of electrodes. 
Although modern ECG electrodes are disposable,  pre-gelled and maintain good skin
contact with little skin preparation, care must be taken with the correct application of
the  electrodes  to  the  correct  locations  limb  lead  reversal  (where  the  +ve  and  –ve
amplifier inputs have been inadvertently swapped) and incorrect chest lead positioning
are both common sources of error  (Schwartz et al., 2002). Electrical interference, or
50Hz mains interference,  is common particularly in a hospital environment. Modern
ECG recorders have the capacity to remove unwanted signals using digital filters but
care must be taken to make sure that such filtering does not remove or distort the signal
being investigated. Movement and muscle artefacts are common and result in a large
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distortion  of  the  trace.  Similarly,  movements  during  sleep  such as  hiccups  must  be
excluded. Baseline drift can occur when electrodes become loose and contact with the
skin  deteriorates.  The  main  method  for  dealing  with  such  artefact  is  to  improve
electrode contact. To aid with interpretation, recordings should be monitored whilst the
trace is being made, and the trace annotated accordingly. 
Ectopic beats are disturbances of the cardiac rhythm arising from outside the SA node.
They may be classified as either premature ventricular contraction or premature atrial
contraction and are most common under periods of stress.  The morphology and timing
of the ECG signals produced by the ectopic beats will vary according to the site of
initiation and the contraction.
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3.3 Heart Rate Variability
HRV describes the amount of variability in time between consecutive heartbeats and can
be measured from the  R wave of each QRS complex.  Before any analysis  can be
performed it is necessary to prepare the ECG dataset: 
 Obtain a suitable ECG recording that satisfies the minimum requirements for
HRV analysis, as laid out by Force, (1996).
 Identify each R wave which acts as a point of reference, and is defined by its
amplitude and time.  The R wave peak can  be located by hand,  but  is  more
commonly located by employing a suitable algorithm.
 Locate and remove any artefacts from the RR interval series.
The output of the previous stage will produce the instantaneous heart rate series, with
one data point for each R wave peak identified within the QRS complex in an array of
time values.  Once this has been done, the data must be re-sampled at selected irregular
intervals. This is because RR intervals are not evenly sampled in time. However it is
this variation that HRV attempts to capture. Spectral analysis based of discrete Fourier
transforms operate on time series with uniform intervals, so it is necessary to resample
at uniform intervals. 
Variability  in  heart  rate  may be  evaluated  by  a  number  of  methods  including  time
domain, non-linear and frequency domain techniques. Each approach has strengths and
weaknesses, and will be covered in the further sections. 
3.3.1 ECG RR Estimation
The  RR  interval  is  the  measurement  of  time,  usually  in  milliseconds,  between
successive R waves. Mean RR is the average of many RR intervals measured over a set
period of time. Heart rate is usually expressed as the number of beats per minute (bpm).
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The challenge with automated RR extraction is the correct identification of the R wave
when there is variation in the baseline. The algorithm used in this study is an adaptive
technique employing a moving average filter, combined with an adaptive 50 Hz mains
filter set to exclude 50 Hz noise. R wave peak detection corrected the slope from each Q
trough  to  R wave  peak  and was  therefore  independent  of  sampling  frequency.  The
algorithm was  insensitive  to  EMG and high frequency noise  and had RR detection
sensitivity and specificity both greater than 99.6% (Christov, 2004). 
3.3.2 Time Domain HRV Methods
These methods are based on the time between two adjacent R waves. When beats are
judged to originate in the sinoatrial  node,  they are considered normal,  and the term
"NN" is used in place of RR.
Mean Heart Rate and Mean NN interval 
Figure 14:  This example shows baseline drift affecting the ECG trace of a 10 second epoch from
infant VIDI-044. The EDF browser software is used.
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The  mean  heart  rate  is  the  average  (mean)  number  of  beats  per  minute  during  the
recording. The mean NN interval is the average (mean) time in milliseconds between
normal (sinoatrial node) RR peaks, i.e. the sinus rhythm. Ectopic beats are excluded
from RR interval records to produce NN interval data.
Standard Deviation of the NN interval (SDNN)
As  NN  intervals  naturally  vary  with  time  (for  example  due  to  respiratory  sinus
arrhythmia) it is useful to quantify this variability. Standard deviation, the square root of
variance, is a commonly used measure of dispersion and can be applied to NN intervals
(equation 1):
SDNN=√ 1N−1∑j= 1
n
(RR j−RR )
2 (1)
where N is the number of intervals, RRj is the NN interval of interest, and RR  is the
mean NN interval over the duration of the recording. SDNN is expressed in ms and
captures all those frequencies responsible for the observed variability over the duration
of  recording,  i.e.  from  single  beat  variability  to  much  longer-term  variability.  The
duration over which SDNN is calculated must be stated: longer recording times are
likely to give higher SDNN, as they incorporate variability from cycles as long as the
recording (Force, 1996).
Root Mean Square of Successive Differences (RMSSD)
Interval differences (rather than intervals themselves) can be used to express heart rate
variability. RMSSD (equation 2) is the square root of the mean squared differences of
successive NN intervals: 
RMSSD=√ 1N−1 ∑j=1
N−1
(RR j+1−RR j )
2 (2)
where N is the total number of intervals, RRj is the NN interval of interest, and RRj+1 is
the next  NN interval.  RMSSD is  expressed in  ms. It  is  a  statistical  measure of the
magnitude of interval differences between normal (sinoatrial node) RR beats, and thus a
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measure of short-term heart rate variability.
3.3.3 Non Linear HRV Methods – Poincaré Plots
Processes with recurrent behaviour but also irregularities, such as heart rate, can have
both aspects visualised using a Poincaré plot. Axes are identical in scale, and each data
point  represents  two  successive  RR  intervals:  the  RR  interval  of  interest  (RR i)  is
mapped to the x-axis, while the previous interval (RRi-1) is mapped to the y-axis. The
resulting scatter plot shows beat-to-beat variability of a set of RR intervals (Figure 15).
If  all  RR  intervals  were  equal  throughout  the  recording,  all  data  points  would
superimpose at one point. Real data points cluster around the line of identity. If RR
intervals  changed  slowly  (successive  intervals  remaining  similar),  the  points  would
disperse approximately along, but close to, the line of identity. If RR intervals changed
rapidly (successive intervals differing substantially), the points would disperse further
Figure 15: An ECG Poincaré plot. The dispersion of points perpendicular to the line of
identity are an indication of short term variability, also defined by SD1. The dispersion of
points along the line of identity, defined by SD2, indicates the long term variability. The x-
axis is the current RR interval, while the y-axis is the consecutive RR interval.
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from the line of identity (Brennan et al., 2001).
The shape of  an ellipse enclosing the data  characterises  its  distribution.  The ellipse
width is the standard deviation of the data perpendicular to the line of identity (SD1 on
the graph) and represents short-term heart rate variability, i.e. a large number of rapid
changes.  It  is  closely  related  to  the  time-domain  RMSSD  described  above,  both
measuring  variability  over  a  single  beat.  SD2 represents  only  long-term variability,
highlighting gradual changes in variability.
3.3.4 Frequency Domain HRV Methods
Frequency domain analysis examines how often events happen, i.e. the frequency of
occurrence. This type of analysis shows the variation of RR intervals in relation to their
frequency,  typically  as  a  frequency  spectrum. A hypothetical  ECG  trace  with  two
sections of equal length, with constant heart rates of 60 bpm (1 Hz) and 90 bpm (1.5
Hz) respectively, would have a frequency spectrum with two peaks, one at 1 Hz, and the
second at 1.5 Hz.
As with EEG spectra, the spectra derived from RR intervals can be broken down into
frequency bands, and the power and relative power (relative to total bandwidth power)
calculated. The frequency bands are listed in Table 5. 
Frequency Band Frequency (Hz)
High Frequency (HF) 0.15 – 0.4 Hz
Low Frequency (LF) 0.04 – 0.15 Hz
Very Low Frequency (VLF)  0.04 Hz
Table 5: Recommended frequency bands for frequency analysis of adult HRV data (Force, 1996). 
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3.4 Heart Rate in the Newborn
The heart rate of a newborn infant can range normally from approximately 90 to 180
beats per minute and is generally higher when the infant is crying or agitated (Schwartz
et al.,  2002). Details from two studies involving sleep are shown in Table 6: Mehta et
al., (2002) study involved a 24 hour recording, and included a mixture of awake and
sleep states, whilst Doyle et al., (2009) focused on HRV values during quiet and active
sleep.
Variable 24 hour Quiet Sleep Active Sleep
Mean (SD) Mean (SD) Mean
Mehta et al., (2002)
HR (bpm) 130 (8) - -
SDNN (ms) 47 (12) - -
RMSSD (ms) 22 (7) - -
Doyle et al., (2009)
HR (bpm) - 110 (7) 114 (7)
SDNN (ms) - 15 (6) 24 (8)
RMSSD (ms) - 12 (5) 11 (5)
Table 6: Heart rate and HRV in the neonate from sleep studies by Mehta et al., (2002) and Doyle et
al., (2009). Heart rate is shown in the first row, whilst HRV is defined by SDNN and RMSSD. The
values in brackets are standard deviations.
The first three rows show the results of a time domain analysis.. It is clear that HR is
slower during sleep than over a 24 hour period which will include wakeful periods, and
is slower in quiet sleep than active sleep. The SDNN, which is a measure of HRV is
higher over 24 hours than during sleep, both because of the longer duration of recording
and the likelihood of more variability in wakeful periods. RMSSD, which captures short
term variability, is also higher over 24 hours than in sleep.
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3.5 Variations in Neonatal Study Analysis 
Parameters
Previous studies  of HRV (in the newborn) have used a range of different  recording
conditions making comparison between studies difficult, and normative values hard to
identify. Differences in recording methods include use of the Holter method of 24 hour
ambulatory recordings, or extraction of ECG data from the PSG. In general, for 24 hour
studies, identification of sleep state has not been made; this is important as heart rate
tends to slow during sleep. There is also considerable variation between studies with the
epoch size for analysis ranging from from 64 seconds to 300 seconds.  Subtle changes
occurring over short periods of time may be lost in the analysis of longer epochs. Table
7 summarises studies published to date showing the variation in techniques used and
highlighting the problems due to a lack of normative values.
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Study Study
group
Mean
GA
(weeks)
Mean
birth-
weight (g)
ECG type Recording
length
fs (Hz) PSD type Epoch/
window
size
Mehta et
al. (2002)
Term
Newborns
39.4 3,250 3 channel
Holter
24 hours 125 FFT ? 300 sec.
Schäffer et
al. (2008) 
Term
Newborns
38.6 3,245 3 channel
Holter
24 hours ? FFT +
(Hamming
window)
300 sec.
Longin et
al. (2005) 
Term
Newborns
39.1 3,448 1 channel
ECG
10 mins. 256 FFT 64 sec.
Spassov et
al. (1994) 
Term
Newborns
37-41 3,142 PSG 4 hours 286 STFT 512 heart
beats (225
sec.) *
Doyle et al.
(2009) 
Term
Newborns
>37 <2,500 EEG &
ECG
1-2 hours 256 Lomb 120 sec
Vandeput
et al.
(2009) 
Preterms
with
respiratory
problems
32.3 2,240 ECG 8 hours 100 FFT ? 300 sec.
Selig et al.
(2011)
Term
Newborns
>37 3,085 ECG 26 mins. ? FFT ?
* Assuming a neonatal HR of 120 – 160 bpm, the epoch size would be 4.3 – 3.2 minutes, or an average 
of 3.75 minutes, although this assumes linear spacing between RR intervals.
Table 7: A summary of ECG studies involving neonates. Each of the studies has included a spectral
analysis based on a recording varying from 10 minutes to 24 hours. Depending on the type of
recording, epoch length varied between 64 seconds and 300 seconds. The table shows the variation
in analysis methodology when performing spectral analysis on neonatal ECG data. GA – gestational
age; PSD – power spectral density; FFT – fast Fourier transform; STFT – short time Fourier
transformation.
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3.6 Cardiac Vagal Tone (CVT)
Vagal tone is a measurement of the activity of the vagus nerve (or tenth cranial nerve),
which originates in the medulla oblongata in the brainstem. The vagus nerve is part of
the parasympathetic nervous system and plays an important role in homoeostasis. Vagal
tone can be measured directly by inserting electrodes into the nerve and indirectly by
observing its effects upon organs such as the heart. By inhibiting the firing of the SA
node, increased vagal activity results in a decrease in heart rate and so heart rate and its
variability can be used to estimate vagal tone.
3.6.1 Estimating Vagal Tone
There are two main time domain methods of estimating vagal tone from heart rate, one
proposed by  Porges (1985) and the other by  Julu and Little (1998). Both have been
patented  and  the  algorithms  built  into  commercial  software,  called  Mxedit  and
Neuroscope respectively.  Although the  Porges (1985) method has been more widely
used, the method of Julu and Little (1998) has distinct advantages over its predecessor. 
Porges (1985) – The Mxedit Software
The ECG signal is used to extract the RR interval and a 21-point moving polynomial
detrending algorithm applied to remove linear and higher order trends such as episodes
of bradycardia. The signal is bandpass filtered (0.3-1.3 Hz) and the variance of the heart
period  extracted.  An  estimate  of  cardiac  vagal  tone  is  then  based  on  the  natural
logarithm of the variance. A typical value for a healthy term (36-42 weeks gestation)
neonate  is  approximately  3.0 (SD  1),  and  for  a  premature  neonate  (27-35  weeks
gestation) 2.2  (SD 0.6) (Lee, 2009). 
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Julu and Little (1998) – The Neuroscope Software
The  approach  taken  by  Julu  and  Little  (1998) in  the  NeuroscopeTM (Pontoppidan,
Copenhagen, Denmark) is based on an RR interval ECG input. The signal is sampled at
5 kHz and each QRS complex compared with a template generated from the initial
stages of the recording. If the QRS complex of interest is sufficiently similar to the
template, a fixed duration 1 mV pulse is generated. A pulse train is thus created, with
pulse separation matching the RR intervals of the ECG. The pulse train thus carries all
the RR interval data in a much simpler signal which is easier to process. It is integrated
with a time constant of 2 seconds and the output passed in parallel into two limbs (high
and low pass) of the algorithm. 
The high  pass  limb first  contains  a  high-pass  (0.2Hz)  filter  which  produces  an AC
voltage synchronised with the variation in RR intervals. An integrator then produces a
DC voltage proportional  to  the peak-to-peak amplitude of the AC signal.  A voltage
controlled oscillator (VCO) then generates a pulse train whose frequency depends on
the DC voltage, i.e. the higher the DC voltage, the higher the frequency of the pulses.
The low pass limb first contains a low-pass (0.015 Hz) filter with a time constant of
10.6 s and then a VCO. Signals from each limb are passed through a phase comparator,
whose  output  is  proportional  to  the  difference  in  frequency  between  the  two VCO
outputs. The phase comparator output is integrated and a DC component added, before
comparing with an experimentally established linear scale, called the linear vagal scale
(LVS). The process is shown in Figure 16. 
A value of zero on the LVS indicates no nerve impulses in the cardiac vagus nerve,
whilst an increase in LVS indicates increased cardiac vagus nerve activity.
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Figure 16: A flowchart describing the method used by the Neuroscope in estimating vagal tone. HRV
- heart rate variability; QRS – components of a heart beat; ECG – electrocardiogram.
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Vagal Tone and HRV Frequency Domain Analysis
The two methods described above are both time domain techniques but HRV frequency
domain analysis can also be used as an indicator of autonomic nervous activity. The low
frequency (LF) band of the HRV power spectrum is related to vagal activity,  as LF
increases with sympathetic  stimulation.  The high frequency (HF) band may also be
connected  to  vagal  activity.  Thus  the  LF/HF  ratio  is  an  important  marker  of
sympathetic/vagal balance on heart rate control (Acharya et al., 2004).
3.6.2 Polyvagal Theory
As an extension of his work on monitoring vagal tone, Porges proposed the polyvagal
theory  (Porges, 2001). This states that the vagus nerve has two distinct branches that
dictate  physiological  state  in  relation  to  psychological  experience.  The  first,  more
primitive  branch  is  called  the  dorsal  vagal  complex  (DVC),  also  described  as  the
'vegetative vagus', and is found in mammals, vertebrates, reptiles and amphibians. Its
purpose is to elicit immobilisation behaviours such as feigning death, allowing animals
under great stress to conserve their metabolic resources. The DVC provides control and
regulation of organs such as the digestive tract, but under prolonged disinhibition lethal
apnoea and bradycardia can occur. This branch of the vagus nerve is unmyelinated.
The second branch is called the ventral  vagal complex (VVC), or the 'smart vagus',
because  it  is  associated  with  'fight  or  flight'  behaviours  such  as  self-soothing  and
calming. Importantly, the VVC also influences heart rate: when vagal tone is high, a
resting,  or  slower,  heart  rate  is  produced.  The vagus  nerve  thus  acts  as  a  brake  or
restraint, without which the sympathetic-adrenal system would be activated. The VVC
is  myelinated  so  that  it  can  respond  quickly  to  activation.  It  is  the  evolutionary
development  of  this  second  branch  that  dictates  psychological  behaviour,  and
consequently  has  been related  to  the  study of  stress,  emotion  and social  behaviour.
When the more evolved branch fails, the primitive systems are activated.
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Clinical Applications of Polyvagal Theory and Vagal Tone
Using  Porges, (1985) method of vagal tone estimation described above,  Reed et al.,
(1999) linked the high heart  rate variability found in the healthy human foetus with
regulation  of  the vagus nerve.  Heart  rate  decelerations,  also mediated  by the vagus
nerve, are a sign of foetal distress. When the influence of the vagal nerve is increased,
the heart becomes more vulnerable to the influence of the more primitive DVC, which
can lead to a markedly slower heart rate. 
3.6.3 Neonatal Vagal Tone Studies
In a study using the Mxedit software, Lee (2009), described CVT in 72 healthy term and
62 premature infants. They showed that healthy term infants had significantly higher
CVT than then premature infants, although there were no significant differences in heart
rate (mean RR intervals). 
In a study involving behavioural states and heart rate patterns in infants, di Pietro et al.
(1987) described how breast-fed neonates had significantly slower heart rate, elevated
heart rate variability and higher CVT than the bottle-fed neonates. The breast-fed group
was also more irritable and difficult to console. The authors concluded that “Results
indicate  that  breast-fed  infants  had  significantly longer  heart  periods,  elevated  heart
period variability, and higher vagal tone than bottle-fed infants. Behaviourally, breast-
fed infants were significantly more irritable, more difficult to console, and more often
unable to complete the alert orientation portion of the assessment.” 
A further study investigating the effects of sponge bathing on vagal tone in premature
infants. Lee, (2002) showed that a sample of 40 premature infants born between 27 and
36 weeks gestation, reacted during bathing with a reduction in CVT and increase in
heart rate, compared with before and after bathing, although there were no significant
differences in behavioural distress. This indicates that vagal tone can be used to monitor
subtle physiological states which heart monitoring may miss.
Examining  the  effect  of  neonatal  cries  and  vagal  tone  on  the  neonatal  during
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circumcision, Porter et al., (1988) showed that the vagal tone was significantly reduced
as the pitch of the infant’s cry increased and they became more stressed.
The body of literature covering vagal tone and healthy neonates suggests that increased
vagal tone results in more regulation of the heart to stressful external stimuli and may
thus  be  advantageous  in  the  infant’s  development.  However,  in  older  infants  (8-11
months) with regulatory disorders,  DeGangi et al., (1991) found higher baseline vagal
tone  was  associated  with  disturbances  in  sleep,  feeding,  self-calming  and  mood
regulation. 
Many of the characteristics described in “regularity disordered” older infants are found
in the neonate with signs of NAS, indicating that vagal tone could be a useful tool in
monitoring these infants. Jansson et al., (2007) found that maternal vagal tone might be
a useful marker for the predisposition of NAS in the newborn infant (as described in
section 1.4.2).  In a study of 50 methadone-maintained pregnant women, vagal tone was
estimated and compared with the severity of NAS in the newborn infant. They found
that the extent of NAS in the infant was related to the vagal response of the mother, and
concluded that  NAS is  “essentially attributable to  disruption or dysregulation of the
autonomic nervous system”. 
It is the monitoring of this disruption or dysregulation of the autonomic nervous system
in the NAS infant, with its effects on both the nervous and cardiovascular system that is
the basis of this thesis.
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4 Electrophysiological Signal 
Processing
4.1 Introduction
This chapter describes the theoretical background to the techniques used to prepare and
analyse the recorded electrophysiological signals.  It covers acquisition of biosignals,
filtering techniques, methods of EEG and ECG analysis and practical considerations.
4.2 Acquisition of Biosignals
The biosignals recorded from the body in this study are continuous voltage signals that
vary  over  time.  These  can  give  an  insight  into  the physiological  processes  creating
them. Before processing, these analogue signals are converted into a digital signal, i.e. a
sequence of discrete values.
Conversion  is  performed  using  an  analogue  to  digital  converter  (ADC).  An  ADC
converts the amplitude of a continuous analogue signal, into an equivalent digital signal
in a process called quantization, occurring multiple times a second (the sampling rate).
The output of this process is a digital representation of the analogue signal. The number
of discrete voltage values produced over the amplitude range of the analogue signal is
defined by the resolution of the ADC. Resolution is expressed in bits (the basic unit in
computing with two states, one and zero), and consequently is expressed as a power of
two: an ADC with an 8 bit resolution can digitise an analogue signal into 256 different
levels (28 = 256), and can be represented as a range from 0-255, or -128 to 127 if the
signal contains negative values. 
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The (time) sampling rate defines the number of times sampling occurs within a set time
period, with the sampling frequency (fs) being the number of samples acquired in one
second. For example, an fs of 256 Hz indicates that the process of quantization occurs
256 times in one second. 
Slowly  changing  input  analogue  signals  can  be  adequately  represented  with  lower
sampling rates, but if the input analogue signal varies rapidly, the sampling rate must be
fast enough to capture all of the frequencies that make up the input signal. 
Aliasing occurs when the analogue signal changes faster than the sampling frequency,
creating anomalous signals called aliases in the output of the DAC. 
Digital to analogue conversion (DAC) can be used to check for aliasing: for example, if
the analogue input was a 200 Hz sinusoid and the sampling frequency was 128 Hz, the
ADC would misrepresent the true signal, and the DAC would show a 72 Hz signal. An
example of aliasing is shown in Figure 17.
The Nyquist-Shannon sampling theorem states that to reconstruct the original signal
accurately, the sampling frequency should be greater than twice that of the maximum
frequency content of the signal being sampled. This sampling frequency is known as the
Nyquist frequency.
Figure 17: An example of aliasing. This example shows an input signal of 200 Hz, being
sampled at 128 Hz. If digital to analogue conversion was performed, the reconstructed signal
would be 72 Hz, showing that the resulting signal is a poor representation of the input signal.
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4.3 Filters
Filters are often required to remove unwanted noise or artefacts  from a signal. This
process should remove all unwanted elements without unduly affecting the component
of interest. 
Analogue filters consist of a set of components with fixed value in an electronic circuit. 
Digital  filters  are  more  flexible,  as  they  are  implemented  computationally  and
consequently can be altered by changing their parameters. This section will focus on the
use of digital filters as opposed to analogue filters.
Filters fall into three main categories:
 High pass  filters  allow signals  above  a  defined  frequency,  blocking  lower
frequencies.
 Low pass filters allow signals below a predefined frequency and block higher
frequencies. 
 Notch  or  band-stop  filters  block  frequencies  between  two  predefined
frequencies, and pass frequencies either side of this value. A commonly used
notch filter is a 50 Hz filter for removing mains electricity interference. 
For  biosignal  acquisition,  filters  are  often applied in pairs  to  create  a  bandpass:  for
example, the recommended filter settings for ECG recordings  (Iber, 2007) are a low
pass filter of 0.3 Hz and a high pass filter of 70 Hz. The transfer function is the ratio of
the output of a system to the input of a system and is defined below (equation 1) where
X(s) is the input, and Y(s) is the output, and H(s) is the transfer function.
H (s )=Y ( s)
X (s )
(1)
A graph, known as a Bode plot, shows a filter’s transfer function, i.e. how the output of
a filter changes with frequency (logarithmic frequency axis) and is shown in Figure 18.
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A Bode plot illustrates the pass band, i.e. the frequencies that the filter passes without
significant attenuation; the stop band, i.e. those frequencies where little or no energy
from the input signal is passed; and the transition band, i.e. the frequencies where there
is a frequency-dependent level of attenuation. In an ideal filter, the transition band is
narrow, and the transition from pass to stop bands has the steepest slope.
Further characteristics include:
 The cut off frequency (corner frequency, f0) – the frequency where the
output from a filter has fallen to a specific proportion. This proportion is
defined as half of the passband power, also called the 3dB point since a
drop of 3dB is equivalent to halving the power. It is 0.51/2 ≈ 0.707 of the
passband voltage.
 Roll  off  –  the  slope  of  the  transition  band,  and is  the  rate  at  which
attenuation increases beyond fo.
 Ripple – the unwanted residual variations that characterise the filter’s
capability to attenuate signal in a linear manner.
For  biosignal  filtering,  narrower  bandpass  filters  are  required  because  the  signal  of
Figure 18: An example of a Bode plot for a low pass filter, attenuating low frequency components in
the pass band. Frequencies in the pass band will be allowed, the stop band blocked, and attenuation
in the transition band dependant on the input frequency.
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interest  is  often  close  to  the  frequencies  of  signals  that  need  to  be  removed.  For
example, when separating adjacent frequency bands from an EEG signal for spectral
analysis, delta, theta, alpha and beta bands need to be separated from the overall EEG
spectrum. The high frequency end of the delta band is 3.99 Hz, while the low frequency
end of the theta band starts at 4 Hz, so it is necessary to have a sufficiently narrow
transmission band that this boundary can be distinguished.
An  ideal  (theoretical)  filter  removes all  frequency  components  outwith  the  desired
bandwidth, has a vertical transition band, and has no effect on the phase of the output
signal. In reality, it is not possible to produce a filter with these characteristics, but it is
possible to design one that satisfies some of the properties of an idealised filter.
Digital filters fall into two categories, depending on how they respond to an impulse as
input signal (their impulse response):
 Finite  Impulse  Response  (FIR)  filter  -  the  impulse  response  has  finite
duration, i.e. settles to zero after a finite length of time.
 Infinite  Impulse  Response  (IIR)  -  the  impulse  response  is  non-zero
indefinitely, although its response usually decays over time.
IIR  filters  require  fewer  computations  than  the  equivalent  FIR filter,  thus  reducing
processing time. They can be designed to emulate the responses of analogue filters such
as the commonly used Butterworth or Chebychev filters.
The phase response of a filter is the change, in degrees or radians, of the phase of the
output signal relative to the phase of the input signal to the filter.  If the phase of a
sinusoidal input to a filter is identical to the phase of the output, the filter has zero phase
response to that signal. Phase response can be linear or non-linear depending on the
filter characteristics, and can accumulate over multiple cycles, i.e. exceed 360°.
4.3.1 Common Filter Designs
The  Butterworth  filter  is  characterised  by  a  nearly  flat  passband  with  no  ripple.
Transition band roll off is smooth, with a roll off rate of 20 dB/decade (or 6 db/octave). 
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The Chebyshev filter has a faster roll off than the Butterworth, but at the cost of having
ripples; the type 1 Chebyshev filter has ripple in the passband, while type 2 Chebyshev
has ripple in the stop band. Chebyshev filters also introduce greater phase distortions
than the Butterworth filter. 
The elliptic filter has a sharper transition than the other two filter types, but introduces
ripple in both the pass band and the stop band, as well as non-linear phase distortions.
This type of filter would be best suited to rejecting frequencies in the stop bands, and
can perform at low-orders, minimising the number of computations required Figure 19.
100
A notch filter passes all frequencies apart from those defined in the stop band, and is
centred around the required frequency, usually mains at 50 or 60Hz. The shape of the
frequency response plot is a 'notch', wider at the top and narrower at the base (Figure
20).  Notch  filters  can  introduce  significant  phase  distortions  and  therefore  are  not
suitable when acquiring biosignals where timing is critical, e.g. evoked potentials. They
will also affect amplitude in nearby frequencies, i.e. the upper range of the EEG for a 50
or 60 Hz filter.
Figure 19: A comparison of the frequency response for four types of IIR filters. Each graph is for a
low pass, 8th order filter with a sampling frequency of 256 Hz, and a cut off of 40 Hz and was
generated using Matlab’s filter design software, fdatool. The top left shows a Butterworth filter with
a nearly flat passband and no ripple. Top right shows a type 1 Chebyshev filter, with ripple in the
passband. Bottom left, a type 2 Chebyshev filter with ripple in the stop band, and bottom right
showing an elliptic filter with a very steep transition band, but ripple in both the pass and stop bands.
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4.4 Analysis of Biosignals
Visual inspection of the trends and patterns of signals can elicit useful deductions about
the  underlying  physiological  system,  but  requires  an  expert  viewer  to  be  clinically
useful:  this  approach  is  commonly  used  for  EEG  interpretation.  More  objective
interpretation  uses  measurements  of  signal  amplitude  and  time,  for  example  by
measuring the time between two R peaks of an ECG. This analysis of signals in the time
domain is widely used in ECG and many other biosignal fields. 
An alternative, objective approach is to examine data in the frequency domain.
The information  in  this  section  is  sourced from the  following references:   Lessard,
(2006); Peters et al., (1998); Sanei and Chambers, (2007); Semmlow, (2004); Tong and
Thakor, (2009); van Drongelen, (2006).
Figure 20: A frequency response curve for a Butterworth 8th order 50 Hz notch filter. Here the
frequencies either side of the stop band (48-52 Hz) are passed, whilst the frequencies around the
filtered frequency are blocked. The graph was generated using Matlab’s filter design software,
fdatool.
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4.4.1 Spectral Analysis
Spectral analysis is a method for estimating the energy content of a time-varying signal
as a function of frequency. In the time domain, it is normal to plot data with the y-axis
representing energy, and the x-axis time, whilst for the frequency domain, the x-axis
shows frequency.  Spectral  analysis  is  based on the  result  of  techniques  such as  the
discrete Fourier transform (DFT),  where the spectrum produced represents energy at  a
range of frequency bins. If a signal contains little diversity of frequency content, it will
closely resembles a sinusoid in the time domain, and its frequency spectrum will  be
similar  to a  single  line  at  the  frequency  of  the  signal.  As  the  signal  increases  in
complexity, and thus is made up of more sinusoids, the frequency spectrum will become
more complex, containing multiple lines representing the various frequencies present. 
Spectral analysis is a powerful tool in the analysis of biosignals and is used extensively
in EEG and ECG analysis. 
Non-stationarity of Biosignals
A  stationary  process  is  defined  as  continuous  and  would  therefore  repeat  itself
indefinitely.  Spectral  analysis  is  based  on  the  Fourier  series,  which  repeats  itself
infinitely and assumes stationarity of a signal. However, biosignals in their raw form are
rarely stationary, and require a degree of manipulation before spectral analysis can be
performed.  As  an  example, consider  one  hour of ECG  recording,  which  is  not
stationary. However, smaller epochs of the ECG approximate to a stationary signal, and
spectral analysis may be performed (Dumermuth and Molinari, 1987).
Fourier Analysis
The Fourier series can be used to describe a periodic time domain signal as the sum of
an infinite series of sinusoids: a fundamental frequency component and its harmonics.
 If a periodic signal is defined as , and has a period of T, then  for all
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values of t.  Consequently a Fourier series representation of the function  can be
expressed as in equation (2).
f ( t )=a0 +a1cos (ω0 t )+a2 cos2 (ω0 t )+…ancos (nω0 t )…
+b1 sin (ω0) t+b2 sin (2ω0 ) t+ … bn sin (nω0 ) t+ … n−1,2,3, … ∞−1
(2)
where , period T = 1/f, n is the nth harmonic of the fundamental frequency
ω0,  and  ai and  bi are  the  Fourier  coefficients  which  govern  the  amplitudes  of  the
sinusoids.
It can be seen from equation (2) that the signal  can be represented by an infinite
number of sinusoids of harmonically related frequencies, in addition to the fundamental
frequency ω0.  Fourier analysis  calculates the values of the coefficients ai and bi, and
determines  the number  of  coefficients  required to  describe  the  input  signal  with
adequate accuracy.
The  Fourier  series  shown  in  equation  (2),  may  be  simplified  as  the  more  general
equation (3):
v (t )=a0+∑
1
∞
(an cos (nωt )+bnsin ( nωt ) ) (3)
where ω= 2πf . 
The complex Fourier coefficients ai and bi are determined as in equations (4), (5) and
(6):
a0=
1
2 T∫ v (t ) dt (4)
an=
1
2 T∫0
T
v (t ) cos (nω0 t )dt (5)
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bn=
1
2T ∫0
T
v ( t ) sin (nω0 t )dt (6)
The process of satisfying these coefficient requirements is called the Fourier transform.
The output of this transformation gives a set of sinusoids with amplitudes and phases
such that when added together, they recreate the original signal. 
The  Discrete  Fourier  Transform  (DFT)  is  a  mathematical  variant  of  the  Fourier
transform used for a finite array of equally spaced, discrete samples. The discrete time
function is transformed into an array of coefficients of a finite combination of complex
sinusoids, ranked by their frequency. The Fast Fourier Transform (FFT) is one algorithm
commonly used to implement the DFT and is optimised for fast computation.
The Power Spectrum
A power  spectrum  (or  periodogram)  is  the  squared  magnitude  of  the  amplitude-
frequency spectrum, and shows the contribution (power) made by a frequency per unit
frequency.
The magnitude of the coefficients can be established using equation (7) and has units of
V/Hz.
cn=√ (an+bn) (an−bn) (7)
where a and b are the Fourier coefficients.
Parseval's theorem (equation 8) states that the square of a function in the time domain
equals the square of the transformed function, i.e. in the frequency domain. Therefore,
the power spectrum can be obtained using equation (9):
∫
−∞
+∞
|v (t )|2 dt= 12 π |X
(ω )|2 dω (8)
where v(t) is the time domain, and the frequency domain is represented by X(ω).
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The coefficients in equation (9) are squared magnitude of the complex coefficients, and
therefore have units of V2/Hz.
cn
2 =an
2+bn
2 (9)
The FFT algorithm requires 2n data points. For example, using a sampling frequency of
256 Hz and a four second window  or epoch results in a signal with  1024  (210)  data
points.  Longer  epochs,  for  example  30  s, could  result  in  loss  of time-domain
information  such as  specific events.  Padding the signal with zeros in the time domain
can prospectively achieve the required number of data points in the frequency domain.
When discontinuities are introduced into a signal, usually due to truncation, rectangular
windowing, or zero-padding, the effect on the power spectrum is spectral leakage. For
example, the sine function shown in Figure 21a does not fit within the time window
exactly, and thus has a non-integer number of cycles. The end of the previous cycle does
not match the beginning of the next cycle, so a discontinuity is introduced. The spectral
leakage  reduces the  line  spectrum at  the  sinusoid frequency,  and  increases  its
representation in adjacent bins (Figure 21b).
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4.4.2 Windowing
To reduce  the  effect  of  leakage,  a  window function,  or  weighting  function,  can  be
applied  to  the  time  domain  signal  before  it  undergoes  a  frequency  transform.
Windowing tapers the signal amplitude to avoid discontinuities and therefore avoids
spectral leakage. However, windowing leads to a loss in energy of the system, as signal
amplitude is  lost.  An example of the tapering effect of windowing for a sinusoid is
shown in Figure 22.
Figure 21: Spectral leakage caused by a non-integer number of sinusoids within a set epoch. The
top graph (a) shows a sinusoid in the time domain, and the bottom (b), its frequency domain
equivalent. As the signal in (a) does not contain an integer number of cycles, spectral leakage in
the frequency domain (b) can be seen in adjacent bins. 
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Four of the most common types of windowing function are described below (Figure
23):
Rectangle window : The simplest form of window is the rectangular or boxcar window.
This replaces all but a predefined set of values at the start and end of the signal with
zeros.  This gives the appearance of the waveform abruptly turning on and off.  This
process  is  simple  to  implement,  but  creates  discontinuities  and so  leads  to  spectral
leakage in the frequency domain.
Welch window : The Welch window consists of a single parabolic section which tapers
the beginning and end of the signal more slowly than the rectangular window.
Hanning window : The Hanning window consists of a polynomial closer to a sine wave,
with more gentle side lobes, so the transitions are less abrupt than other windows.
Figure 22: Windowing used to reduce the effects of spectral leakage. (a) shows a tapered sinusoid,
with the start and end of the signal having zero amplitude. Its frequency transformation is shown in
(b).
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4.4.3 The Welch Periodogram
As windowing reduces the energy in the system, one method of minimising this loss is
to overlap adjacent, windowed sections of the signal. A commonly used technique of
applying  windowing  and  overlapping  is  known  as  the  Welch  periodogram  (Welch,
1967).  If  the  overlap  is  half  the  window  length,  then  each  sample  will  make
approximately the same contribution to the overall spectrum, as windowing emphasises
data from the centre of a segment at the expense of data at its edges. The epoch is split
into multiple segments of equal length with 50% overlap between adjacent segments.
Hanning windows are applied to each segment, and their periodograms computed using
the DFT (Figure 24).
All periodograms are then time-averaged. This has the effect of averaging each epoch's
frequency  output,  thus  reducing  noise,  but  at  the  cost  of  frequency  resolution
(Semmlow,  2004).  It  is  a  commonly  used  tool  in  EEG  and  ECG spectral  analysis
because  of  its  noise  reduction  capabilities  and  its  relatively  low  computational
overheads. This approach is suitable for examining the underlying trends in the EEG
signals, but is not suitable for evoked potential analysis, as the averaging effect smooths
out  important  components:  "A smeared  spectral  estimate  is  a  consequence  of  the
windowing" (Kay and Marple, 1981).
Figure 23: The generalised window shapes of the rectangular, Welch and Hanning window
functions.
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By introducing smearing across the bins, power at the band power boundaries is altered:
for example, power close to the 4 Hz delta/theta boundary may be smeared across the
adjacent frequency bins, giving misleading values for band power. 
4.4.4 The Short Time Fourier Transformation (STFT) –
Spectrogram
A limitation of the Fourier transform is that all time information is lost when data is
transformed from the time domain to the frequency domain, so although the frequency
of events is known, the timing of an event is not. 
To overcome this,  a  spectrogram can be  employed.  The spectrogram is  an  array of
epochs 'stacked up' on each other in layers, so that each layer represents a further epoch
in  time.  For  example,  for  a  1  second  epoch,  if  an  event  was  evident  in  the  third
epoch/layer, then it can be assumed that the event occurred during the third second.
However, temporal resolution is limited: if the epochs are too short, spectral leakage
diminishes the reliability of the spectral analysis.
Figure 24: The Welch periodogram showing the epoch separated into three segments with 50%
overlap between each. Each segment is then windowed. In this example, the latter 50% of
segment 1 overlaps the first 50% of segment 2. 
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An example of a spectrogram is shown in  Figure 25. The spectrogram is built up by
layers of epochs from the left of the figure. The power is represented by the colour, with
lower values being darker, such as blue, whilst high values of power are represented in
red. The figure shows that, over the period of 1 second, the signal changes frequency
from 1000 Hz to 3000 Hz. It gives an indication of not only the frequency of the signals,
but the time at which they occur.
Figure 25: The spectrogram. In this example the frequency of the input signal varies between
1000 and 3000 Hz. The amplitude of the signal also varies with darker colours indicating low
amplitude, and higher colours high frequency. The frequency of the signal varies with time
being at a minimum of 1000 Hz at 0.5 seconds, and a maximum of 3000 Hz at 1 second, before
repeating itself.
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4.5 EEG Signal Processing
4.5.1 Absolute and Relative Band Power
A spectrum can be split into bands and the power within each band can be calculated as
an absolute value, or relative to the power of the entire spectrum (Figure 26). These
bands are: delta (0-4 Hz), theta (4-8 Hz), alpha (8-12 Hz) and beta (12-30 Hz). Although
gamma (30  Hz  upwards)  is  used  in  adult  EEG spectral  analysis,  it  is  not  used  in
neonatal analysis and so is not discussed further here.
The total power is the area under the entire curve between two frequencies, usually 0
and 30 Hz (equation 10):
TotalPower (TP )=∑
0Hz
30Hz
( X (f )2 ) (10)
where X(f) is the power function. Absolute band power is the sum of the power under
the  curve  between  the  band  frequency  boundaries.  Relative  band  power  is  the
percentage of band power relative to total power, and an example for delta power is
described in equation (11):
Figure 26: EEG band power. The four bands shown are delta (0-4 Hz), theta (4-8 Hz), alpha (8-12
Hz) and beta (12-30 Hz).
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Relativepower ( delta )= deltabandpower (0−4 Hz )
Totalpower (0−30 Hz )
x100 (11)
4.5.2 Spectral Edge Frequency
The spectral edge is defined as that frequency below which 95% of the total power (cut
off frequency = 30Hz) is accumulated  (Fell et al., 1996). Spectral edge measurements
have a long history of use in adult EEG, for example in assessing depth of anaesthesia,
and  have  also  been  shown  to  correlate  with  gestational  age  in  healthy  neonates,
suggesting a role for measuring cerebral maturation or stress levels (Bell et al., 1991).
4.6 ECG Signal Processing
As with EEG spectra, the frequency spectrum of HRV can be broken down into bands
(Table 8), and the power within each band can be calculated.
Band Frequency (Hz)
High Frequency (HF) 0.15 – 0.4 Hz
Low Frequency (LF) 0.15 – 0.4 Hz
Very Low Frequency (VLF) 0.0033 – 0.04 Hz
Ultra Low Frequency (ULF) 0 – 0.003 Hz
Table 8: Frequency ranges of each ECG band power (Mehta et al., 2002).
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4.7 Summary
This chapter has summarised the key elements of signal processing, starting with the
methods  of  acquiring  biosignals  and  methods  of  removing  unwanted  noise  by  the
application  of  filters.  The  use  of  the  Fourier  transform  as  the  basis  of  frequency
analysis, with sections on spectral leakage, and methods of limiting its effect with the
application  of  windowing  techniques,  were  then  described.  The  short-time  Fourier
transformation was introduced as a  tool  for  identifying when event  occurs within a
series of epochs, without losing the frequency information from the spectral analysis.
Finally applications and quantifiable variables were described with the application of
spectral analysis to both EEG and ECG.
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5 Software
5.1 Introduction
This chapter describes the custom software developed for EEG analysis, and the open
source and proprietary software used for ECG analysis, for all data acquisition and for
all data storage.
Open  source  means  the  source  code  is  available  to  view,  modify  and  distribute.
Proprietary  (closed  source)  means  the  source  code  is  owned  by  the  distributing
organisation  or  author,  and  is  not  available.  For  this  project  no  single  proprietary
software solution that satisfied all of the requirements was available.
A major part of the work I undertook for this thesis was the development of the custom
software for EEG analysis. The work comprised specification, design, writing of code
and testing. I also wrote the custom databases for the study.
5.2 Data Acquisition
All  data  were  acquired  using  Xltek  Neuroworks  system (Nautus  Medical,  Oakville,
Ontario, Canada), software version 5.4.0 (build 503), running on a Microsoft Windows
XP platform,  a  proprietary  hardware/software  combination.  It  consists  of  a  small
hardware box connected to  a  laptop.  It  collected all  the electrophysiological  signals
recorded in  this  study,  i.e.  12-channel  EEG, ECG, EMG, respiratory  variations  and
EOG. It was also used to record simultaneous video, which was required for identifying
sleep states and recording any unusual movements.
The  Xltek  system  is  used  in  the  EEG  department  at  the  Royal  Hospital  for  Sick
Children, Glasgow for all routine, clinical work. The same system was selected for the
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study to provide maximum consistency with routine, clinical practice of the consultant
paediatric  neurologist  (Dr  Mary  O’Regan)  who  interpreted  the  EEGs  of  the  study
infants.
The  Xltek  Wave  viewer  software  is  part  of  the  Xltek  EEG  system,  and  allowed
inspection of multiple channels of electrophysiological data with real time video. It also
displayed  time-labelled  annotations  recorded  manually  during  the  recording  which
allowed post-hoc identification of artefacts (Figure 27).
Figure 27: Xltek Wave viewer software. The data shown are from VIDI study infant  #118, recorded
at age 23 hours. Annotations and comments made during the recording are listed in the left hand
window. The main electrophysiological data are shown in the central (green) window; EEG channels
are at the top, EOG, EMG and respiratory follow, and the ECG is at the bottom in red. The video
channel has not been included to maintain patient anonymity, but was also viewed when the
neurologist interpreted the PSG.
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5.3 Data Storage
For  uniformity  of  electrophysiology  data  file  format  and  ease  of  transfer  between
systems,  all  data  required  for  PSG (EEG,  ECG,  EOG,  EMG and respiratory)  were
stored in the open source European data format (EDF) file format proposed by Kemp et
al.,  (1992). This format has a header containing general information, such as patient
identification, recording start/end time, duration of recording, as well as the technical
specifications  of  each  signal,  including  calibration  details,  sampling  rate  and  filter
settings. Because EDF files are coded as 16-bit integer ASCII (American Standard Code
for Information Interchange) characters, the data are viewable without encoding using a
standard text editor. The Xltek Wave viewer software was used to create EDF format
data output rather than its propriety, closed source format.
EDF files were imported using the cross platform (Microsoft Windows XP Professional
Service Pack 3 & Linux) BioSig software toolbox 2.61 (Schlogl and Brunner, 2008) as a
parser. An example of the output from the Biosig header file is shown below (Table 9).
Variable Function
HDR.FileName File name
HDR.SampleRate Sampling frequency, fs (Hz)
HDR.FILE.size File Size
HDR.NS Number of channels
HDR.NRec*HDR.SPR Number of samples
HDR.PatientName Patient name
HDR.Manufacturer.Model
Manufacturer make and model of the
bio-amplifier used.
Table 9: Examples of Biosig header file variables. HDR – Header; Fs – sampling frequency; NS –
number of channels; Nrec - number of records; SPR – sampling rate (Hz).
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5.4 Data Analysis
5.4.1 EEG
No  proprietary  analysis  system  satisfied  all  of  the  EEG  analysis  requirements.  I
therefore developed a custom application, written to be used in conjunction with the
manually scored, classical PSG analysis.
Specification and design In general, the purpose of the software was to import files
from the Xltek Neuroworks system, perform a series of computational procedures, and
output the results both graphically and as a text file for importing into the PSG database.
The specific requirements were:
 Import EDF files, extract header information and information concerning the
montage configuration. 
 Extract user-definable epochs for analysis
 Allow selection of individual epochs using a graphical user interface (GUI) 
 Apply the following digital signal processing (DSP) methods:
• Optional filters (notch, high and low pass), both based on Butterworth filters
with user selectable parameters e.g. filter order, high and low pass cutoffs.
See chapter 4.3.
• Linear de-trending of the signal in the time domain by removing the epoch
average value from each data point.
• If required to apply a Hamming window to the epoch, the parameters defined
by the user. See chapter 4.4.2.
 Perform time domain analysis and extract maximum signal amplitude, mean
amplitude and epoch variance. 
 Perform  frequency  domain  analysis  using  power  spectra,  and  extract  the
following features: SEF 95% (0-30 Hz and 2-20 Hz), absolute and relative
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band powers; delta (0-4 Hz), delta low (0-2 Hz), delta high (2-4 Hz), theta (4-8
Hz), alpha (8-12 Hz), beta (12-30Hz). See chapter 4.5.1.
 Plot time domain graphs, frequency domain graphs and and a histogram of the
distribution of the amplitude data. 
 Plot 2D/3D colour density spectral array, based on the results of the output of
combining the power spectra for all epochs analysed.
 Output numerical data to a text file for importing into the PSG database and
into a summary report for printing.
Initially a proprietary solution was sought to satisfy these requirements, as this would
mean  development  time  for  the  analysis  phase  of  the  project  would  be  kept  to  a
minimum. Two packages were investigated; Prana Software Suite1 (PhiTools, 1, rue du
Général  de  Castelnau,  67000  Strasbourg,  France),  and  g.Bsanalyze2 (g.Tec,  Guger
Technologies OG, zH Frau Mag. Barbara Vogt, Sierningstraße 14, 4521 Schiedlberg). 
The  Prana  software  was  available  as  a  demonstration  version  that  had  limited
functionality  for  testing  purposes.  When  installed  on  the  test  machine  (Intel  P4  3
gigahertz CPU with 1 gigabytes of memory – later upgraded to 2 gigabytes) it ran too
slowly to be usable due to the PC's limited memory, and the large video files to be
imported. The g.Tec software, at that time, could not output variables such as spectral
edge, which were considered essential for the analysis.
Consequently a bespoke solution was required. For this reason, an agile approach was
used for the development of the EEG software, where the project is broken down into
small tasks, and each task was completed before moving on to the next: the process is
iterative  as  requirements  can  be  modified  before  the  start  of  the  next  task.  This
evolutionary approach was suitable  as the precise outcomes of the project were not
always clear at the outset, and was preferred to the more rigid waterfall design method
where  the  design  specifications  cannot  easily  be  adjusted  during  the  coding  phase
(Figure 28). 
The  agile  approach  suited  the  pragmatic  requirements  of  the  study,  where  EEG
1 http://www.phitools.com/
2 http://www.gtec.at/Products/Software/g.BSanalyze-Specs-Features
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quantitative analysis techniques were researched in parallel with designing the software
requirements. Requirements could be modified to match my improving understanding
of  EEG  analysis,  improving  programming  skills,  and  to  accommodate  unforeseen
difficulties. 
An agile approach was chosen for the development of the EEG software for the 
following reasons: 
1. To  avoid  delay  in  software  development,  EEG  quantitative  techniques  were
researched in parallel with requirement design, requiring an agile approach to
flexibly develop software in response to improved EEG analysis understanding.
Use of the waterfall method would have necessitated completion of the research
prior to software development and thus delayed the start of writing the code. 
2. Many small pilot modules of code had to be developed, and not all of them were
included  in  the  final  application.  The  agile  approach  gave  the  flexibility  to
include or exclude modules accordingly. 
3. The MATLAB® programming language was learned at  the same time as the
requirements  were  established.  As  better  methods  of  algorithm  design  were
learnt  and understood, they could be more easily  incorporated into the main
program (code base).
 The agile approach gave the flexibility to include or exclude modules accordingly.
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Legislation and version control: Although  the  project  did  not  aim  to  develop
software  for  sale  in  the  European  Union,  the  processes  laid  down  in  the  relevant
standard  (IEC  62304)  for  medical  device  software  were  followed:  requirement
establishment; architecture and design of the system; implementation (coding); testing
and deployment. IEC 62304 is the international standard, harmonised by the European
Union and a benchmark for compliance with the regulatory requirements of the Medical
Device Directive MDD 93/42/EEC. It establishes a framework for developing safety
critical and highly reliable software via the software design process. 
The open-source version control system Fossil3 was used to monitor changes  during
software development. The nature of each change and its reason were documented so
that if a problem occurred, it was possible to track back to find errors in the source code.
Fossil was chosen for its small size and built-in bug tracking.
Language: The  analysis  software  was  written  in  the  proprietary  mathematical
programming language Matlab® (MathWorks, Natick, MA, USA). This software was
suitable for the purposes of the study as it allowed manipulation of matrices, plotting of
functions  and  data,  algorithm implementation,  and generation  of  GUIs.  It  was  also
suitable for transfer of software across systems (i.e. Microsoft Windows and Linux).
Matlab® includes a Signal Processing Toolbox, which allowed development of off-line
3  http://www.fossil-scm.org/index.html/doc/trunk/www/index.wiki
Figure 28: Software design methodologies. On the left, the waterfall method showing each stage that
needs completion before progression to the next, and on the right, the agile approach, that updates
the requirements in relation to changing user needs.
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(that  is,  not  in  real-time)  spectral  analysis  software.  Although  other  open-source
programming languages such as Python4 (using the scientific add on library SciPy5) or
R6 (statistical  programming language), were also considered,  Matlab® was preferred
because  of  its  excellent  reference  material  available  for  signal  processing,  and  the
numerous, freely available sections of code (Matlab Central)7 available for testing.
Minimum hardware and software requirements: The primary development platform
was a Hewlett Packard / Compaq desktop PC with a 3GHz Intel P4 central processing
unit (CPU), and 2 gigabytes of internal Random Access Memory (RAM). The operating
system was Microsoft Windows XP SP38. The software was also developed in part on a
Hewlett Packard 2730p laptop, with a 1.83 GHz Intel Dual Core 2 CPU and 2 gigabytes
of RAM, but running Cannonical’s Lubuntu9 version 12.04 with version 3.2+ of the
Linux  kernel.  The  software  was  developed  on  two  platforms  to  take  advantage  of
portability, and Linux’s lower resource requirements. 
Overview of system: The flow diagram (Figure 29) summarises the processes for the
EEG analysis software. The user selects a suitable EDF file, and the software reads in
its header, presenting the user with the details such as patient information and recording
details.  The  user  then  selects  the  individual  channels  for  analysis  to  reduce  the
computational load; only the data being analysed was ever held in memory, as opposed
to  reading  in  the  entire  dataset.  The  channels  of  data  from the  requested  pairs  of
electrodes (e.g. C3-O1) were then extracted from the dataset. The user then selected
options  of digital  filtering,  windowing and/or  linear  de-trending of each epoch.  The
main analysis loop was then initiated, performing power spectrum estimation on the
selected epoch. Spectral results from each epoch were added to an ongoing array, then
exported to a text file. The GUI was then shown (Figure 32) and the user could inspect
any individual epoch, or look at overall trends.
4 www.python.org
5 www.scipy.org
6 www.r-project.org
7 www.MathWorks.co.uk/matlabcentral/g
8  http://windows.microsoft.com/en-US/windows/products/windows-xp
9  http://lubuntu.net/
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Figure 29: The EEG analysis software systems flowchart showing each stage necessary for the
analysis.
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EDF header extraction Figure 30 is an example of the header file from an EDF
file  read  by  the  BioSig  parser,  highlighting  all  the  key  variables  for  the  analysis
software.  Information contained within the header  file  about  sampling  rate,  channel
labels and amplitude were used during spectral analysis.
Version=0.10
generated=2012­06­18 16:36:11.7
[Fixed Header]
Filename = C:\PilotNIRSedf\PRANA_reduced_data.edf
Format  = EDF
SizeOfFile = 393472
NumberOfChannels = 3
SamplingRate   = 128
Number_of_Samples = 65408
RecordingDateTime = 2011­02­01 15:40:01.000
Patient.
Name    = 
Id = PRANA
Gender   = unknown
[Channel Header]
#No Label fs [Hz] GDFTYP TH­  TH+ PhysDim
 1 Time     128.0 3  ­32768 32767 s
 2 channel 1  128.0 3  ­32768 32767 uV^2/Hz
 3 channel 2  128.0 3  ­32768 32767 uV^2/Hz
[Event Table]
NumberOfEvents=0 SampleRate=128.000000
Sampling Header information
===========================
Sampling Frequency: 128
Number of data points: 65408
Duration of recording: 511 seconds or 00:08:31 hrs:mins:sec
Frequency: 128 Hz
Number of data points: 65408
Basic Header information
========================
Sampling Frequency: 128
Number of data points: 65408
Duration of recording: 511 seconds or 00:08:31 hrs:mins:sec
Figure 30: BioSig EDF file header output.
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Epoch selection An initial design requirement was that the software could read in
a user-defined sample from one channel of data, and run all the analytical procedures on
this data. One hour of multichannel PSG data with video is typically 400-600 Mb, which
is a large dataset for a low specification PC (2 Gb RAM, Intel P4 3.0GHz), so the final
software  allowed  analysis  of  short  epochs  (user  definable,  but  for  this  study  four
seconds), repeated to cover the entire hour's worth of data, one channel at a time. The
software allowed the user to select the required channel, the start position of the epoch
(in seconds), the number of epochs and the duration of the epochs. The software then
ran  an  iterative  process,  extracting  the  epoch  under  investigation  [epochData]  by
defining  the  start  [posStart]  and  end  [posEnd]  positions  within  the  array  [allData]
(Figure 31). Epoch lengths are rarely longer than 1 minute: at a sampling frequency of
256  Hz,  this  created  15,360  data  points  per  epoch  which  was  manageable  by  the
computers used.
Following analysis (see below), the output array of parameters were stored in a text file
for  reconstruction as graphs or tables,  minimising CPU and memory overheads and
allowing a large dataset to be analysed in sections.
Figure 31: The epoch selection method. The image above is of artificially created data to
demonstrate the epoch selection process used by the analysis software. The user defines the
epoch length, the number of epochs required and the time position of the start of the first
epoch. Each subsequent epoch is then analysed.
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Numerical analyses Briefly, data epochs were transformed into the frequency domain
using the discrete Fourier transform (DFT) (see section  4.4.1),  squared to produce a
power spectrum, as per the method10 described by van Drongelen, (2006). The software
output  was  a  three  column  array  containing  respectively  an  index  number,  the  bin
frequency (Hz); and power at that frequency (V2/Hz).
Absolute  and  relative  powers  were  calculated  from  this  output.  Frequency  values
corresponding to  EEG band boundaries (see  Table 13)  were stored,  and power was
calculated by adding the power in all bins between (and including) the two boundaries.
If the boundary did not correspond to an exact bin frequency, for example where the
frequency resolution did not exactly match the boundary value, the nearest lower value
was  stored.  Relative  band  powers  were  computed  as  percentages  of  the  total  band
power.
Spectral edge frequencies were calculated in a similar manner. The area under the curve
was  calculated  between  two  frequency  ranges  (0-30Hz or  2-20Hz).  This  represents
100% of the power. 95% of this power was then calculated and then the frequency at
which this value occurred noted as the spectral edge frequency (see section 4.5.2). 
The main GUI This has five sections (Figure 32). 1 (left): file/epoch information
and signal processing details. Any processing applied by the user from the command
line was summarised here (filtering; windowing or de-trending).  2 (top,  centre):  the
main graph window plotted the current epoch in the time domain (top) and frequency
domain (bottom),  showing amplitude  and power spectra  (these graphs were derived
from the results of the DFT, with the power spectrum being created from the DFT). An
amplitude  histogram  was  also  plotted.  Cursor  functionality  allowed  amplitude
measurements to be made directly from the time domain graphs, although in the final
analysis  this  function  was  not  used,  as  it  was  more  applicable  to  evoked  potential
analysis  not  time  series  analysis.  3  (centre):  the  epoch  selector  panel  was  used  to
navigate between epochs and to highlight obvious artefacts. An ‘artefact’ button was
used to flag the epoch as unsuitable for analysis, and the user could exclude it from the
final analysis. 4 (bottom): displays user selectable graphs showing the output from the
frequency analysis of the entire dataset ([allData], or the entire data range selected by
10 https://books.google.co.uk/books?id=Oa7OtAqJk5wC&lpg=PP1&dq=signal%20processing%20for
%20neuroscientists&pg=PA107#v=onepage&q&f=false
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the user). The graph options were colour density spectral array (CDSA), or graphs of
delta power, total power, band power (delta, theta, alpha and beta all plotted on the same
graph),  or  spectral  edge  (95%)  frequency.  The  purpose  was  to  show how different
parameters varied over the entire recording, but the final analysis  only showed user
defined  pre-selected  epochs  that  were  deemed  artefact  free.  5.  (right):  the  analysis
output panel showed the parameters for each epoch from both time domain (maximum
amplitude, epoch variance and mean amplitude) and frequency domains (both absolute
(V2/Hz)  and  relative  (%)  delta,  theta,  alpha  and  beta  power  values;  total  power
(V2/Hz);  SEF 95% frequency for the following ranges of 0-30Hz and 2-20Hz, and
measured in Hertz). It is these values that were written to the text file output, and used
for the final statistical analysis. Each epoch was examined using the GUI, highlighting
artefacts or problems where necessary. Annotations were exported in a separate text file.
Figure 32: The EEG analysis software main window. The left hand panel shows the file header
information, the user selected epoch details, and any signal processing options selected initially. The
central panel shows the frequency and time domain graphs, with the colour density spectral array
(CDSA) below. The right hand panel shows the results of the analysis for that epoch.
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Text file output The output text files were in the comma separated value (*.csv)
format, and were imported into the PSG database (Microsoft Access, see section 5.5.2)
and into the relevant EEG or ECG analysis software. The files were called output.csv,
and were stored in the analysis folder for each infant. Each epoch was identified by
subject study number, epoch times and epoch details, so that each channel of data could
be identified. This allowed comparison of all channels of the PSG montage in both time
and space (electrode position). A truncated example of the text file output looks like:
Filename,fs,Channel,posStart,posEnd,epochNo,RMS, ... 
VIDI_46_output.edf,128,channel 1­channel 2,0,4,1,1.0754,...
VIDI_46_output.edf,128,channel 1­channel 2,4,8,2,2.4213,...
where the top line defines the entries in the subsequent lines, and entries are separated
by commas.  In this  example,  the second line contains  data  from the file  (filename)
VIDI_46_output.edf, sampling frequency (fs) is 128 Hz, electrode montage (Channel) is
channel 1-channel 2, the epoch start (posStart) is at 0 seconds, the epoch end (posEnd)
is at 4 seconds, the sequential index number called the epoch number (epochNo) is 1
and the RMS voltage of the epoch is 1.0754 V.
Testing The EEG analysis software was tested using a text file, converted into
the EDF format using EDFbrowser. The 16 different test signals were: a square wave,
two sawtooths, a reversing, periodic impulse function, a noise signal, seven sinusoids
with different frequencies, a flattened sinusoid and three DC signals (Figure 34). All
signals had a constant amplitude except the noise signal. 
The sinusoids, DC offset, and pulse signals were generated in LibreOffice Calc and a
screen shot of the spreadsheet developed to create the test signals shown in Figure 33.
The square wave, sawtooth and noise functions were written in MATLAB using short
programs.
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When all the test signals had been produced they were merged into a single spreadsheet
(LibreOffice Calc) and imported into EDF browser to generate the EDF compatible file
for testing the EEG analysis software, the Kubios HRV software and the Neuroscope
CVT software. A screen shot of the final file is shown in Figure 34.
Figure 33: A screenshot of the spreadsheet used to create the test signals. This example shows three
test signals (sine, DC offset and pulse) for testing the HRV/ECG software. In the top left corner, the
user enters the amplitude of the signal, frequency in Hz, the sampling frequency, and phase change
(if desired). Each column was then populated automatically and the resulting signals plotted in the
graph at the top left. The output of the spreadsheet was then copied to a separate worksheet, exported
to text file, and converted to an EDF file using EDF browser.
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Signals were chosen to create precisely predictable spectra, and were used to look for
any errors causing (for example) leakage into adjacent bins. Signals had at least 1024
data points to emulate a 4 second epoch with a sampling frequency of 256 Hz.
When testing the EEG analysis software, a number of errors were found in the EEG
analysis  software.  Spectral  leakage  was  identified  when  using  a  fixed  amplitude
sinusoid.  This  was  due  to  a  very  small  error  in  the  test  signal  where  the  sinusoid
generated as the test signal did not contain an integer number of cycles. The signal was
recreated to have an exact integer number of cycles, and the error was eliminated. Also,
the amplitude of the signal in the frequency domain was lower than expected when
tested with the DC offset signal. This was because the power spectrum had not been
normalised beforehand, and when corrected, the problem was resolved. 
Figure 34: Graphical output of the EDF test file illustrating the 16 test signals used. The signals are
as follows; a square wave, two sawtooths, a reversing, periodic impulse function, a noise signal,
seven sinusoids with different frequencies, a flattened sinusoid and three DC signals. All the signals
had a constant amplitude except the noise signal.
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The band power algorithm was tested using a 4 second vector (the same length as a
typical epoch, and therefore with a frequency resolution of 0.25 Hz) and containing only
'ones'.  This  was  designed to produce  bins  each with  power  of  1μV2/Hz,  and tested
frequencies up to the Nyquist frequency 128 Hz (Figure 35).
Index Frequency (Hz) Power
(µV2/Hz)
Boundary
1 0.00 1
2 0.25 1
3 0.50 1 Delta lower
4 0.75 1
... ...
16 3.75 1
17 4.00 1 Delta upper
18 4.25 1
... ... ...
n Nyquist
Frequency
1
Figure 35: The band power test array, illustrating the boundaries of the EEG delta band at 0.5 and 4
Hz corresponding to index values of 3 and 17. Band power is therefore 15 µV2/Hz, the sum of power
in bins 3–17 inclusive (n=15 bins), each of 1 µV2/Hz.
The same process was repeated for the other bands, theta, alpha and beta. The output
from the software is shown below (Figure 36). No errors were found using this process.
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Please enter the epoch length in seconds: 4
Each bin will represent 0.25 Hz.
Results
=======
Length of epoch: 4 sec
Sampling Frequency: 256 Hz
Number of data points in epoch: 1024
Minimum Resolvable Frequency: 0.25Hz
 
absDeltaPower (0.5­4Hz): 15 uV^2/Hz
absThetaPower (4.25­8Hz): 16 uV^2/Hz
absAlphaPower (8.25­12Hz): 16 uV^2/Hz
absBetaPower (12.25­30Hz): 72 uV^2/Hz
 
absTotalPower: 119 uV^2/Hz
 
relDeltaPower: 12.605 %
relThetaPower: 13.4454 %
relAlphaPower: 13.4454 %
relBetaPower: 60.5042 %
 
relTotalPower 0.5­4: 100 %
Figure 36: Example of band power testing results.
The spectral edge algorithm was tested by using the same array as the band power. As
the total power had already been established from the band power testing (119 V2/Hz),
the SEF is 95% of the total power (113.05 V2/Hz). The index value that corresponds to
this frequency in the array is position 113, which corresponds to 28 Hz. The process is
shown in (Figure 37).
absTotalPower: 119 uV^2/Hz
SEF95 totalpower (0.5­30 Hz): 113.05 uV^2/Hz
SEF95 index position: 113
SEF95: 28 Hz
Figure 37: Example of spectral edge frequency testing. If the absolute total power between two
frequency boundaries is 119 V2/Hz, 95% of this value is 113.05 V2/Hz. The array index value that
is closest to 113.05 V2/Hz is 113, which represents a frequency of 28 Hz.
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5.4.2 ECG
The requirements for ECG analysis software were: ability to estimate the RR interval;
ability to derive standard ECG HRV parameters in both time and frequency domains,
and  ability  to  derive  CVT parameters  as  a  proxy  measurement  of  parasympathetic
nervous system function. These requirements could be met using existing software, so
the process of specification,  design and implementation of custom software was not
required for ECG data analysis. The data was acquired using the Xltek Neuroworks
system.
Data preparation Each 60 second epoch of ECG was visually inspected; if major
artefact  was  present,  the  epoch  was  discarded.  Manually  marked  comments  and
artefacts were then exported via comma separated text file and imported into the PSG
database, so that the artefacts can be excluded from the final analysis. Inspection was
undertaken  using  the  EDF  browser11 software  version  1.48,  written  by  Teunis  van
Beelen,  and covered  by the  GPL version  2  software  license  which  allows  free  use
providing the author is suitably acknowledged. EDF browser allows viewing and some
analysis of electrophysiological signals in EDF format.
RR interval EDF browser was also used for automated measurement and extraction
of the RR time intervals (time between each heart beat) of the ECG. The method used in
EDF browser was proposed by Christov (2004). A screen shot of the software is shown
in Figure 38. The RR intervals were exported in ASCII text file format.
11  www.teuniz.net/edfbrowser/
133
The Kubios HRV software version 2.0  (Tarvainen and Niskanen, 2008) was used to
analyse the RR interval  data.  It  was written by the Biosignal Analysis  and Medical
Imaging Group (BSAMIG) at the Department of Physics, University of Kuopio, Kupio,
Finland. The software was developed in MATLAB® 2008a (The MathWorks, Inc) and
was compiled to a deployable standalone application with the MATLAB® Complier
4.8. Its use was covered by the University of Kupio software license.
Parametric methods of spectral density estimation (e.g. autoregression) were available
in the Kubios HRV software, but were not used for the final analysis, as the technique
assumes the signal is stationary, stochastic and can be described using a small (known)
number of parameters (Akaike, 1969), prior knowledge not available in this case. It was
decided  to  use  the  non-parametric  Fourier  analysis  based  methods,  as  they  do  not
require prior knowledge about the signal to be analysed. Fourier analysis has been used
Figure 38: A screenshot of EDF browser main window, showing the ECG recorded from an infant
from another study for illustrative purposes. Positions of movement artefacts are manually
highlighted with time stamps. The 'rulers’ allow measurement of the amplitude, timing and
frequency of sections of the ECG. The right hand window shows all the manually marked
annotations, and comments that the user has applied.
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in many other similar neonatal studies, making comparison easier  (Bell et al.,  1991;
Doyle et al., 2007; Scher, 2004).
ASCII text files were imported into the analysis software. The output was in a comma
separated value text file format.
The  main  window  has  three  panels  (Figure  39):  one  for  header  data  and  analysis
parameters; one for a time domain plot of the ECG which can be cursored; and one for
the results of analyses. 
Figure 39: The Kubios HRV software main window. This analysis was from VIDI subject #136, and
the epoch analysed was scored as active sleep. The top left section shows file details, any pre-
processing smoothing parameters and analysis parameters. The main window shows 60 minutes of
RR interval data. Data cursors can select regions to be analysed. The lower panel shows the results
of analyses, either time domain, frequency domain or non-linear. In this example, time-domain
analysis results are visible.
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Time-domain analysis Time domain analyses calculated the mean heart rate (HR,
beats per minute, bpm), mean RR interval (ms) standard deviation of mean HR (normal
RR peaks, NN intervals) (SDNN, ms) and the square root of the mean of the squares of
successive  NN  interval  differences  (RMSSD,  ms).  Histograms  of  the  parameter
distributions were plotted (Figure 40).
Frequency domain analysis FFT spectrum estimation  analysis  was  conducted,  with
band power calculated and given numerically and shown in colour plots (Figure 41).
The relative power (to total  power) of very low frequency, low frequency and high
frequency  signals  (VLF,  LF,  HF)  and  the  LF/HF  power  ratio  were  calculated  (see
section 3.3.4).
Figure 40: The Kubios HRV time-domain analysis window. This analysis was from VIDI subject
#136, and the epoch analysed was scored as active sleep. SDNN – standard deviation of the NN
(RR) intervals; HR – heart rate; STD HR – standard deviation of the heart rate; RMSSD – root mean
squared standard deviation, NN50 – the number of pairs of successive NNs that differ by more than
50ms (not used for newborns as NN (mean RR) is often much greater than 50ms); TINN - triangular
index evaluated through triangular interpolation.
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Nonlinear analysis Poincaré  plots  were  made,  giving  SD1 and SD2,  measures  of
short- and longer term variability. Figure 42 shows the output of the non-linear analysis,
both graphically and numerically, with the Poincaré plot highlighting the cluster of data
around the diagonal axis. The last section of the report includes the non-linear Poincaré
plots,  with the  SD1 and SD2 measurements,  showing the  variation  of  RR intervals
graphically (section 3.3.3).
Figure 41: The Kubios HRV frequency-domain analysis window. This analysis was from subject
#136, and the epoch analysed was scored as active sleep. The power spectrum estimated using the
fast Fourier transform is shown on the left showing the following outcome parameters used this
technique (VLF – very low frequency; LF – low frequency; HF – high frequency; LF/HF low
frequency/high frequency ratio). A plot of the autoregressive parametric technique is shown on the
right for illustrative purposes, but was not used for further analysis.
Figure 42: Kubios non-linear analysis window. This analysis was from subject #136, and the epoch
analysed was scored as active sleep. SD1 and SD2 are the standard deviations of the Poincaré plot.
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5.4.3 CVT
The NeuroscopeTM TONE software12 version 3.14f (Medifit Instruments Ltd, Enfield,
England, was used to calculate vagal tone measurements, based on the method proposed
by (Julu, 1992). NeuroscopeTM is proprietary software, and was made available for use
by Dr Stig Hansen, Department  of Clinical Physics and Bioengineering,  Institute of
Neurology, Southern General Hospital, Glasgow. 
The software works on the principle that heart rate can be predicted from measurements
of parasympathetic activity from the vagus nerve (Katona et al., 1970), and is done by
analysing the RR intervals from the ECG. By comparing QRS complexes to a template
generated from the initial stages of a recording, if such complexes are similar enough to
this template a 1 mV pulse is generated. The time between these pulses is equivalent to
the RR interval. These pulses are then sent into two circuits, a high pass limb and a low
pass  limb.  The high  pass  tracks  the  incoming signal  faithfully,  whilst  the  low pass
produces  a  damped  version  of  the  signal.  If  variability  is  low,  there  is  only  minor
damping so the signals in each limb are similar, and the NeuroscopeTM output is small,
or zero. If variability is high, then more damping occurs, and the difference between the
two limbs is greater, and the CVT score higher. A constant heart rate, with no variability
would  give  an  output  of  zero.  The  measured  output  is  then  compared  with
experimentally  derived  data,  and  a  score  for  vagal  tone  presented  (Julu  and  Little,
1998). A more detailed description of the methods of CVT estimation can be found in
section 3.6.1.
To use the NeuroscopeTM software, ECG data was exported from the Xltek software in
EDF format. To make these files directly compatible with the NeuroscopeTM software, a
custom made conversion program, written and applied by Dr Stig Hansen, was used.
Although I did not have access to this code, the program performed two operations,
removal of DC shift (a baseline removed from each sample point) and application of a
simple five point smoothing algorithm (all points having equal weight). The output file
was then be loaded into the NeuroscopeTM software.
12www.medifitgroup.com/Neurology.htm
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As the software was originally designed to run on a standard PC running Microsoft MS-
DOS and was not Microsoft Windows XP compatible, it was run within the DOSBox13
emulation application. A screenshot of the software can be seen in Figure 43.
Testing The  CVT NeuroscopeTM software  was  tested  using  a  series  of  pulses
generated using the function generator spreadsheet described above (Figure 33). The
first signal was designed to test whether the filters could distinguish higher or lower
than normal frequencies: this was important as the neonates heart rate is normally up to
twice that of an adult. The low frequency pulse train was equivalent to a frequency of
13www.dosbox.co  m
Figure 43: The NeuroscopeTM software running in DOSbox showing data from VIDI study number
#136, during active sleep. The top graph shows the changes in RR interval. As the software measures
the changes in RR variability to produce an estimate of CVT, the bottom graph mirrors this but
matches the output with an experimentally derived linear scale. Here the user has selected an epoch,
shown as the two dotted lines, and the CVT estimates are shown on the right hand side. The CVT
values for both cursor positions and the average CVT between the two cursors are shown below this.
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0.34Hz or approximately 20 bpm, and the high frequency pulse train was 3.34Hz or
approximately 200 bpm (Figure 44). This testing highlighted a limitation in the software
at high frequencies, and Dr Hansen accordingly amended his conversion software.
The second test signal (Figure 45) was designed to test whether the software could still
identify  the  pulse  train  (frequency  0.5Hz,  or  120  bpm)  when  there  was  significant
positive or negative drift on the signal as was sometimes the case with the subjects in
this study. In both cases, the software accurately identified the correct location of the
pulses i.e. the simulated R wave.
Figure 44: Pulse trains for testing the CVT software. The left hand figure shows the high frequency
pulses (200 bpm), whilst the right shows the low frequency signal (20 bpm). Both frequencies were
chosen to match extremes of heart rate of a newborn infant.
Figure 45: Pulse trains to test how the NeuroscopeTM software deals with drift. The left hand figure
shows a low frequency signal (~20 bpm) with a growing baseline. The right hand figure shows the
same frequency signal with a decaying baseline.
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5.5 Databases
5.5.1 VIDI Study Database
The VIDI study database was necessary for four reasons. Firstly,  there were around
75,000  data  items  associated  with  the  study:  155  patient  records  with  up  to  500
variables per patient. Secondly, to minimise the level of data management, and reduce
the  amount  of  work  required  before  the  dataset  could  be  closed,  a  means  of  error
checking  on  the  front  end  interface  was  required.  Thirdly,  the  database  had  to  be
accessible on multiple NHS Greater Glasgow & Clyde PCs, but still include security
features and comply with the Data Protection Act. Patient identifiers were not stored and
the  dataset  was  not  used  outside  the  realm  of  the  health  board.  It  was  written  in
Microsoft Access 2003.
The main purposes were to help in the collection of case report form (CRF) data, ease
the transfer of data to an electronic format, help deal with any data management issues,
and finally to output the corrected datasets for statistical analysis. 
Its structure was relational, i.e. the dataset was split over a number of tables linked by
the unique identifier,  or primary key (study number),  thus avoiding duplication,  and
giving faster access as not all the data is needed at one time. A dual data entry system
was employed so that the same infant could not be registered twice into the system. This
involved entering the study number twice on the recruitment screen, where the system
checked the uniqueness of the number entered. This can be seen in Figure 46.
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Correct registration of the study number is important to maintain referential integrity in
the database. To avoid using an inefficient flat file approach, where all the data is stored
in a large table and where there is likely duplication of information, the entire dataset
was broken down into a number of smaller tables, and linked via a key. A key is a
unique  identifier  (usually  a  number)  that  links  one  or  more  tables  together.  In  this
database, the study number was a primary key, in that it was a unique identifier of a
infants record. Other tables called 'child' tables were then linked to this primary key
with foreign keys (a field in a sub-table that matches the primary key) so that each study
number could have numerous sub-tables. An example of this linking via keys is shown
in Figure 47. 
This gives the database flexibility in that once a infant has been registered it can have
many  linked  tables  associated  with  it.  An  important  factor  is  referential  integrity
between these tables, in that a study number cannot be removed without first removing
the child tables so a record could not exist in a sub table without a link to its primary
key.
Figure 46: The registration screen for the VIDI database. The user enters the study number to be
registered twice (the first cell being highlighted in yellow), enters the date of birth, recruitment type
and the exposure status. The system then checks if the study number has been registered already, and
allows the user to continue if not.
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One of the requirements of the system was that it had to be accessible to multiple users
concurrently. For this a server-client model with a separate user interface (stored on the
client machine) from the back-end database (stored on a file server) was employed.
Although Microsoft Access is not designed for large numbers of concurrent users, it can
handle small  numbers  (up to  5) using this  client  server  model.  Record locking was
enforced so that users could not work on the same record at the same time, so it did not
have the power of a full transaction server like Microsoft’s SQL Server. 
The user interface was designed for easy navigation between patient records and also to
restrict  what the user could enter in order to keep the underlying data accurate and
consistent.  The  interface  was  constructed  in  Visual  Basic  for  Applications  6.3.8863
(Microsoft  Corporation, Redmond, Washington, USA), and linked with the back-end
database  using  Object  Database  Connectivity  (ODBC,  Microsoft  Corporation,
Redmond,  Washington,  USA).  Although  ODBC  is  old  compared  to  object  linking
embedding (OLE), it is compatible with many analysis systems, for easy data transfer
Figure 47: The relationship diagram of the VIDI database showing the linking between the primary
key in [tblRegistration] and the sub-tables. Note that referential integrity was enforced so that child
tables cannot be removed without first removing the record from [tblRegistration]. The window in
the bottom right hand corner shows the details of the relationship between [tblRegistration] and
[tblEEG_Epochs], in that they are linked by the primary key [StudyNo], and have a one to many
relationship i.e. a study number can have many EEG epoch records.
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across different operating systems i.e. Windows to Linux.
Paper case report forms (CRFs) were used to collect data from the medical records, and
were  transferred  into  the  database.  This  was  done as  paper  is  more  convenient  for
collecting data  when no computer  is  to  hand,  and it  also gives  a  hard copy of  the
information in case of electronic data loss. 
The paper CRF was designed to mirror the database user interface, and a combination of
drop down lists and restricted text input boxes, supported an interface that was easy to
use, but adequately protected from data entry mistakes. Free text could be stored in
cases where the input options were not applicable so entries could still be successfully
coded but flagged up during the data management process. An example screen shot
from the database is shown in Figure 48.
On completing the study, there were very few corrections required before closing and
locking  the  dataset  to  start  the  statistical  analysis;  this  highlights  the  adequately
Figure 48: The VIDI database. This section shows the demographics form. Drop down menus were
used to avoid typographic errors during data entry. LBW – low birth weight; SGA – small for
gestational age; OFC – occipital frontal circumference; BMI – body mass index
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controlled  nature  of  the  data  entry.  Corrections  required  were  usually  missing  data
fields, as the GUI stopped the entry of unformatted data.
5.5.2 PSG Study Database
A second database was written in Microsoft Access 2003 to hold the PSG data for those
VIDI study infants from whom PSGs were recorded.
A folder was created for each patient containing the results of analysis for each channel
and the results stored as individual text files. Each file corresponded to a channel in the
EEG montage, and was imported into the database to allow cross channel averaging and
analysis. Each channel was merged to create one large record for each patient.
This database held output parameters from the EEG analysis and the results of the sleep
state scoring, bringing both the classical EEG analysis and the spectral analysis together.
Highlighted  artefacts  were  also  stored,  with  their  time  locations,  giving  an  overall
picture of the individual patients’ results. It is from this database that both the entire
dataset for each patient was analysed, as well as the in-depth spectral analysis for each
individual patient.
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5.6 Summary
Software development was a major element of this project. Initial research of available
software  led  to  the  decision  to  develop  custom  software,  or  to  use  proprietary
applications. Where custom software was developed, recognised software engineering
processes  -  planning,  requirements,  development,  testing  and  distribution  -  were
followed wherever possible, so that the output was of an acceptably high standard with
optimal reliability.
By  writing  custom software,  I  gained  a  comprehensive  understanding  of  the  tools,
programming infrastructures, and software methodologies. This in turn led to a better
understanding of the strengths and weaknesses of analytical tools used elsewhere, as
well as a greater appreciation of the limitations of the commercially available packages.
The combination of software solutions employed enabled the appropriate acquisition,
processing, storage and analysis of the very large dataset used in this study.
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6 Study Design
6.1 Introduction
This chapter introduces all aspects of the study not covered in more detail in the later
chapters  on  ECG  or  EEG.  It  includes  the  study  protocol  and  description  of  the
recruitment, patient demographics and toxicology results. This study was run as part of
a larger study, entitled 'Vision in Drug dependent Infants' (VIDI), examining the effects
of methadone exposure upon visual development in infancy. The study described in this
thesis  incorporated  a  subset  of  subjects  from  the  VIDI  study  population  who
additionally  underwent  polysomnography.  Collaboration proved highly beneficial  for
both  studies;  patient  recruitment,  collection  of  urine  and  meconium  samples,  and
medical history were performed by Dr Laura McGlone (neonatal trainee who undertook
the VIDI study) and database design and development of custom analysis software for
the VIDI study were carried out by myself. 
6.1.1 Study Protocol
The study was undertaken in the neonatal unit at the Princess Royal Maternity (PRM) in
Glasgow. The hospital provides support for the majority of drug misusing women in the
area.  Drug-misusing  mothers  who  had  been  prescribed  substitute  methadone  in
pregnancy were approached, and asked for consent for inclusion in this study. Exclusion
criteria included significant prematurity (>36 weeks gestation), congenital abnormalities
and/or neonatal illness. 
The  investigation  followed  the  format  of  a  case/control  study  where  drug-exposed
neonates  were  compared  with  matched  unexposed  neonates,  following  the  same
exclusion criteria. To minimise the confounding effects of birth weight (±250 grams),
socio-economic  status  (socio-economic  DEPCAT group ±1;  (McLoone P.  2004) and
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gestation (completed week of gestation) revealed in a pilot study, control infants were
selected by these criteria. 
Ethics  approval  was  obtained  from  the  Glasgow  Royal  Infirmary  Research  Ethics
Committee prior to the start of the study (REC reference number 08.S0704.40), and
approved by the Greater Glasgow and Clyde Health Board (Project number YN 08 NN
325).  The study was conducted in compliance with the principles of 'Good Clinical
Practice'  (GCP).  Recruitment  started on the  15th  October  2008,  and ended on 30th
March 2010.
6.1.2 Recruitment of Subjects
Mothers of infants suitable for entry into the study were identified by Dr McGlone in
conjunction with the midwifery staff on the postnatal wards of the PRM. Interviews
were conducted with the attending midwife, and after a discussion describing the study,
mothers were given verbal and written details to consider if they wished to be enrolled.
If in agreement, a copy of the consent forms for both the mother and the study records
were signed, and a patient information sheet given. Copies of these consent sheets were
stored in the infants' notes, and kept as part of the study documentation. The mothers'
general practitioners were also informed that they had been enrolled in the study.
6.1.3 Data Collection
Infant  drug  exposure  during  pregnancy  was  determined  from  a  combination  of
confidential interview with the mother (all conducted by Dr McGlone), and review of
the maternal records including urine toxicology obtained during pregnancy (see below).
Details  concerning  smoking  and  alcohol  use  during  pregnancy  were  also  collected.
Socioeconomic  group  was  defined  using  the  Carstairs  DEPCAT  scoring  system
(McLoone P et al, 2004). This system uses data from the national 2001 census to define
geographical areas in relation to socio-economic groups. DEPCAT scores are based on
postcode, and defined by factors such as the presence of overcrowding, unemployment,
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car ownership, social class (based on occupation). The most affluent area has a score of
one, whereas the most socially deprived regions score seven.
Neonatal data collected included birth weight, gestation, sex, head size (occipito-frontal
circumference – OFC), Apgar scores at birth, method of delivery and method of feeding.
OFC was measured at the time of recording of electrophysiological data.
6.1.4 Assessment of NAS
NAS  severity  was  measured  during  the  neonates  stay  in  hospital,  including  any
necessary pharmacological treatment. NAS severity was assessed using the modified
Lipstiz  scoring method which is  routine practice at  the PRM  (Lipsitz,  1975).  Twice
daily  scoring  by  midwifery  staff  on  the  postnatal  ward  was  undertaken  with  two
consecutive scores determining a need for pharmacological treatment (see section 1.2).
All treatment was recorded as well as the duration of the neonates stay in hospital.
6.1.5 Confidentiality
To comply with both the NHS Greater Glasgow and Clyde policy on data protection and
the principles  of  GCP, study data  was stored in  a  password protected database (see
section  5.5.1). Enrolled subjects were given unique study numbers, with the look up
table of numbers to names being stored on paper in a locked filing cabinet at the PRM.
Access to the database was restricted to the users only.
6.1.6 Toxicology Assessment
In addition to maternal urine toxicology at 36 weeks' gestation, neonatal toxicology was
undertaken  by  analysis  of  urine  and  meconium (the  neonates  earliest  stool).  These
samples were collected during the electrophysiology recording session, and sent to the
appropriate laboratory for analysis. The urine samples were analysed by the regional
toxicology  laboratory  based  at  Gartnavel  General  Hospital  in  Glasgow.  The  Abbot
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enzyme multiplied immunoassay technique (EMIT) was used. The meconium samples
were analysed under the supervision of Dr Gail Cooper, based at the Department of
Forensic  Medicine  and  Science  at  the  University  of  Glasgow.  Enzyme-linked
immunosorbent assay screening plus phase and liquid-liquid extraction were used in
conjunction  with  gas  chromatography-mass  spectroscopy  to  detect  the  major  drug
groups including methadone exposure. This method also included detection of elevated
acid ethyl esters, indicative of prenatal alcohol exposure. A level greater than or equal to
10,000 nanograms/gram was used  to  indicate  excessive  alcohol  consumption during
pregnancy (Gareri et al., 2008). 
6.1.7 Combined Drug Exposure
The results of the toxicology assessment for both the mother and the neonate as well as
maternal medical case note review and confidential maternal interview were used to
establish an accurate picture of in utero drug exposure. Positive exposure was defined as
a positive result from any of the toxicology samples, or the maternal history. Prescribed
maternal methadone dose at delivery was also recorded. 
6.1.8 Electrophysiology Recording
Recordings were made within the first 48 hours of life including PSG and visual evoked
potentials.  This  is  described in  detail  in  section  7.2.1.  Following completion  of  the
recording the neonate was returned to his or her mother in the post natal ward, and the
mother  thanked  for  their  participation  in  the  study.  No  payment  was  made  to  any
participant. 
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6.2 Results
6.2.1 Excluded Data
Although 55 subjects were recruited into this study, only 45 were included in the final
analysis. 6 cases and 4 controls were excluded as polysomnography was not possible. A
more detailed account of the reasons why this is the case can be found in EEG results
section 7.3.1.
6.2.2 Neonatal and Maternal Demographics
A summary of the data collected for the neonate and maternal demographics is shown in
Table 10 and statistical comparisons between groups are also shown where necessary.
During recruitment, the neonates were frequency matched on birth weight (+/- 250g),
gestation and the maternal socio-economic status (DEPCAT score).
The other variables, when related to exposure, and a source of possible confounding
were tested using either Mann Whitney U tests, or Fischer exact tests depending on the
data type. As long as unmatched variables were similar they cannot be confounders. 
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Cases 
median (n=20)
Controls
median (n=25)
p-
value
CI (95%)
Neonatal Details
Sex (male/female) 9 (45%) / 11 (55%) 12 (48%) / 13 (52%) 0.84 (0.23, 3.63)
Birth weight (grams) 3078 3125 0.08 (-395, 318)
Gestation (weeks) 39.5 39.1 0.36 (-3.4, 1.0)
Head circumference – 
OFC (cm)
34.3 34.5 0.44 (-1.3,0.5)
5-min Apgar score 9 9 0.37 (-1,0)
Mode of Delivery
Spontaneous Vertex 
Delivery (SVD)
15 (75%) 17 (68%) Not related to exposure
Ventouse 2 (10%) 1 (4%) Not related to exposure
Lower Uterine Segment 
Caesarean Section 
(LUSCS) - Elective
1 (5%) 5 (20%) Not related to exposure
LUSCS - Emergency 1 (5%) 2 (8%) Not related to exposure
Other 1 (5%) 0 (0%) Not related to exposure
Feeding & Neonatal Length of Stay
Bottle/Formula 4 (20%) 3 (12%) Not related to exposure
Breast 14 (70%) 21 (84%) Not related to exposure
Mixed 2 (10%) 1 (4%) Not related to exposure
Length of Hospital Stay 
(days)
8.6 2.6 Not related to exposure
Maternal Details
Maternal Age 30 24 0.11 (-1.0,8.0)
Maternal Smoking 19 (95%) 14 (56%) 0.003 (5, 50)
Maternal BMI 24 25 0.39 (-6,2)
Maternal DEPCAT 7 5 0.31 (0, 2)
Maternal Alcohol 
consumption
2 (10%) 1 (4%) 0.16 (0.7, 12.0)
Table 10: Neonate and maternal demographic data. The table shows median values for the neonate,
covering delivery and  maternal information. Birth weight, gestation and socio-economic status were
all matched during recruitment (highlighted in bold). Other factors such as mode of delivery and
feeding were not related to the exposure. Where factors could be potential confounders, statistical
tests were performed comparing the two groups.
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Comparison of the two neonatal groups on the matched variables showed no statistical
difference for birth weight (cases 3078g vs controls 3125g; Mann-Whitney  p=0.08),
gestation   (cases  39.5  weeks  vs  controls  39.1  weeks;  Mann-Whitney  p=0.36)  and
maternal socio-economic status (DEPCAT score), (cases 7 vs controls 5; Fischer exact
p=0.31).
For  the  unmatched  variables,  no  significant  difference  was  shown  for  head
circumference (OFC), although the cases had marginally smaller heads (cases 34.3 cm
versus controls 34.5 cm; Mann-Whitney p=0.44) or Apgar scores (cases 9 vs controls 9;
Fischer exact p=0.37). Although not related to exposure, noticeable was that most of the
neonates,  cases  70%  (14/20)  vs  controls  84%  (21/25),  were  bottle  fed,  not  the
recommended breast fed.
A higher proportion of drug exposed mothers smoked during pregnancy (cases 19/20
95% verses  controls  14/25  56  %).  Although  this  may  be  indicative  of  lower  birth
weights (Abel, 1980), this was not evident in this dataset. 
Maternal BMI was marginally lower in the cases (24) vs controls (25); Mann-Whitney
p=0.39). Alcohol consumption during pregnancy was higher in the cases (10% 2/20) vs
controls (4% 1/25).
Length of stay of the cases was over three times greater (cases 8.6 days vs controls 2.6
days)  indicating  the  significant  increased  clinical  time  required  to  manage  these
neonates.
For a frequency matched case control study like this, there is no need to use matched-
pair analysis such as conditional logistic regression as there is no need to control for the
matching variables when they are not associated to the exposure, as they could not be
potential  confounders.  For  this  reason,  conditional  logistic  regression  was  not
performed including any of the matched variables. However, Table 10 shows that none
of the unmatched variables, that were related to exposure, were statistically different,
apart  from  smoking.  Consequently  a  comprehensive  logistic  regression  would  be
performed for any future publication of results, exploring the role of smoking in the
analysis.
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6.2.3 Drug Exposure Results
Details of drug exposure are shown in Table 11. All the neonates defined as cases had
been exposed to methadone  in utero. Other opioids (60%) and cannabis (55%) were
found in over half of the study subjects. Of the total number of cases, 5 (25%) were
exposed to methadone only, that is no trace of other exposure was found.
Exposure Type Number % of total (20)
Methadone 20 100
Other opioids 12 60
Benzodiazepines 11 55
Amphetamines 5 25
Cocaine 2 10
Cannabis 11 55
Table 11: Other drug exposure amongst the methadone-exposed group. All the cases had been
exposed to methadone.
6.2.4 NAS Assessment Results
NAS scores for the cases are shown in Table 12. 4 (20%) of these neonates went on to
require  pharmacological  treatment  for symptoms of  withdrawal.  This  value is  lower
than expected as it is more normal for around half of neonates exposed to methadone in
utero (Dryden  et  al.,  2009) to  show signs  of  NAS.  None  of  the  neonates  showed
evidence of seizure activity. 
Maximum NAS Score Number (n=20)
1-4 14
5 3
6-10 3
Table 12: Number of cases grouped by their NAS scores.
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6.3 Summary
The purpose of this chapter was to describe the study and the factors that potentially
affect  the  electrophysiology  that  will  be  covered  in  greater  depth  in  the  following
chapters. Of note, it is important to highlight that the two groups have been matched on
a number of factors making them comparable. Methadone is the common exposure to
all  of  the  cases,  and  none  of  the  controls.  Even  though  multi-drug  exposure  was
common amongst the cases, 25% had been exposed to methadone only, and no trace of
other drugs found.
155
7 EEG Experiments
7.1 Introduction
This chapter covers the methods of recording, interpreting and analysing the EEG data
then presents the findings.
7.2 Methods
7.2.1 PSG Experimental Set-up
The recordings were made within the Neonatal Unit at the Princess Royal Maternity
Unit, in Glasgow. The room used was small and windowless, with only minimal outside
noise, thus making it suitable for sleep studies. The room temperature was warm, to aid
the  neonate  sleeping,  and  kept  at  a  constant  level.  As  well  as  the  neonate  under
investigation, present during the recordings were medical physicist (Richard Boulton –
RB)  and  neonatologist  (Dr  Laura  McGlone  -  LMcG),  and  if  they  requested,  the
parents/guardians. The study status of the neonate i.e. methadone-exposed / unexposed,
was known prior to the recording. The neonate was then fed (if this had not happened
prior to the recording). A urine bag was attached to the neonate (by LMcG) so that a
sample could  be collected  after  the recording for  analysis.  Finally,  the neonate  was
swaddled, and helped to settle in the cot, in the supine position.
As the VIDI study involved two branches, visual and neurological, the visual part would
take place first, with the application of three scalp electrodes, followed by recirding of
flash and flicker visual evoked potentials (VEPs). On completion, the neonate was then
be prepared for one hour of polysomnography (by RB). This involved the application of
a full set of electrodes (as described below), necessary for a sleep study. Impedance
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measurements were made at the beginning and end of each recording, and the results
were embedded into the PSG recording.
The lights were dimmed, and when the neonate was suitably settled, recording of the
PSG began. The neonate was videoed for the duration of the recording to aid in the
visual interpretation of the sleep states at a later date. Frequent notes were also made,
highlighting  any  significant  factors  such  as  movement  or  artefacts,  that  may  affect
interpretation.
On completion of the recording, the lights were switched on again, and the electrodes
removed. Any urine sample collected, and meconium gathered beforehand was sent for
toxicological analysis, and the neonate was returned to its mother. The neonates were
given no medication prior to or during the recording. 
The equipment used for the polysomnography was the Xltek HD Ambulatory system
(model  EMU128FS  head  box).  This  is  a  portable  system  that  integrates  up  to  24
channels for data acquisition with video capability. It was used to record 12 channels of
EEG plus EOG, EMG, ECG and changes in respiration. EMG was included to measure
muscle activity under the jaw to indicate any sucking movement that is important in
sleep  state  identification.  Respiratory  measurements  were  performed  using  a
piezoelectric stress gauge wrapped around the neonates chest, and were used in sleep
state identification. An example of a neonatal set up for polysomnography is shown in
Figure 49.
The Xltek HD system was attached to a standard laptop PC running Microsoft Windows
XP as  the  operating  system,  and the  NeuroworksTM software  for  recording.  A more
comprehensive description of the NeuroworksTM software can be found in section 5.2.
Considering that the recordings included video, the sampling frequency was set to 256
Hz, giving a reasonable balance between resolution and file size. As each PSG was
approximately one hour in duration (including calibration and impedance testing), the
resulting file size was approximately 600 mega bytes (Mb) per recording session. 
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EEG Electrodes
The montage used was a standard neonatal montage, recommended by the American
Clinical  Neurophysiology  Societies  guidelines  for  continuous  EEG  monitoring  in
neonates (Shellhaas et al., 2011). The montage details are shown in Figure 50.
Figure 49: A settled infant during a PSG, showing the recording headbox (top left corner),
multiple electrodes, and a scalp net to hold the electrodes in place.
Figure 50: Montage details for neonatal PSG (from the NeuroworksTM software), in
accordance with the international 10-20 system.
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Firstly, the site for each electrode was cleaned using an alcohol swab and abraded with
NuPrep.  Silver-silver  chloride  electrodes  with  Ten20  conduction  paste  were  then
attached  to  the  scalp  and  held  in  place  with  a  gauze  material.  When  all  the  EEG
electrodes had been applied, and impedances tested, a scalp net was used to hold them
in place during the recording. 
Other electrodes
The ECG was recorded from three leads, attached in accordance with the modified three
electrode biopolar system, as described in section 3.2.2. They were attached on the right
(R) and left arms (L), and the left side of the abdomen (F) respectively. The resulting R
wave deflection was upwards. Using two disposable stick-on electrodes, muscle activity
(EMG) was recorded under the chin. Ocular activity (EOG) was recorded to identify
blink activity with the left electrode being placed above the outer canthus of the left eye,
and the right, below the outer canthus of the right eye. Finally, the respiratory band was
placed around the rib cage and above the nipple line. 
Pre-recording Filters
The Xltek trex headbox comes with a built in anti-aliasing filter. The filter cut-off is
40% of the sampling frequency (fs), or 80% of the Nyquist frequency. For a 256 Hz
sampling frequency, signals of frequencies higher than approximately 100 Hz would
have some degree of aliasing. The manufacturer's documentation shows that this was
the only filtering that occurs during the recording. Digital filtering was available whilst
viewing the recording e.g. notch, high and low pass filters. 
Signal Quality and Recording Practicalities
The Xltek headbox was calibrated prior to each recording session using the inbuilt test
signal  module,  which applied a  predefined set  of  test  signals  to the amplifiers,  and
examining the output for noise and drift. 
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Impedance  measurements  were  made using the  NeuroworksTM software  prior  to  the
onset of recording, and electrodes would be reapplied/altered if levels were greater than
10 kΩ.
Recording EEG in the neonates is difficult, and when they show the early signs of NAS
even more so. It was not unusual for sudden jerky movements (myoclonus) from the
neonate to detach an electrode whilst the neonate slept, requiring reapplication with the
potential for disturbance. To be able to capture all three sleep stages within one hour it
was  necessary  for  the  neonate  to  be  settled  throughout;  any  interference  with  the
recording could end the PSG. 
With  this  in  mind  it  was  common  for  impedance  levels  to  change  throughout  a
recording.  Wherever  possible,  the electrode would be reattached and the impedance
lowered,  but  at  the  risk  of  waking  up the  sleeping neonate.  If  levels  could  not  be
lowered  without  disturbing  the  neonate  significantly,  the  high  impedance  would  be
noted  and  excluded  from  the  later  analysis.  On  a  small  number  of  occasions  the
reapplication of electrodes woke the already agitated neonate so that no further sleep
measurements were possible. 
There  were  also  a  small  number  of  instances  when  a  neonate  did  not  sleep  at  all
throughout the recording session, thus making the data recorded unsuitable for analysis.
7.2.2 PSG Classical Interpretation
The  classical  interpretation  was  performed  by  inspection  by  paediatric  consultant
neurologist, Dr Mary O'Regan (Fraser of Allander Paediatric Neurosciences Unit, Royal
Hospital for Sick Children, Glasgow). The data recorded at the PRM was transferred via
an  encrypted  (Truecrypt  –  512 bit  -  Twofish-Serpent  encryption algorithm)  portable
hard drive, and uploaded to the Xltek server system. The data had no patient identifiers
embedded in it, and was only identifiable by the study number, thus Dr O'Regan was
unaware (blinded) to the exposure status of the neonate under investigation. 
The interpretation involved examining all channels of data in conjunction with the video
and notes, and identifying epochs of data for each of the three sleep states (active, quiet
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and indeterminate). By using the EEG, ECG and respiratory channels with the physical
appearance of the neonate (video), an estimate of the sleep stage was determined. The
characteristics of each sleep stage are described in the chapter on EEG (section 2.3.3).
These epochs were also deemed as artefact free, and ranged from seconds to minutes in
duration. It was these epochs on which the spectral analysis was based.
Although the entire  1  hour  of  PSG data for  each neonate was inspected it  was  not
always possible to identify epochs of suitable quality for analysis. In a small number of
recordings (n=10) no sections of sleep were identified because the neonate failed to
sleep, or was too agitated throughout the recording.
It was initially intended that the PSG would be scored for sleep stages and a hypnogram
constructed showing the sleep architecture of the neonate throughout the 1 hour period.
However, due to the challenges of recording as well as the agitated nature of some of
the neonates, Dr O'Regan reported that it would not be possible to construct complete
hypnograms, as they would contain too many missing segments. These segments would
be periods where it was not possible to define accurately what sleep stage that neonate
was in. For this reason, the EEG analysis was based on the epochs of artefact free data
only.
In total 56 1 hour recordings were interpreted and scored for sleep states.
7.2.3 PSG Spectral Analysis
The output  of  the  classical  interpretation  discussed  above was taken and a  spectral
analysis  performed.  This  derived  frequency  information  on  the  nature  of  the  EEG
signals under investigation. To do this, a spectral analysis application was written, with
a more comprehensive description to be found in section 5.4.1.  To be able to perform
this  analysis,  a  number  of  parameters  had  to  be  quantified,  before  each epoch was
analysed. 
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7.2.4 Spectral Analysis Parameters
Below is a summary of the parameters used with the EEG analysis software.
 4 second epochs, giving a frequency resolution of 0.25 Hz.
 A sampling frequency of 256 Hz, giving 1,024 data points per epoch.
 A power of 2 data points, so the data was not padded.
 No windowing/smoothing.
 No overlap.
 Output Analysis Parameters (Band Power and SEF 95%).
Band Power
As covered in section 4.5.1, the frequency of the signal can be broken down into four or
more ranges, categorised as delta, theta, alpha and beta. When the signal is transformed
from the time domain to the frequency domain using a discrete Fourier transformation
and a power spectrum established, these boundaries still apply. Consequently the band
power of the DFT is defined as the summation of the energy between two frequencies, f1
and f2 as shown in the Table 13.
Band Power f1 (Hz) f2 (Hz)
Delta 0.5 4
Theta 4 8
Alpha 8 12
Beta 12 30
Total Power 0.5 30
Table 13: EEG band power ranges from Tonner and Bein, (2006).
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However, the power spectrum is a representation of the power at each frequency bin,
which in turn is defined by the frequency resolution of the signal (equation 12).
Frequency Resolution= 1
Length of epoch ( s)
(12)
For example, if the epoch length was 4 seconds, the frequency resolution would be ¼ or
0.25 Hz. If the frequency resolution was 1 Hz, as would be the case for an example with
a 1 second epoch, it would not be possible to accurately resolve the lower boundary of
the  delta  power  range,  as  this  is  0.5  Hz.  So  to  be  able  to  resolve  the  lower  delta
boundary, an absolute minimum frequency resolution of 0.5 Hz is required.
Other Neonatal Studies Using Band Power
Table 14 shows a summary of a range of studies that all use band power as an output
variable.  It  highlights  the  lack  of  standardisation  between  studies,  in  that  fixed
boundaries for band power have not been established. Although most studies 'roughly'
follow the generalised version shown in Table 13, many establish their own boundaries
to highlight a specific neurological condition e.g. use of delta power in conjunction with
sigma power (a sub frequency of beta) for neonatal seizure detection.
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Author Subjects Year PSD
Type
Windowing Delta
(Hz)
Theta
(Hz)
Alpha
(Hz)
Beta
(Hz)
Total
Power
(Hz)
Scher et al. Neonates
term &
Preterm
1997 DFT Kaiser 0.5-4 4-8 8-13 13-22 0.5-22
Scher et al. Neonates
term &
Preterm
1994 DFT Kaiser 0.5-4 4-8 8-13 13-22 0.5-22
Okumura et
al.
Preterm
Neonates
2006 DFT None - 4-6 & 6-
8
8-13 13-20 &
20-30
-
Paul et al. Neonates 2003 DFT None 0.5-1.5
& 1.6-3
3.1-5 &
5.1-8
8.1-14 - -
Bell et al. Neonates 1991 DFT 10%
Hanning
0.3-1 &
2-3
4-7 8-13 14-30 0.3-30
Schramm
et al.
Neonates
term &
Preterm
2000 DFT None 0.4-1.5
& 1.5-
3.5
3.5-7.5 7.5-
12.5
12.5-
19.5 &
19.5-25
0.4-25
Ktonas et
al.
Infants 1995 DFT Cosine 0.5-1.5 - - 11.5-
15.5
-
Victor et al. Preterm
Neonates
2005 DFT None 0.5-3.5 4-7.5 8-12.5 13-30 0.5-30
Fagioli et
al.
Infants 1999 DFT None 0.5-1.5 - - 11.5-
15.5
-
Drummund
et al.
Adult 1991 DFT None 0-4 - 8-20
(alpha+beta
/delta)
0-20
Table 14: A summary of multiple studies that use spectral band power output. This table compares
studies involving preterm, neonates or infants, and highlights the differences in band power ranges
used between studies. It also shows if any windowing of the data was performed and the window
function used.
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Spectral Edge Frequency (SEF)
Table 15 is a summary of a selection of papers that used spectral edge in their analysis.
It can be seen that the parameters for SEF vary from study to study, making comparison
between studies difficult. The ranges are also dependent on the analogue filter settings
(if used) of the study. If a high pass filter was used for example, there would be no
reason to have a lower SEF boundary of zero, as the filtering would remove the power
at these very low frequencies. However, if no high pass filter is applied, then the trace is
at risk of being contaminated by drift and DC offset. If no low pass filter is applied then
the  trace  is  at  risk  of  contamination  from  high  frequency  artefact  such  as  EMG
(Whitham et al., 2007). 
A compromise is to have a lower SEF boundary just above the high pass filter setting,
so that very low frequency artefacts are removed i.e. 0.3 Hz, and a low pass filter setting
of 35 Hz to remove higher frequency contamination. Considering the roll off of the 0.3
Hz high pass filter, a sensible setting for the SEF would be 0.5 Hz. Consequently, the
SEF calculations for this study were based on a spectrum of 0.5 – 30 Hz. Also by using
this range, results could be compared with the study performed by  Bell et al., (1991)
which is considered the most comprehensive application of SEF in neonates.
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Author Subject Year Epoch
Length
(sec)
Data
Points
Frequency
Resolution (Hz)
SEF % SEF
Low
(Hz)
SEF
High
(Hz)
Bell et al. Neonates 1991 4 512 0.25 95 0.3 30
Korotchikova
et al.
Neonates 2009 4 1024 0.25 90 0.5 32
Doyle et al. Neonates 2007 4 1024 0.25 90
0 1
1 4
4 30
2 20
Drummond
et al.
Adult 1991 4
Not
known
0.25 90 0 20
Greene et al.
Neonates 2008 2 512 0.5 90
0.5 20
0.5 32
2 20
Fell et al. Adult 1996 Not
known
1000 Not known 90 0.5 45
Inder et al. Neonates 2002 4 1024 0.25 90 2 20
Kobayashi et
al.
Neonates/
Infants
2011 1 500 1 90 0 20
Miyashita et
al.
Adult 2003 2 256 0.5 50, 90
& 95
? ?
Sleigh et al. Adult 1999 5 Not
known
0.2 95 5 30
Thordstein et
al.
Neonates 2004 Not
known
1024 Not known 95 0 30
Victor et al. Preterm
Neonates
2005 2 512 0.5 95 0.5 30
Wong et al. Neonate 2006 60 24,000 0.1667 90 2 20
West et al. Preterm
Neonates
2006 4 1024 0.25 90 2 20
Table 15: A summary table showing a number of different studies and the variation used in spectral
edge parameters. It highlights that there is considerable variation in the spectral edge frequency used
(50%-95%), with varying boundaries for total power (0-30Hz), highlighting the difficulty in having
a standardised value for comparison with other studies.
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7.2.5 Filters
As discussed earlier, the Xltek recording system only applies an anti-aliasing filter (if
necessary,  and  dependent  on  the  sampling  frequency)  whilst  the  recording  is  being
made, so no other filters are used. Raw EEG signals have amplitudes in the microvolt
range, and can contain frequency information up to 300 Hz. However, it is more normal
in the neonatal sleep EEG to examine a much lower frequency range such as 0.1 Hz to
35/70 Hz.
Using high pass filters, the lower boundary is often between 0.3 and 1.0 Hz  (Butkov et
al., 2007) to eliminate slow frequency artefacts such as those caused by perspiration,
breathing or  'popping artefacts'  (direct  pressure against  an electrode).  Guidelines  on
neonatal EEG advise the use of low frequency filters between 0.25 and 0.5 Hz to avoid
affecting low frequency signals  (Scher, 1996). However, studies by  Thordstein et al.,
(2005) and  Vanhatalo et  al.,  (2002) showed that  even these settings would remove
valuable information about  infra-slow EEG activity.  For  these reasons no high pass
filter was applied to the study data, because of the uncertainty of the effect it would
have on the low-frequency data. This is the approach used by  Doyle et al., (2007) in
their EEG investigations. 
As the analysis was based on FFTs, if the beginning and the end of the epochs differed
in amplitude significantly, the algorithm would introduce a degree of spectral leakage.
As it has already been stated, windowing (tapering) was not used in this analysis; de-
trending methods were used instead.  This involves removing the mean value of the
epoch from the vector under analysis, and is commonly used in FFT processing. The
result  is  that  very  low  frequencies,  such  as  drift,  are  removed  from  the  epoch.
Consequently this has a similar effect to the removal of low frequency signals by the
application  of  a  high  pass  filter,  but  without  loss  of  very  low  frequencies  while
minimising discontinuities of the start/end amplitudes within the epoch and therefore
introducing spectral leakage. The application of trend removal to an unfiltered signal
was considered the least destructive approach, so this was the approach used.
The main spectral output from which other variables were derived (such as band power
and SEF) is total power (TP), with a band width of 0.5-30Hz. If a low pass filter had
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been used, it would have had to have a very steep roll off close to the 30 Hz boundary,
or it may have affected the top end of the total power calculation. This would have
meant that large artefacts just above the 30Hz boundary would have negatively affected
the TP calculation, but as the epochs selected were identified as being 'artefact' free, a
low pass filter was not considered necessary. 
7.2.6 Mains Filtering & Notch Filters
Mains interference (50/60 Hz) can contaminate EEG signals. The cause is often a poor
connection  between  the  electrode  and the  scalp,  and  is  usually  rectified  by  the  re-
application of the electrode. However, in polysomnography where long recordings (1 –
24 hours) are normal, it is not uncommon to have mains interference at some point. It is
not recommended to apply a mains filter whilst recording, but it is desirable to have the
option to view data without mains interference after the recording when inspecting the
data. The standard way of doing this is by using a notch filter, or a bandpass filter with
steep roll off before and after the frequency to be removed e.g. 47 Hz and 53 Hz. The
application of  a  notch  filter,  especially  a  high order  filter,  can introduce  significant
phase distortion between channels, and should be used sparingly.
Since this study was based on spectral analysis, an investigation was made examining
the effect of applying a notch filter prior to the recording of the data. The national grid
keeps the mains frequency in the UK at approximately 50 Hz, and is a sine wave. The
normal operating tolerance is +/- 0.2 Hz (49.8-50.2 Hz), although the national grid is
obliged to maintain the tolerance between +/- 0.5 Hz (49.5-50.5 Hz). The daily mains
frequency is recorded, and can be found at the following website:
 www.nationalgrid.com/uk/Electricity/Data/Realtime
On examining study data where there was mains interference present, the frequency
appeared to span a number of frequency bins between 47-53 Hz despite the tolerance for
the  national  grid  being  at  worst  +/-  0.5 Hz,  giving  a  spread of  only 49.5-50.5 Hz.
Consequently,  the apparent  spread of energy was due to  spectral  leakage caused by
truncating the sine wave, rather than a drift in the mains source frequency. 
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This study examines data between the range of frequencies 0 to 30 Hz, and for EEG
analysis  is  called  Total  Power  (TP).  The  application  of  a  50  Hz  notch  filter  will
therefore have no effect on the frequencies that make up the TP band as any effect of
leakage does not spread far enough to contaminate the TP band. Experimental evidence
showed that unfiltered spectra values do not differ when a zero-phase 50 Hz notch filter
is applied.
7.2.7 Data Management and the Processing of Data
The EEG analysis software had two main roles: to analyse individual 4 second epochs,
then to  average groups of four together in the frequency domain e.g.  4 x 4 second
epochs giving 16 second epochs. This was the analysis for each channel, so a short
program was written to create 16 second epochs across all 12 EEG channels. This data
formed the results for that sleep state and were stored in a spreadsheet. When all the
epochs had been analysed, they were then imported into the VIDI database to re-link the
results with the demographic and exposure data. Finally the re-linked data was stratified
by a user definable variable e.g. case / quiet sleep.  Figure 51 shows the process in its
entirety.
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The final dataset was prepared using Microsoft Access, and cleaned using a spreadsheet
(LibreCalc  4.1)  before  statistical  analysis,  performed  using  the  R  statistical
programming language  (R Core Team, 2013) in conjunction with the R-Commander
(Fox, 2005) graphical user interface.
Figure 51: The overall work flow showing the stages from extracting data from the PSG to the final
statistical analysis.
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7.3 Results and Analysis
7.3.1 Excluded Data
The  dataset  had  55  subjects  consisting  of  26  cases  and  29  controls.  However,  as
described earlier,  a number of the PSGs could not be used for analysis. In total,  10
complete PSGs (6 cases, 4 controls) were excluded from the overall EEG analysis for
the reasons shown in Table 16.
Study 
Number
Status Reason
42 Case The neonate was very unsettled, PSG not scored.
43 Case EEG abandoned. The neonate was very unsettled.
47 Case Montage problems during the recording.
64 Case No sleep stages identified. Sleep not achieved.
65 Control Persistent artefact on T4-O2 and FP1-T3, not suitable for spectral 
analysis.
68 Case No sleep stages identified.
74 Case High level of artefact throughout recording.
79 Control Persistent artefact on O1, not suitable for spectral analysis, no 
sleep stages marked.
95 Control Sleep not achieved.
145 Control Sleep not achieved, very unsettled neonate.
Table 16: Reasons why certain study neonates were excluded from the analysis.
Sleep Outliers
A small number (n=5) of sections were removed because of artefact on sections that had
been scored. The likely reason was artefact of significantly large amplitude on one or
two channels which skewed the overall average of the epoch. The sections removed
from the final analysis are shown in Table 17.
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Study Number Sleep State Reason
48 QS Excessively high power values caused by artefact.
59 IS Excessively high power values caused by artefact.
82 QS Excessively high power values caused by artefact.
94 IS Excessively high power values caused by artefact.
102 AS Excessively high power values caused by artefact.
Table 17: Sleep epochs removed from the analysis due to artefact.
After removal of these results, the dataset consisted of 45 subjects (20 cases and 25
controls). Although all 45 subjects had an hour of polysomnography it was not possible
to identify all three sleep  states for any of the subjects. Figure 52 Shows the percentage
of identifiable sleep states for each study group.   Not one of the 45 neonates achieved
all three sleep stages during their PSG.
Figure 52: The distribution of epochs by sleep state. This graph shows that for each sleep state it was
not possible to identify all three sleep states for each infant, either because such states did not occur
during the one hour of PSG, or because they could not be defined with any degree of accuracy. For
example, 70% of the cases had at least one epoch of quiet sleep identified during the recording.
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7.3.2 Statistical Analysis
The final statistical analysis for the EEG parameters was based on the dataset of 45
neonates. The choice of statistical test was based on two methods, visual inspection of
the histograms and the results of the Shapiro-Wilk normality tests  (Shapiro and Wilk,
1965).  The  tests  then  compared  the  cases  and  controls  based  on  the  sleep  state
identified. The Shapiro-Wilk test indicates a degree of normality when the p-value is
greater or equal to 0.05. The 'W' score is the test statistic and the results are shown
below.
Normality Testing for Controls
Active Sleep Quiet Sleep Indeterminate
Sleep
Variable W Score p-value W Score p-value W Score p-value
Absolute Delta Power (V2/Hz) 0.70 0.00 0.87 0.02 0.94 0.26
Absolute Theta Power (V2/Hz) 0.63 0.00 0.94 0.27 0.56 0.00
Absolute Alpha Power (V2/Hz) 0.63 0.00 0.92 0.13 0.78 0.00
Absolute Beta Power (V2/Hz) 0.67 0.00 0.85 0.01 0.75 0.00
Absolute Total Power (V2/Hz) 0.70 0.00 0.88 0.01 0.75 0.00
Relative Delta Power (%) 0.95 0.45 0.94 0.31 0.57 0.00
Relative Theta Power (%) 0.95 0.44 0.97 0.70 0.98 0.97
Relative Alpha Power (%) 0.95 0.45 0.84 0.00 0.98 0.94
Relative Beta Power (%) 0.95 0.56 0.90 0.05 0.93 0.12
SEF 95% (5-30 Hz) 0.97 0.77 0.88 0.02 0.86 0.01
SEF 95% (2-20 Hz) 0.94 0.34 0.95 0.35 0.89 0.03
Absolute Delta Low Power (V2/Hz) 0.71 0.00 0.86 0.01 0.94 0.22
Absolute Delta High Power (V2/Hz) 0.63 0.00 0.98 0.91 0.56 0.00
Relative Delta Low Power (%) 0.96 0.69 0.99 0.98 0.75 0.00
Relative Delta High Power (%) 0.93 0.23 0.96 0.56 0.97 0.71
Table 18: Shapiro-Wilk (1965) normality tests of controls for the EEG variables. A p-value greater
than 0.05 indicates an adequate normality of the distribution. The table shows that not every variable
is normally distributed. Bold text indicates normally distributed data.
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Normality Testing for Cases
Active Sleep Quiet Sleep Indeterminate
Sleep
Variable W Score p-value W Score p-value W Score p-value
Absolute Delta Power (V2/Hz) 0.65 0.00 0.97 0.89 0.60 0.00
Absolute Theta Power (V2/Hz) 0.67 0.00 0.91 0.15 0.53 0.00
Absolute Alpha Power (V2/Hz) 0.68 0.00 0.93 0.29 0.52 0.00
Absolute Beta Power (V2/Hz) 0.68 0.00 0.90 0.12 0.51 0.00
Absolute Total Power (V2/Hz) 0.65 0.00 0.97 0.87 0.59 0.00
Relative Delta Power (%) 0.93 0.36 0.94 0.38 0.95 0.42
Relative Theta Power (%) 0.95 0.56 0.85 0.02 0.98 0.96
Relative Alpha Power (%) 0.94 0.51 0.81 0.01 0.96 0.59
Relative Beta Power (%) 0.93 0.38 0.85 0.02 0.96 0.55
SEF 95% (5-30 Hz) 0.97 0.91 0.86 0.03 0.96 0.65
SEF 95% (2-20 Hz) 0.85 0.04 0.95 0.54 0.97 0.73
Absolute Delta Low Power (V2/Hz) 0.65 0.00 0.97 0.91 0.60 0.00
Absolute Delta High Power (V2/Hz) 0.68 0.00 0.93 0.27 0.53 0.00
Relative Delta Low Power (%) 0.97 0.77 0.96 0.72 0.95 0.50
Relative Delta High Power (%) 0.91 0.20 0.95 0.61 0.92 0.12
Table 19: Shapiro-Wilk (1965) normality tests of cases for the EEG variables. A p-value greater than
0.05 indicates an adequate normality of the distribution. The table shows that not every variable is
normally distributed. Bold text indicates normally distributed data.
The results of the normality tests and the visual inspection of the histograms show there
is a combination of both normally distributed and non-normally distributed data. To be
able to use statistical tests such as t-tests, an adequate degree of normality is required.
Although a number of parametric transformations were tried to normalise the data (logs,
square root and squared) there were still problems of skewness, making parametric tests
unsuitable.
For these reasons non-parametric tests were used instead. The Mann-Whitney U test
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(also called the Wilcoxon rank sum test) is a non-parametric alternative to t-tests, where
medians are used as opposed to mean values. Where a statistically significant result was
found, Bonferroni corrections were then applied to the Mann-Whitney results to deliver
a  more  conservative  estimate  of  the  statistical  significance  of  the  difference  in  the
medians.
7.3.3 EEG Frequency Domain Results
The results  of  the  EEG spectral  analysis  follows.  Each variable  has  been presented
graphically  for  visual  comparison using  box plots,  and also  in  a  table  showing the
results of the Mann-Whitney test. Although absolute band power results are not usually
presented in publications due to the large variability in potential amplitudes, they are
presented here for completeness. Also the total power band power estimate, which is a
commonly used output variable, is based on these absolute values. Relative band power
values are more frequently presented as band power divided by the total band power,
and are therefore more suitable when amplitudes vary considerably.
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Absolute Delta (0-4 Hz) Band Power
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (V2/Hz) n Median (V2/Hz)
Active 13 1499 18 1382 0.24 (-312, 2141)
Indeterminate 17 1268 20 1132 0.27 (-123, 716)
Quiet 14 1687 19 1370 0.65 (-320, 582)
Table 20: Results of Mann-Whitney U tests comparing absolute delta band power for cases and
controls for each sleep state.
No statistical difference was found between the absolute delta power medians for any
sleep state, indicating that there was no difference identifiable between the study groups
using this statistical methodology. 
Figure 53: Box plots for absolute delta (0-4 Hz) band power for all three sleep states, with cases shown in
grey. The top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively, while the
whiskers show Q1 or Q3 ±1.5 of the interquartile range. The black line within the box indicates the
median value and outliers are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS: quiet
sleep.
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Absolute Delta (Low: 0-2 Hz) Band Power
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (V2/Hz) n Median (V2/Hz)
Active 13 1377 18 1251 0.25 (-319, 1599)
Indeterminate 17 1140 20 1048 0.31 (-143, 674)
Quiet 14 1528 19 1212 0.63 (-285, 534)
Table 21: Results of Mann-Whitney U tests comparing absolute delta low (0-2 Hz) band power for
cases and controls for each sleep state.
As for absolute delta power, no statistical difference was found between the absolute
delta  (low)  power  medians  for  any  sleep  state,  again  indicating  no  difference
identifiable between the study groups using this methodology. 
Figure 54: Box plots for absolute delta low (0-2 Hz) band power for all three sleep states, with cases
shown in grey. The top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively,
while the whiskers show Q1 or Q3 ±1.5 of the interquartile range. The black line within the box indicates
the median value and outliers are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS:
quiet sleep.
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Absolute Delta (High: 2-4 Hz) Band Power
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (V2/Hz) n Median (V2/Hz)
Active 13 147 18 105 0.13 (-15, 169)
Indeterminate 17 129 20 96 0.17 (-12, 71)
Quiet 14 138 19 141 0.73 (-33, 51)
Table 22: Results of Mann-Whitney U tests comparing absolute delta high (2-4 Hz) band power for
cases and controls for each sleep state.
Once again, no statistical difference was found between the absolute delta (high) power
medians for any sleep state, indicating that there was no difference identifiable between
the study groups using this statistical methodology. 
Figure 55: Box plots for absolute delta high (2-4 Hz) band power for all three sleep states, with cases
shown in grey. The top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively,
while the whiskers show Q1 or Q3 ±1.5 of the interquartile range. The black line within the box indicates
the median value and outliers are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS:
quiet sleep.
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Absolute Theta (4-8 Hz) Band Power
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (V2/Hz) n Median (V2/Hz)
Active 13 62.2 18 54.9 0.18 (-5.7, 131.9)
Indeterminate 17 69.2 20 49.7 0.048 (0.1, 40.8)
Quiet 14 71.9 19 65.8 0.46 (-7.8, 20.9)
Table 23: Results of Mann-Whitney U tests comparing absolute theta band power for cases and
controls for each sleep state.
Although a small, statistically significant difference was found between the cases and
controls for intermediate sleep, that difference was no longer present when a Bonferroni
correction  was  applied.  The  other  sleep  stages  were  shown  to  not  be  statistically
significant using this technique.
Figure 56: Box plots for absolute theta (4-8 Hz) band power for all three sleep states, with cases shown in
grey. The top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively, while the
whiskers show Q1 or Q3 ±1.5 of the interquartile range. The black line within the box indicates the
median value and outliers are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS: quiet
sleep.
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Absolute Alpha (8-12 Hz) Band Power
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (V2/Hz) n Median (V2/Hz)
Active 13 20.1 18 17.9 0.59 (-6.7, 49.1)
Indeterminate 17 16.7 20 14.5 0.60 (-3.7, 6.8)
Quiet 14 17.5 19 17.4 0.74 (-3.6, 5.1)
Table 24: Results of Mann-Whitney U tests comparing absolute alpha band power cases and controls
for each sleep state
No statistical difference was found between the absolute alpha power medians for any
sleep state. This indicates that there was no difference identifiable between the study
groups using this statistical methodology. 
Figure 57: Box plots for absolute alpha (8-12 Hz) band power for all three sleep states, with cases shown
in grey. The top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively, while the
whiskers show Q1 or Q3 ±1.5 of the interquartile range. The black line within the box indicates the
median value and outliers are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS: quiet
sleep.
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Absolute Beta (12-30 Hz) Band Power
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (V2/Hz) n Median (V2/Hz)
Active 13 20.1 18 17.9 0.24 (-3.3, 45.2)
Indeterminate 17 16.7 20 14.5 0.18 (-2.0, 8.9)
Quiet 14 17.5 19 17.4 0.55 (-2.5, 4.1)
Table 25: Results of Mann-Whitney U tests comparing absolute beta band power cases and controls
for each sleep state.
Again, no statistical difference was found between the absolute beta power medians for
any sleep state.  This  indicates  that  there was no difference identifiable  between the
study groups using this statistical methodology. 
Figure 58: Box plots for absolute beta (12-30 Hz) band power for all three sleep states, with cases shown
in grey. The top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively, while the
whiskers show Q1 or Q3 1.5 of the interquartile range. The black line within the box indicates the
median value and outliers are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS: quiet
sleep.
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Absolute Total (0-30 Hz) Band Power
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (V2/Hz) n Median (V2/Hz)
Active 13 1587 18 1489 0.24 (-318, 2476)
Indeterminate 17 1372 20 1201 0.23 (-131, 772)
Quiet 14 1794 19 1477 0.65 (-349, 616)
Table 26: Results of Mann-Whitney U tests comparing absolute total (0-30 Hz) band power for cases
and controls for each sleep state.
No statistical difference was found between the absolute total power medians for any
sleep state again indicating that there was no difference identifiable between the study
groups using this statistical methodology. 
Figure 59: Box plots for absolute total power (0-30 Hz) band power for all three sleep states, with cases
shown in grey. The top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively,
while the whiskers show Q1 or Q3 ±1.5 of the interquartile range. The black line within the box indicates
the median value and outliers are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS:
quiet sleep.
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Relative Delta (0-4 Hz) Band Power
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (%) n Median (%)
Active 13 89 18 90 0.89 (-2.22, 2.06)
Indeterminate 17 91 20 91 0.15 (-1.88, 0.48)
Quiet 14 92 19 92 0.91 (-1.42, 1.36)
Table 27: Results of Mann-Whitney U tests comparing relative delta band power for cases and
controls for each sleep state.
No statistical difference was found between the relative delta power medians for any
sleep state. This indicates that there was no difference identifiable between the study
groups using this methodology. 
Figure 60: Box plots for relative delta power (0-4 Hz) band power for all three sleep states, with cases
shown in grey. The top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively,
while the whiskers show Q1 or Q3 ±1.5 of the interquartile range. The black line within the box indicates
the median value and outliers are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS:
quiet sleep.
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Relative Delta Low (0-2 Hz) Band Power
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (%) n Median (%)
Active 13 81.3 18 80.2 0.77 (-2.89, 3.35)
Indeterminate 17 81.0 20 81.2 0.70 (-3.02, 1.54)
Quiet 14 81.6 19 82.3 0.77 (-3.20, 2.34)
Table 28: Results of Mann-Whitney U tests comparing relative delta low band power for cases and
controls for each sleep state.
No statistical difference was found between the relative low delta power medians for
any sleep state again indicating that there was no difference identifiable between the
study groups using this methodology. 
Figure 61: Box plots for relative low delta power (0-2 Hz) band power for all three sleep states, with
cases shown in grey. The top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile
respectively, while the whiskers show Q1 or Q3 ±1.5 of the interquartile range. The black line within the
box indicates the median value and outliers are shown by small circles. AS: active sleep; IS:
indeterminate sleep; QS: quiet sleep.
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Relative Delta High (2-4 Hz) Band Power
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (%) n Median (%)
Active 13 9.71 18 9.67 0.86 (-1.21, 1.22)
Indeterminate 17 9.68 20 9.61 0.84 (-1.44, 1.21)
Quiet 14 9.90 19 9.74 0.65 (-1.50, 2.16)
Table 29: Results of Mann-Whitney U tests comparing relative delta high band power for cases and
controls for each sleep state.
No statistical difference was found between the relative high delta power medians for
any sleep state.  This  indicates  that  there was no difference identifiable  between the
study groups using this methodology. 
Figure 62: Box plots for relative high delta power (2-4 Hz) band power for all three sleep states, with
cases shown in grey. The top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile
respectively, while the whiskers show Q1 or Q3 ±1.5 of the interquartile range. The black line within the
box indicates the median value and outliers are shown by small circles. AS: active sleep; IS:
indeterminate sleep; QS: quiet sleep.
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Relative Theta (4-8 Hz) Band Power
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (%) n Median (%)
Active 13 5.86 18 5.10 0.72 (-0.87, 1.39)
Indeterminate 17 6.12 20 5.23 0.05 (-0.02, 1.64)
Quiet 14 5.56 19 5.30 0.99 (-0.36, 0.33)
Table 30: Results of Mann-Whitney U tests comparing relative theta band power for cases and
controls for each sleep state.
No statistical difference was found between the relative theta power medians for any
sleep  state,  although  relative  theta,  as  for  absolute  theta  was  closest  to  having  a
statistical  significance.  However  these results  still  indicate  no difference identifiable
between the study groups using this statistical methodology. 
Figure 63: Box plots for relative theta power (4-8 Hz) band power for all three sleep states, with cases
shown in grey. The top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively,
while the whiskers show Q1 or Q3 ±1.5 of the interquartile range. The black line within the box indicates
the median value and outliers are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS:
quiet sleep.
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Relative Alpha (8-12 Hz) Band Power
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (%) n Median (%)
Active 13 1.98 18 1.73 0.41 (-0.28, 0.54)
Indeterminate 17 1.76 20 1.52 0.42 (-0.14, 0.42)
Quiet 14 1.22 19 1.34 0.99 (-0.36, 0.33)
Table 31: Results of Mann-Whitney U tests comparing relative alpha band power for cases and
controls for each sleep state.
No statistical difference was found between the relative alpha power medians for any
sleep state, once again indicating that there was no difference identifiable between the
study groups using this methodology. 
Figure 64: Box plots for relative alpha power (8-12 Hz) band power for all three sleep states, with cases
shown in grey. The top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively,
while the whiskers show Q1 or Q3 ±1.5 of the interquartile range. The black line within the box indicates
the median value and outliers are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS:
quiet sleep.
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Relative Beta (12-30 Hz) Band Power
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (%) n Median (%)
Active 13 1.90 18 2.29 0.36 (-0.97, 0.36)
Indeterminate 17 2.03 20 1.75 0.76 (-0.40, 0.42)
Quiet 14 1.17 19 1.34 0.99 (-0.36, 0.33)
Table 32: Results of Mann-Whitney U tests comparing relative beta band power for cases and
controls for each sleep state.
As before, no statistical difference was found between the relative beta power medians
for any sleep state, again indicating that there was no difference identifiable between the
study groups using this methodology. 
Figure 65: Box plots for relative beta power (12-30 Hz) band power for all three sleep states, with cases
shown in grey. The top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively,
while the whiskers show Q1 or Q3 ±1.5 of the interquartile range. The black line within the box indicates
the median value and outliers are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS:
quiet sleep.
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Average Spectral Edge Frequency (0.5-30 Hz)
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (Hz) n Median (Hz)
Active 13 28.5 18 28.7 0.51 (-0.76, 0.46)
Indeterminate 17 28.3 20 28.7 0.26 (-0.94, 0.25)
Quiet 14 27.9 19 28.4 0.34 (-0.91, 0.41)
Table 33: Results of Mann-Whitney U tests comparing spectral edge frequency (0.5-30 Hz) for cases
and controls for each sleep state.
None of the comparisons  showed a statistical difference. Bell et al., (1991), showed the
SEF 95% for healthy term neonates was 22.4 – 26 Hz during active sleep. This study
shows  higher  medians  for  SEF 95% indicating  that  the  total  power  between  these
frequencies is more dispersed than for the Bell et al., (1991) study i.e. more activity in
the higher frequency ranges (theta, alpha and beta), suggesting that these study neonates
do not reach the same depth of sleep compared with healthy neonates. 
Figure 66: Box plots for spectral edge frequency 95% (0.5-30 Hz) band power for all three sleep states,
with cases shown in grey. The top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile
respectively, while the whiskers show Q1 or Q3 ±1.5 of the interquartile range. The black line within the
box indicates the median value and outliers are shown by small circles. AS: active sleep; IS:
indeterminate sleep; QS: quiet sleep.
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Average Spectral Edge Frequency (2-20 Hz)
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (Hz) n Median (Hz)
Active 13 18.9 18 19.1 0.15 (-0.47, 0.10)
Indeterminate 17 18.7 20 18.7 0.70 (-0.20, 0.40)
Quiet 14 18.5 19 18.7 0.35 (-0.59, 0.22)
Table 34: Results of Mann-Whitney U tests comparing spectral edge frequency (2-20 Hz) for cases
and controls for each sleep state.
In this analysis, SEF 95% for 2-20 Hz showed no statistical difference between groups.
This range is more suitable for electrically noisy environments such as NICU, so the
passband is not as wide as the method suggested by Bell et al., (1991). However delta
activity is the predominant frequency in the sleeping neonate (Scher, 1996), so to have a
cut off at 2 Hz loses all low frequency band power (0-2 Hz).
Figure 67: Box plots for spectral edge frequency 95% (2-20 Hz) band power for all three sleep states,
with cases shown in grey. The top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile
respectively, while the whiskers show Q1 or Q3 ±1.5 of the interquartile range. The black line within the
box indicates the median value and outliers are shown by small circles. AS: active sleep; IS:
indeterminate sleep; QS: quiet sleep.
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7.3.4 EEG Frequency Domain Median Comparisons
The tables that follow (tables  35,  36 and 37) highlight the relative difference between
each variable, as a guide to how they differ from each other. Their purpose is to show
any large differences when the previous statistical analysis has shown none. The method
of calculating the percentage median is shown in equation  13, with the results of the
comparison shown below.
Relative Difference=(Case Median−Control Median)
Case Median
×100 (13)
EEG Frequency Domain Median Comparison for Active Sleep
Variable Cases
(n=20)
Controls
(n=25)
Relative
Difference (%)
Absolute Delta Power  0-4 Hz (V2/Hz) 1499 1382 7.8
Absolute Delta Low Power  0-2 Hz (V2/Hz) 1377 1251 9.2
Absolute Delta High Power  2-4 Hz (V2/Hz) 147 105 28.6
Absolute Theta Power 4-8 Hz (V2/Hz) 62 55 11.3
Absolute Alpha Power  8-12 Hz (V2/Hz) 20 18 10.0
Absolute Beta Power 12-30 Hz (V2/Hz) 20 18 10.0
Absolute Total Power (V2/Hz) 1587 1489 6.2
Average SEF 95% (0.5-30 Hz) Hz 28.5 28.7 -0.7
Average SEF 95% (2-20 Hz) Hz 18.9 19.1 -1.1
Table 35: Relative differences in median values between cases and controls for active sleep. In all
but one of the variables, the cases median values were higher than the controls, especially in the high
delta band (2-4 Hz), highlighted in bold. A positive percentage difference indicates that the cases
have higher medians than the controls. 
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EEG Frequency Domain Median Comparison for Indeterminate Sleep
Variable Cases
(n=20)
Controls
(n=25)
Relative
Difference (%)
Absolute Delta Power 0-4 Hz (V2/Hz) 1268 1132 10.7
Absolute Delta High Power  2-4 Hz (V2/Hz) 1140 1048 8.1
Absolute Delta Low Power 0-2 Hz (V2/Hz) 129 96 25.6
Absolute Theta Power 4-8 Hz (V2/Hz) 69 50 27.5
Absolute Alpha Power 8-12 Hz (V2/Hz) 17 15 11.8
Absolute Beta Power  12-30 Hz (V2/Hz) 17 15 11.8
Absolute Total Power 0-30 Hz (V2/Hz) 1372 1201 12.5
Average SEF 95% (0.5-30 Hz) Hz 28.3 28.7 -1.4
Average SEF 95% (2-20 Hz) Hz 18.7 18.7 0
Table 36: Relative differences in median values between cases and controls for indeterminate sleep.
In all but one of the variables, the cases median values were higher than the controls, especially in
the absolute low delta (0-2 Hz) and theta (4-8 Hz) bands, highlighted in bold. A difference indicates
that the cases have higher medians than the controls. 
EEG Frequency Domain Median Comparison for Quiet Sleep
Variable Cases
(n=20)
Controls
(n=25)
Relative
Difference (%)
Absolute Delta Power 0-4 Hz (V2/Hz) 1687 1370 18.8
Absolute Delta High Power 2-4 Hz (V2/Hz) 1528 1212 20.7
Absolute Delta Low Power 0-2 Hz (V2/Hz) 138 141 -2.2
Absolute Theta Power 4-8 Hz (V2/Hz) 72 66 8.3
Absolute Alpha Power 8-12 Hz (V2/Hz) 18 17 5.6
Absolute Beta Power 12-30 Hz (V2/Hz) 18 17 5.6
Absolute Total Power 0-30 Hz (V2/Hz) 1794 1477 17.7
Average SEF 95% for (0.5-30 Hz) Hz 27.9 28.4 -1.8
Average SEF 95% for (2-20 Hz) Hz 18.5 18.7 -1.1
Table 37: Relative differences in median values between cases and controls for quiet sleep. There are
large differences between groups for absolute high delta (2-4 Hz), highlighted in bold. The large
difference in delta power would account for the difference shown in delta power (0-4 Hz) and the
total power (0-30 Hz). A positive difference indicates that the cases have higher medians than the
controls. 
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The largest differences between the groups are summarised below:
 Active sleep: 28.6 % greater delta high power in cases.
 Indeterminate sleep: 25.6 % greater delta low power, and 27.5 % greater theta
power in cases.
 Quiet sleep: 20.7 % greater delta high power in cases.
These results show that during sleep, the cases had larger amplitude activity in the delta
band (0-4 Hz) for all sleep states. This increased activity is also shown in that the total
power  for  the  cases  is  higher  than  for  the  controls.  Absolute  theta  power (4-8  Hz)
activity for the cases is also higher in the indeterminate sleep stages. These raised levels
in  the  cases  may  be  an  indicator  of  abnormal  sleep  states,  indicative  of  impaired
homoeostatic regulation of the autonomic nervous system.
7.4 Summary
The two groups were matched on a number of factors during recruitment (gestation,
birth  weight  and  socio-economic  status),  ensuring that  the  two  study  groups  were
similar. The results of the EEG analysis show that there were no differences between the
study groups using spectral analysis and comparing medians with non-parametric tests.
However,  non-statistically  significant  observations  can  be  seen  in  the  sleep  states
between groups, with the cases showing greater absolute power than controls in the
absolute delta and theta bands. 
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8 ECG and CVT Experiments
8.1 Introduction
This chapter describes the recording, interpretation and analysis of the ECG and vagal
tone. It covers equipment, software used, the recording parameters and justification for
their use and methodology used to acquire data. Finally the results of the analysis are
given. 
8.2 Methods
8.2.1 Experimental Set Up
The ECG was recorded as part of the PSG, and was described in section 7.2.1. Briefly
this involved attaching three electrodes on the chest of the infant to record the electrical
activity of the heart during sleep, and identifying the RR intervals necessary for HRV
analysis. The sampling frequency of the Xltek PSG equipment was 256 Hz, and the
recording length was approximately one hour, with the aim of capturing all three sleep
states. 
Epochs  were  selected  for  analysis  based  on  sleep  state  as  determined  by  EEG.
Interpretation of the EEG was undertaken by a consultant paediatric neurologist, blinded
to the infant's prenatal drug exposure group and subsequent clinical course. Selected
epochs included quiet,  active  and indeterminate  sleep.  Ideally  epoch lengths  of  120
seconds or greater should be selected, but very few scored sections of this length could
be found without movement artefact. An epoch length of 60 seconds was chosen as a
compromise between being too short to be able to identify the overall trend of the ECG,
and so long that it would include artefact: shorter epoch lengths with no artefact were
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considered more desirable than longer epochs containing artefact. Removal of artefact
was  not  considered  as  this  would  often  introduce  mismatch  between  start  and  end
points, and would distort the baseline voltage.
8.2.2 ECG Analysis
HRV analysis is defined as the variation in the time interval between heart beats, or RR
intervals as seen on the ECG. Prior to analysis, the points in time where the R wave
occurs are identified and marked. Although this can be done manually, it is more usual
to perform an automated RR interval extraction, thus allowing consideration of a large
number of peaks within a data set (see section 5.4.2). This peak to peak dataset is then
the basis for analysis in either the time or frequency domain. 
8.2.3 Software Used
The three software requirements for the analysis were as follows.
1. Accurate estimation of the RR interval from the ECG recording.
2. Analysis of HRV in the time domain.
3. Analysis of HRV in the frequency domain.
The applications chosen to satisfy these requirement were EDF browser for RR interval
extraction, and Kubios HRV software for time and frequency domain analysis, both of
which have been described in section 5.4.2.
8.2.4 ECG Time Domain Variables
The time domain analysis was based on direct measurements of the RR interval file
produced from the EDF browser software, and analysed by the Kubious HRV software.
The variables used for the time domain are shown in Table 38. Note that NN is the time
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between successive R waves,  when the ECG is considered normal,  so for a normal
ECG, RR and NN are interchangeable.
Parameter Abbreviation
Mean heart rate HR
Standard deviation of the mean heart rate HR_stdev
Mean RR interval MeanRR
Standard deviation of the RR intervals SDNN
Root mean squared of successive differences of the RR interval RMSSD
Poincaré plot standard descriptor 1 & 2 SD1 & 2
Table 38: HRV time domain variables used in this analysis.
8.2.5 ECG Frequency Domain Variables
The frequency domain analysis was also performed using the Kubios HRV software and
based  on  power  spectral  density  estimation  using  the  Welch  method  (Welch
periodogram) described by Welch, (1967). This technique uses windowing to taper the
beginning and the end of the epoch to reduce noise in the estimated power spectrum, but
at the cost of reducing the frequency resolution. It is a technique that is more suited for
identifying trends over longer windows (such as 60 seconds) than finding short bursts of
activity such as spikes.
For this analysis, the window chosen was 4 seconds, acquired at 256 Hz, giving 1024
data-points per window. Since the length of the epoch was 60 seconds,  15 analysis
windows (each 4 second long) were used to cover the epoch. This approach was similar
to Doyle et al., (2009), although they used a Lomb periodogram as opposed to a Welch
periodogram. 
Band power was then estimated from the periodogram using the ranges set out by the
European Society Guidelines for HRV analysis (Force, 1996). The ranges are shown in
Table 39.
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Frequency Band Lower Limit (Hz) Upper Limit (Hz)
Very low frequency (VLF) 0 0.04
Low frequency (LF) 0.04 0.15
High frequency (HF) 0.15 0.40
Table 39: Band power ranges and parameters used for the HRV analysis.
However there is variation between studies concerning limits, as shown in Table 40. 
Study ULF
(Hz)
VLF (Hz) LF or MF
(Hz)
HF (Hz) Total Power
(ms2/Hz)
LF/HF
(Mehta et al., 
2002)
<0.0033 0.0033-0.04 0.04-0.15 0.15-0.40 ¸ ¸
(Schäffer et al., 
2008)
<0.003 0.003-0.04 0.04-0.24 0.24-1.04 ¸ ¸
(Longin et al., 
2005)
- 0.01-0.05
(LF)
0.05-0.2
(MF*)
0.2-1.0 ¸ MF/HF
(Spassov et al., 
1994)
- 0.01-0.034
(LF*)
0.04-0.1
(MF*)
0.125-0.34 - -
(Doyle et al., 
2009)
- 0.01-0.04 0.04-0.2 >0.2 - ¸
(Selig et al., 
2011)
- Used but not
defined
Used but not
defined
Used but not
defined
- ¸
* Note that some studies used LF or MF to mean the same frequency range.
Table 40: Variables and ranges used for spectral analysis across a range of neonatal HRV studies.
ULF- ultra low frequency; VLF – very low frequency; LF – low frequency; MF - mid frequency; HF
– high frequency.
As a guide,  high frequency (HF) represents parasympathetic activity,  low frequency
(LF) sympathetic activity, very low frequency (VLF), mainly parasympathetic activity,
and the low frequency/ high frequency ration (LF/HF) is  considered as a marker of
sympathetic-parasympathetic balance (Schäffer et al., 2008).
The variables used for both the frequency domain analysis are shown in table Table 41.
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Parameter Abbreviation
Frequency analysis – Very low frequency (VLF) Spec_VLF
Frequency analysis – Low frequency (LF) Spec_LF
Frequency analysis – High frequency (HF) Spec_HF
Frequency analysis – Total power Spec_Total
Frequency analysis – LF/HF ratio Spec_LF/HF
Table 41: HRV frequency domain variables used in this analysis.
8.2.6 CVT Analysis
The NeuroscopeTM TONE software (version 3.14f) by Medifit Instruments Ltd was used
to produce the vagal tone measurements (www.medifitgroup.com/Neurology.htm). Prior
to analysis two steps of pre-processing were performed. These steps were applied to the
raw ECG file in EDF file format. Since the NeuroscopeTM software incorporates an RR
extraction facility, it was not necessary to use the EDF browser function. 
The first step removed DC shift or any decaying baseline. The second step applied a
simple five point smoothing algorithm, each point with equal weight. This latter step
removed or smothed any unsual peaks or spikes that might have been apparent during
the visual scoring of PSG and selection of apparently artefact free sleep epochs. An
example of the NeuroscopeTM software can be seen in  Figure 68. Both pre-processing
steps  were  performed  using  custom propriety  software  written  by  Dr  Stig  Hansen,
Department of Clinical Physics and Bioengineering at the Southern General Hospital,
Glasgow.
As the software was originally designed to run on a standard PC running Microsoft MS-
DOS and was not Microsoft Windows XP compatible, it was run within the DOSbox
emulation application (www.dosbox.com).
For each epoch, the start and the end points were highlighted manually, as seen by the
dotted  vertical  lines  in  Figure  68.  The  CVT and  its  standard  deviation  were  then
calculated using the method developed by Julu, (1992). As the selection of epochs was
performed manually, any small artefact that was not identified during the PSG scoring,
or altered by the pre-processing was carefully avoided at this stage.
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The variables used for CVT analysis are shown in table Table 42.
Parameter Abbreviation
Cardiac vagal tone (CVT) CVT
Standard deviation of CVT CVT_stdev
Table 42: Cardiac vagal tone variables used in this analysis.
The final output was a comma separated value (*.csv) file which was then imported into
a database for later analysis.
Figure 68: The Neuroscope software running within the DOSbox emulation software. A one minute
epoch used has been selected between the dotted vertical lines, to avoid the large artefacts. The
estimate of vagal tone is shown in the right hand column.
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8.2.7 Data Management and Statistics
When data from the Kubios HRV and NeuroscopeTM software were complete, the results
were transferred into a spreadsheet (LibreOffice Calc 4.1) before being imported into
the VIDI study database for re-linking and merging with the other study data. 
On completion of the data management phase, the database was locked, and the dataset
was  prepared  for  statistical  analysis.  This  was  done  using  a  combination  of  the  R
programming  language  (R Core  Team,  2013) and the  R-Commander  graphical  user
interface (Fox, 2005).
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8.3 Results
Data were grouped according to in utero drug exposure and sleep state (quiet, active and
intermediate), giving six groups for analysis and comparison. To understand the nature
of  the  data  before  statistical  analysis,  the  following  section  is  a  description  of  the
different groups in relation to each other.
8.3.1 Statistical Analysis
Normality Testing
The first part of the analysis consisted of testing the subsets of data to see if they were
normally distributed. This was done by using a combination of histograms and Shapiro-
Wilk normality testing  (Shapiro and Wilk, 1965). The results are shown in the tables
below. A dataset can be considered normally distributed if the p-value >= 0.05. It was
apparent  from  the  results  of  statistical  testing  as  well  as  visual  inspection  of  the
histograms that much of the data was not normally distributed. Attempts were made to
transform the data (x2 and log10), but these proved unsuccessful and it was therefore
decided to use non-parametric tests for data analysis. 
Table 43 and  Table  44 show the results  of  the  normality  testing with the  normally
distributed variables shown in bold. The results show that there are both normally and
normally distributed variables within the dataset.
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Active Sleep Quiet Sleep Indeterminate Sleep
Variable W Score p-value W Score p-value W Score p-value
CVT 0.91 0.17 0.83 0.01 0.46 0.00
CVT_stdev 0.77 0.00 0.84 0.02 0.35 0.00
MeanHR 0.94 0.48 0.82 0.01 0.94 0.27
MeanHR_stdev 0.56 0.00 0.85 0.02 0.71 0.00
MeanRR 0.94 0.50 0.78 0.00 0.91 0.08
RMSSD 0.81 0.01 0.90 0.11 0.84 0.01
SD1 0.86 0.04 0.90 0.10 0.84 0.01
SD2 0.93 0.31 0.96 0.71 0.92 0.11
SDNN 0.92 0.24 0.96 0.71 0.91 0.10
Spec_VLF 0.90 0.12 0.82 0.01 0.75 0.00
Spec_LF 0.87 0.05 0.78 0.00 0.55 0.00
Spec_HF 0.71 0.00 0.86 0.04 0.67 0.00
Spec_Total 0.90 0.12 0.85 0.03 0.67 0.00
Spec_LF/HF 0.85 0.03 0.63 0.00 0.88 0.02
Table 43: Shapiro-Wilk normality tests of cases for the ECG variables. A p-value equal to or greater
than 0.05 indicates adequate normality in the distribution. The table shows that not every variable is
normally distributed. Bold text indicates normally distributed data.
Active Sleep Quiet Sleep Indeterminate Sleep
Variable W Score p-value W Score p-value W Score p-value
CVT 0.91 0.17 0.83 0.01 0.46 0.00
CVT_stdev 0.77 0.00 0.84 0.02 0.35 0.00
MeanHR 0.94 0.48 0.82 0.01 0.94 0.27
MeanHR_stdev 0.56 0.00 0.85 0.02 0.71 0.00
MeanRR 0.94 0.50 0.78 0.00 0.91 0.08
RMSSD 0.81 0.01 0.90 0.11 0.84 0.01
SD1 0.86 0.04 0.90 0.10 0.84 0.01
SD2 0.93 0.31 0.96 0.71 0.92 0.11
SDNN 0.92 0.24 0.96 0.71 0.91 0.10
Spec_VLF 0.65 0.00 0.87 0.02 0.63 0.00
Spec_LF 0.78 0.00 0.93 0.16 0.55 0.00
Spec_HF 0.63 0.00 0.50 0.00 0.89 0.02
Spec_Total 0.76 0.00 0.82 0.00 0.70 0.00
Spec_LF/HF 0.90 0.06 0.78 0.00 0.68 0.00
Table 44: Shapiro-Wilk normality tests of controls for the ECG variables. A p-value equal to or
greater than 0.05 indicates adequate normality in the distribution. The table shows that not every
variable is normally distributed. Bold text indicates normally distributed data.
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8.3.2 ECG Time & Frequency Domain Results
Each variable has been described graphically (box plots) for visual comparison, and
presented in a table showing the results of the Mann-Whitney test for non-parametric
data.  Where  the  Mann-Whitney  test  showed  a  statistically  significant  differences,
Bonferroni corrections were applied.
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Mean Heart Rate
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (bpm) n Median (bpm)
Active 13 119 19 120 0.88 (-10.70, 8.03)
Indeterminate 18 118 20 120 0.78 (-6.83, 5.54)
Quiet 14 116 19 116 0.42 (-12.61, 3.73)
Table 45: Results of Mann-Whitney U tests comparing median values for mean heart rate for cases
and controls for each sleep state.
No statistical difference was found between the median values of mean heart rate for
any sleep state.  This  indicates  that  there was no difference identifiable  between the
study groups using this statistical methodology. 
Figure 69: Box plots for mean heart rate for all three sleep states, with cases shown in grey. The top and
bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively, while the whiskers show Q1 or
Q3 ±1.5 of the interquartile range. The black line within the box indicates the median value and outliers
are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS: quiet sleep.
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Mean Heart Rate (Standard Deviation) SDNN
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (ms) n Median (ms)
Active 13 34.0 18 20.1 0.27 (-3.4, 20.3)
Indeterminate 17 33.6 20 23.9 0.10 (-2.1, 21.7)
Quiet 14 32.6 19 24.1 0.12 (-1.9, 16.7)
Table 46: Results of Mann-Whitney U tests comparing median values for mean heart rate (standard
deviation) for cases and controls for each sleep state.
No statistical  difference  was  found  between  the  median  values  of  mean  heart  rate
(standard  deviation)  for  any sleep  state.  This  indicates  that  there  was no difference
identifiable between the study groups using this statistical methodology. 
Figure 70: Box plots for mean heart rate standard deviation (SDNN) for all three sleep states, with cases
shown in grey. The top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively,
while the whiskers show Q1 or Q3 ±1.5 of the interquartile range. The black line within the box indicates
the median value and outliers are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS:
quiet sleep.
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Mean RR Interval
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (ms) n Median (ms)
Active 13 509 19 499 0.79 (-31.2, 46.5)
Indeterminate 18 511 20 506 0.70 (-23.5, 32.5)
Quiet 14 517 19 517 0.38 (-17.6, 54.1)
Table 47: Results of Mann-Whitney U tests comparing the medians of the mean RR intervals for
cases and controls for each sleep state.
No statistical difference was found between the median values of mean RR interval for
any sleep state.  This  indicates  that  there was no difference identifiable  between the
study groups using this statistical methodology. 
Figure 71: Box plots for mean RR interval for all three sleep states, with cases shown in grey. The top and
bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively, while the whiskers show Q1 or
Q3 ±1.5 of the interquartile range. The black line within the box indicates the median value and outliers
are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS: quiet sleep.
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RMSSD
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (ms) n Median (ms)
Active 13 18.0 19 14.1 0.27 (-2.5, 10.3)
Indeterminate 18 21.6 20 15.3 0.51 (-6.10, 11.2)
Quiet 14 23.4 19 16.5 0.032 (0.7, 17.4)
Table 48: Results of Mann-Whitney U tests comparing the medians of RMSSD for cases and
controls for each sleep state.
Although quiet sleep showed a statistically significant difference between groups, on the
application of the Bonferroni correction (3 sleep states x 0.032 = 0.096), the difference
was no longer statistically significant. Otherwise, no difference was found between the
median values of RMSSD values for any sleep state using this statistical methodology. 
Figure 72: Box plots for RMSSD for all three sleep states, with cases shown in grey. The top and bottom
of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively, while the whiskers show Q1 or Q3 ±1.5
of the interquartile range. The black line within the box indicates the median value and outliers are shown
by small circles. AS: active sleep; IS: indeterminate sleep; QS: quiet sleep.
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Poincaré Plots (SD1)
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (ms) n Median (ms)
Active 13 13.0 19 10.0 0.11 (-1.0, 9.8)
Indeterminate 18 15.4 20 10.9 0.51 (-4.4, 8.0)
Quiet 14 16.6 19 11.7 0.03 (0.7, 17.4)
Table 49: Results of Mann-Whitney U tests comparing the medians of Poincaré Plot SD1 for cases
and controls for each sleep state
Although quiet sleep showed a statistically significant difference, on the application of
the Bonferroni correction (3 sleep states x 0.032 = 0.096), the difference was no longer
significant. No statistical difference was therefore found between the median values of
SD1 for any sleep state. This indicates that there was no difference identifiable between
the study groups using this statistical methodology. 
Figure 73: Box plots for Poincaré plot SD1 for all three sleep states, with cases shown in grey. The top
and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively, while the whiskers show
Q1 or Q3 ±1.5 of the interquartile range. The black line within the box indicates the median value and
outliers are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS: quiet sleep.
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Poincaré Plots (SD2)
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (ms) n Median (ms)
Active 13 46.5 19 26.7 0.27 (-5.1, 27.6)
Indeterminate 18 45.4 20 32.5 0.07 (-1.5, 27.2)
Quiet 14 39.3 19 32.1 0.21 (-4.4, 23.0)
Table 50: Results of Mann-Whitney U tests comparing the medians of Poincaré Plot SD2 for cases
and controls for each sleep state.
No statistical difference was found between the median values of Poincaré SD2 for any
sleep state. This indicates that there was no difference identifiable between the study
groups using this statistical methodology. 
Figure 74: Box plots for Poincaré plot SD2 for all three sleep states, with cases shown in grey. The top
and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively, while the whiskers show
Q1 or Q3 ±1.5 of the interquartile range. The black line within the box indicates the median value and
outliers are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS: quiet sleep.
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Spectral Analysis – VLF 
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (ms2/Hz) n Median (ms2/Hz)
Active 13 486 19 86 0.19 (-41, 529)
Indeterminate 18 395 20 84 0.02 (26, 781)
Quiet 14 114 19 125 0.44 (-49, 191)
Table 51: Results of Mann-Whitney U tests comparing the medians of VLF for cases and controls
for each sleep state.
Although  indeterminate  sleep  showed  a  statistically  significant  difference,  on  the
application of the Bonferroni correction (3 sleep states x 0.02 = 0.06), the difference
was  no  longer  significant.  No  statistical  difference  was  found  between  the  median
values  of  VLF  for  any  sleep  state.  This  indicates  that  there  was  no  difference
identifiable between the study groups using this statistical methodology.
Figure 75: Box plots for VLF for all three sleep states, with cases shown in grey. The top and bottom of
the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively, while the whiskers show Q1 or Q3 ±1.5 of
the interquartile range. The black line within the box indicates the median value and outliers are shown by
small circles. AS: active sleep; IS: indeterminate sleep; QS: quiet sleep.
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Spectral Analysis – LF
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (ms2/Hz) n Median (ms2/Hz)
Active 13 319 19 242 0.56 (-141, 354)
Indeterminate 18 234 20 199 0.17 (-48, 371)
Quiet 14 230 19 185 0.72 (-88, 253)
Table 52: Results of Mann-Whitney U tests comparing the medians of LF for cases and controls for
each sleep state
 
No statistical difference was found between the median values of LF for any sleep state.
This indicates that there was no difference identifiable between the study groups using
this statistical methodology. 
Figure 76: Box plots for LF for all three sleep states, with cases shown in grey. The top and bottom of the
boxes show the 1st (Q1) and 3rd (Q3) quartile respectively, while the whiskers show Q1 or Q3 ±1.5 of the
interquartile range. The black line within the box indicates the median value and outliers are shown by
small circles. AS: active sleep; IS: indeterminate sleep; QS: quiet sleep.
211
Spectral Analysis – HF
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median (ms2/Hz) n Median (ms2/Hz)
Active 13 82 19 57 0.30 (-19, 157)
Indeterminate 18 93 20 50 0.24 (-20, 87)
Quiet 14 106 19 65 0.64 (-48, 87)
Table 53: Results of Mann-Whitney U tests comparing the medians of HF for cases and controls for
each sleep state.
No statistical difference was found between the median values of HF values for any
sleep state. This indicates that there was no difference identifiable between the study
groups using this statistical methodology. 
Figure 77: Box plots for HF for all three sleep states, with cases shown in grey. The top and bottom of the
boxes show the 1st (Q1) and 3rd (Q3) quartile respectively, while the whiskers show Q1 or Q3 ±1.5 of the
interquartile range. The black line within the box indicates the median value and outliers are shown by
small circles. AS: active sleep; IS: indeterminate sleep; QS: quiet sleep.
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Spectral Analysis – LF/HF Ratio
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median n Median
Active 13 2.6 19 4.6 0.20 (-3.54, 0.61)
Indeterminate 18 3.7 20 2.6 0.19 (-0.68, 2.80)
Quiet 14 1.9 19 2.3 0.77 (-1.62, 1.14)
Table 54: Results of Mann-Whitney U tests comparing the medians of LF/HF ratio for cases and
controls for each sleep state.
No statistical difference was found between the median values of LF/HF ratio values for
any sleep state.  This  indicates  that  there was no difference identifiable  between the
study groups using this statistical methodology. 
Figure 78: Box plots for LF/HF ratio for all three sleep states, with cases shown in grey. The top and
bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively, while the whiskers show Q1 or
Q3 ±1.5 of the interquartile range. The black line within the box indicates the median value and outliers
are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS: quiet sleep.
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8.3.3 ECG Time and Frequency Domain Median 
Comparisons
The median values were presented for each variable for each sleep state  (ECG time
domain -  Table 55,  Table 56,  Table 57, ECG frequency domain -  Table 58,  Table 59,
Table 60). The difference between the two groups for a sleep state was shown indicating
what percentage magnitude the cases differ from the controls, and is calculated using
equation 13 on page 190. A positive difference shows that the median value for the case
is larger. 
ECG Time Domain Median Comparison for Active Sleep
Variable Cases
(n=20)
Controls
(n=25)
Relative
Difference (%)
Mean Heart Rate (bpm) 119 120 -0.8
Mean Heart Rate (bpm) standard deviation 
SDNN
34.0 20.1 40.9
Mean RR interval (ms) 509 499 2.0
RMSSD (ms) 18.0 14.1 21.7
Poincarè Plot – SD1 (ms) 13.0 10.0 23.1
Poincarè Plot – SD2 (ms) 46.5 26.7 42.6
Table 55: Relative differences in ECG time domain medians between cases and controls for active
sleep. A positive percentage difference indicates that the cases have higher medians than the
controls. The largest difference shown is the SDNN, indicating that the variability between cases and
controls is largest during active sleep.
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ECG Time Domain Median Comparison for Indeterminate Sleep
Variable Cases
(n=20)
Controls
(n=25)
Relative
Difference (%)
Mean Heart Rate (bpm) 118 120 -1.7
Mean Heart Rate (bpm) standard deviation 
SDNN
33.6 23.9 28.9
Mean RR interval (ms) 511 506 1.0
RMSSD (ms) 21.6 15.3 29.2
Poincarè Plot – SD1 (ms) 15.4 10.9 29.2
Poincarè Plot – SD2 (ms) 45.4 32.5 28.4
Table 56: Relative differences in ECG time domain medians between cases and controls for
indeterminate sleep. A positive percentage difference indicates that the cases have higher medians
than the controls. Here the SNDD, and Poincarè plot output (SD1 and SD2) are highest, again
indicating increased variability between cases and controls.
ECG Time Domain Median Comparison for Quiet Sleep
Variable Cases
(n=20)
Controls
(n=25)
Relative
Difference (%)
Mean Heart Rate (bpm) 116 116 0.0
Mean Heart Rate (bpm) standard deviation 
SDNN
32.6 24.1 26.1
Mean RR interval (ms) 517 517 0.0
RMSSD (ms) 23.4 16.5 29.5
Poincarè Plot – SD1 (ms) 16.6 19 -14.5
Poincarè Plot – SD2 (ms) 39.3 32.1 18.3
Table 57: Relative differences in ECG time domain medians between cases and controls for quiet
sleep. A positive percentage difference indicates that the cases have higher medians than the
controls. SDNN and RMSSD, two measures of variability are shown to be greater in the cases.
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ECG Frequency Domain Median Comparison for Active Sleep
Variable Cases
(n=20)
Controls
(n=25)
Relative
Difference (%)
Very Low Frequency (VLF) ms2/Hz 486 86 82.3
Low Frequency (LF)  ms2/Hz 319 242 24.1
High Frequency (HF)  ms2/Hz 82 57 30.5
LF/HF Ratio 2.6 4.6 -76.9
Table 58: Relative differences in ECG frequency domain medians between cases and controls for
active sleep. A positive percentage difference indicates that the cases have higher medians than the
controls. The VLF difference in the controls is larger than in the cases, indicating greater
parasympathetic activity. The LF/HF ratio is greater in the controls.
ECG Frequency Domain Median Comparison for Indeterminate Sleep
Variable Cases
(n=20)
Controls
(n=25)
Relative
Difference (%)
Very Low Frequency (VLF)  ms2/Hz 395 84 78.7
Low Frequency (LF)  ms2/Hz 234 199 15.0
High Frequency (HF)  ms2/Hz 93 50 46.2
LF/HF Ratio 3.7 2.6 29.7
Table 59: Relative differences in ECG frequency domain medians between cases and controls for
indeterminate sleep. A positive percentage difference indicates that the cases have higher medians
than the controls. As with active sleep, the VLF value is greater in the controls, indicating more
parasympathetic activity.
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ECG Frequency Domain Median Comparison for Quiet Sleep
Variable Cases
(n=20)
Controls
(n=25)
Relative
Difference (%)
Very Low Frequency (VLF)  ms2/Hz 114 125 -9.6
Low Frequency (LF)  ms2/Hz 230 185 19.6
High Frequency (HF)  ms2/Hz 106 65 38.7
LF/HF Ratio 1.9 2.3 -21.1
Table 60: Relative differences in ECG frequency domain medians between cases and controls for
quiet sleep. A positive percentage difference indicates that the cases have higher medians than the
controls. In quiet sleep the HF is larger in the controls indicating more parasympathetic activity.
Summary
The conventional measurement of heart rate (mean RR and RR interval) showed very
little difference between the two groups, although the measures of variability (SDNN
and RMSSD) showed larger differences, indicating greater variability in the cases. The
Poincarè plot parameters SD1 and SD2 showed a higher degree of variability for active
and indeterminate sleep, but not quiet sleep. 
The  spectral  analysis  showed  larger  differences  between  the  groups,  especially  in
measurement  of  VLF,  an  indicator  of  parasympathetic  activity.  In  active  and
indeterminate sleep the cases had 82 % and 79 % greater values than the controls, whilst
in quiet sleep, the controls had greater parasympathetic responses, denoted by HF.
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8.3.4 Comparison of the ECG Results with Other 
Studies
Table  61 shows  a  summary  of  ECG  studies  in  the  neonate  that  have  included  a
comprehensive  time  domain  HRV analysis,  and in  some cases  a  frequency  domain
analysis. With the exception of the studies by Selig et al., (2011) and Vandeput et al.,
(2009) that included preterm infants, all were performed on healthy term infants. For
comparison purposes,  only the cases and controls  from the current  study have been
included in this table. 
What is apparent, is that many of the normative studies do not record sleep stages with
any  detail,  and give  results  over  a  24  hour  recording.  This  introduces  considerable
variability between studies even for commonly used HRV analysis such as RR interval
(456  –  495  ms)  and  mean  HR (109  –  131  bpm).  A lack  of  standardisation  in  the
recording and analysis of neonate HRV data precludes precise cross study comparisons.
However, in general terms, although the study group had been recruited from a very
specific population, the results do not differ greatly from other published studies. 
The data from other studies are more variable when examining the frequency domain
results. This is because of the varied methods and protocols used for the generation of
the spectra and band power calculations. Some studies only publish the relative band
power results  (the percentage of power),  and do not show the absolute  values from
which  these  are  based.  Although  relative  power  values  may  be  of  more  use,  for
completeness, the absolute values would be more complete. 
Study This study Mehta et al.
(2002)
Schäffer et
al. (2008)
Longin et al.
(2005)
Spassov et al.
(1994)
Doyle et al.
(2009)
Vandeput et al.
(2009)
Selig et al. (2011) 
Age Group Neonate term
controls
Neonate term
cases
Neonate Neonate Neonate Neonate Neonate
(normal)
Preterm (Mean
GA 32 weeks)
Term Preterm 
Sleep Status AS, QS & IS AS, QS & IS Awake &
asleep
- Undefined but
eyes closed
QS AS QS AS AS QS Awake &
asleep
Awake &
asleep
Time domain results
RR (ms) 499-517 509-517 456 457 495 498 472 - - 408 432 485.3 411.2
SDNN (ms) 20.1-24.1 18.5-18.9 47.0 63.9 49.7 35.2 29.9 14.8 23.8 26.7 12.2 22.6 13.8
HR (bpm) 117-121 116-119 130 131 122 - - 110 114 - - - -
RMSSD (ms) 14.1-16.5 18.0-23.4 21.6 19.3 20.5 - - 11.9 11.4 8.0 7.2 11.1 5.9
SD1 (ms) 10.0-11.7 13.0-16.6 - - - - - 33.7 129.9 - - - -
SD2 (ms) 26.7-32.5 39.3-46.5 - - - - - 76.1 32.4 - - - -
Frequency domain results
Relative VLF 
(%)
23.1-26.7 26.8-53.3 24.2 34.7* - - - 32.9 41.3 - - 46.6* 47.3*
Relative LF 
(%)
11.3-54.6 35.0-54.0 12.4 15.2* - 18.4 10.8 36.4 46.4 - - 41.5* 47.9*
Relative HF 
(%)
13.6-15.0 11.6-19.2 5.3 3.8* - 16.2 23.1 32.2 13.0 - - 11.8* 11.4*
LF/HF 2.33-4.6 1.9-2.6 2.7 3.75 - 1.4 0.5 1.65 4.38 - - 4.7 7.6
* indicates that the value was computed from the results presented in the original paper.
Table 61: Other relevant studies involving HRV analysis for preterm and term infants, both in the time and frequency domains, involving a neonatal population. QS - quiet
sleep; AS - active sleep; IS - indeterminate sleep.
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8.3.5 CVT Results
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median n Median
Active 13 3.5 19 1.9 0.002 (0.81, 4.27)
Indeterminate 18 3.7 20 2.4 0.03 (0.06, 2.62)
Quiet 14 4.6 19 3.2 0.37 (-0.52, 2.42)
Table 62: Results of Mann-Whitney U tests comparing the medians of CVT for cases and controls
for each sleep state.
The statistical analysis showed that during active sleep, CVT scores were statistically
different between the cases and controls, although this was not the case for quiet sleep.
Bonferroni  corrections  demonstrated that  cases  had significantly higher  CVT during
active  sleep  (p=0.006)  and  a  trend towards  higher  CVT during  indeterminate  sleep
(p=0.099).
Figure 79: Box plots for CVT for all three sleep states, with cases shown in grey. The top and bottom of
the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively, while the whiskers show Q1 or Q3 ±1.5 of
the interquartile range. The black line within the box indicates the median value and outliers are shown by
small circles. AS: active sleep; IS: indeterminate sleep; QS: quiet sleep.
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CVT Standard Deviation
Cases Controls p-value 95% Confidence intervals of the
difference (cases minus controls)n Median n Median
Active 13 1.2 19 0.5 0.005 (0.2, 5.9)
Indeterminate 18 0.9 20 0.6 0.21 (-0.1, 0.7)
Quiet 14 0.9 19 0.9 0.48 (-0.31, 0.68)
Table 63: Results of Mann-Whitney U tests comparing the medians of CVT (standard deviation) for
cases and controls for each sleep state.
After application of Bonferroni corrections the cases demonstrated significantly higher
CVT SD (i.e. CVT variability) during active sleep (p=0.015).
The two CVT measurements  – median  CVT, and variability  of  CVT – showed the
greatest difference between cases and controls, specifically for active sleep, and is the
basis for the analysis that follows.
Figure 80: Box plots for CVT standard deviation for all three sleep states, with cases shown in grey. The
top and bottom of the boxes show the 1st (Q1) and 3rd (Q3) quartile respectively, while the whiskers
show Q1 or Q3 ±1.5 of the interquartile range. The black line within the box indicates the median value
and outliers are shown by small circles. AS: active sleep; IS: indeterminate sleep; QS: quiet sleep.
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8.3.6 Comparison of Cases who Subsequently 
Required Treatment for NAS Versus Cases who Did 
Not Require Treatment
The  analysis  so  far  compared  methadone-exposed  infants  (cases)  with  unexposed
controls. The cases can also be divided into infants who did (n=5) or did not (n=45) go
on to develop significant NAS (requiring treatment). Although five cases received oral
morphine for the treatment of signs and symptoms of NAS, three of these (#43, #47 and
#74) had to be excluded from analysis because no PSG was achieved due to irritability
or  the  infant  not  sleeping.  Table 64 shows the  individual  results  of  the two treated
infants for each sleep state, in comparison with the medians for the not-treated cases. 
Variable Sleep Stage Not treated
(medians) n=13
infant #54
(medians)
infant #112
(medians)
CVT AS 4.41 3.44 3.54
IS 3.24 3.82 5.90
QS 4.52 5.19 *
VLF (ms2/Hz) AS 486 302 906
IS 328 498 2555
QS 96 457 *
* Indicates that the QS was not found for this infant during PSG scoring
Table 64: CVT and VLF results for the two infants that were treated for NAS.
For  the  two  infants  who  were  subsequently  treated  for  NAS  there  is  not  obvious
relationship difference in CVT or VLF compared to those infants who did not develop
significant NAS. Clearly this subset of data (n=2) is very small; more data would be
required to determine if there truly is no difference. Infants who subsequently required
treatment  might  very  well  have  been more  irritable  during the PSG, and thus  have
proved more difficult to record PSG data from. A larger study set would be needed to
confirm the preliminary findings that CVT/VLF does not predict severity of NAS.
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8.3.7 Comparison of CVT and Length of Stay for the 
Treated Group
The results can be seen in  Table 65. This shows that the length of stay for exposed
infants is  over  twice as long as  for controls,  and their  CVT is significantly higher:
however, Figure 81 shows that CVT is not an indicator of length of stay.
Mean (days) Range (days) CVT CVT range
Case 8.1 (3-19) 5.10 0.5-33.2
Control 3.0 (2-4) 2.95 0.7-9.8
Table 65: Mean length of stay in relation to CVT for the study infants.
Figure 81: A scatter plot showing the length of hospital stay for cases and controls in relation to their
test CVT score.
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Similarly, the VLF spectral power band was close to showing a trend between groups,
with a statistical difference p-value of 0.056. 
Variability of CVT for the cases was greater, and the medians higher, for each sleep
state relative to controls. This is despite those measurements displayed here being made
when  the  infant  was  settled,  and  the  sleep  epochs  identified  as  artefact  free.  This
variability of CVT amongst the cases indicates that the parasympathetic nervous system
Figure 82: Cardiac vagal tone for cases versus controls for each sleep state. The upper boundary
(upper hinge) of the box represents the 75th percentile, the lower boundary (lower hinge) the 25th
percentile and the black line the median. The upper and lower whiskers represent the limits of the
nominal range inferred from the upper and lower quartiles. The small circles represent outliers.
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was  in  a  less  stable  state  than  in  the  controls,  suggesting  impaired  or  damaged
homeostatic regulation.
Figure 83 shows increased level of variability amongst the cases, with wider nominal
ranges, and raised medians compared with the controls. Although the differences did not
achieve  statistical  significance  (p-value=0.056),  the  trend is  in  line  with  CVT data,
confirming the validity of the latter measurements.
It  suggests that the parasympathetic regulation that occurs during quiet  sleep is less
Figure 83: A box plot of VLF (very low frequency) spectral power (ms2/Hz) for cases versus controls
for each sleep state.
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adversely affected than during active and indeterminate sleep. From a practical point of
view,  the  infants  were  far  more  settled  during  periods  of  quiet  sleep  than
active/indeterminate  sleep,  with  an  EEG is  defined  by high  voltage,  low frequency
signals.  There may be less need for the parasympathetic nervous system to regulate
during these more settled periods. 
8.3.8 The Relationship Between CVT and VLF
As both CVT and VLF are considered representative of parasympathetic activity, it was
necessary  to  test  the  presence  of  a  relationship.  This  relationship  was  explored  by
producing the scatter plot shown in Figure 84. On visual inspection of the graph it can
be seen  that  the  cases,  represented  by  small  circles  appear  more  scattered  than  the
controls. Controls tended to be grouped together with lower VLF and CVT scores. This
could indicate that in the control group there is less variation, suggesting highly variable
levels amongst the cases. 
Figure 84: Scatter plot of VLF power versus cardiac vagal tone for cases and controls. Cases are
represented by circles, and controls by triangles.
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8.3.9 Sensitivity & Specificity
From this  study,  cardiac  vagal  tone  has  been  shown  to  have  the  most  statistically
significant difference between the exposed and unexposed groups. With this data a 2x2
contingency  table  was  constructed  to  identify  CVTs  capacity  to  accurately  predict
exposure. The structure of a 2x2 table is shown in Figure 58.
Test
Condition
Positive
Condition
Negative
Outcome
positive
True Positive False Positive Precision
Outcome
negative
False Negative True Negative
Negative
predictive value
(NPV)
Sensitivity Specificity
Table 66: The structure of a 2x2 contingency table.
If a CVT  3.0 from the active sleep dataset is used as a cut-off, the following 2x2 table
was constructed. 
Test Exposed (n=13)
Not Exposed
(n=19)
CVT  3.0 10 3 Precision = 76.9%
CVT < 3.0 3 16 NPV = 84.2%
Sensitivity =
76.9 %
Specificity =
84.2 %
Table 67: 2x2 contingency table using CVT>=3 during active sleep.
Figure 56 shows that the sensitivity, or the percentage correctly predicted to have been
exposed, is 76.9%, whilst the specificity, which is the percentage correctly predicted to
have not been exposed is 84.2%. 
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8.3.10 Receiver Operator Characteristic (ROC) Curve
ROC curves are visual representations of the data shown in 2 x 2 contingency tables.
They are used to show a how good a predictive technique is in relation to the number of
errors it  makes. For different cut-off levels, a curve can be constructed showing the
relationship between the sensitivity and 1-specificity of a test. For the ROC curve to
reflect a more-useful-than-chance predictive technique, it should lie to the left of the
diagonal, or 45 degree line, shown on Figure 86 as the red line running from (0,0) to
(1,1). A useful indicator of the goodness of a predictive test is the area under the ROC
curve (AUROC). In the example shown in Figure 85, the numerical integration methods
using the trapezoidal rule was used to calculate AUROC.
As CVT was found to be the most significant variable as a predictive test,  an ROC
curve  was constructed  for  a  range of  values  from 2 to  6.  Contingency tables  were
constructed  for  each  cut-off  point  with  the  results  being  shown in  Figure  86.  The
calculations were performed in LibreOffice Calc 4.2.
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Figure 85: An example calculation for the ROC curve showing CVT during active sleep with a
CVT cut-off of 3. The 2x2 is shown at the top, followed by the values calculated for sensitivity
and specificity. The table at the bottom is a summary of sensitivity and specificity results for cut
off values between 2 and 6, and were used for plotting the ROC curve.
Figure 86: An ROC curve for CVT with a range of cut-off values (2-6) during active sleep.
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The AUROC was calculated to be 0.834 or 83 %. It must be noted that the ROC curve
has  been constructed  with only five points  because the  sample size  was small,  and
values between the integer cut-off's showed very little, if any, change in the sensitivity
and 1-specificity values. Also, the AUROC is only an approximation of the true area
under the curve. However, as a predictive test, as shown by the ROC curve, CVT shows
promise in isolating which infants were exposed, and more likely to develop NAS.
8.4 Summary
For  each  group  of  in  utero drug  exposed  cases  or  control  infants,  none  of  the
conventional  time or  frequency domain  measurements  based on the ECG showed a
statistically significant difference between sleep states. 
However, CVT was significantly higher in the exposed group than in the unexposed
group.
 AS Cases 3.5 (3.0-7.2) vs 1.9 (1.6-2.7) p-value 0.002.
 IS Cases 3.7 (2.7-5.4) vs 2.4 (1.8-2.9) p-value 0.033.
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9 Discussion & Conclusion
9.1 EEG Discussion
The  final  analysis  of  the  EEG  spectral  analysis  showed  no  statistically  significant
difference  between  the  two  groups  for  any  sleep  stage,  but  relative  percentage
differences highlighted areas of difference. These are summarised in  Table 68, where
the percentage difference is positive if the cases value is larger.
  Relative difference for each sleep state
EEG variable Active Indeterminate Quiet
Absolute Delta Power 0-4 Hz (V2/Hz) 7.8 % 10.7 % 18.8 %
Absolute Delta Low 0-2 Hz (V2/Hz) 9.2 % 8.1 % 20.7 %
Absolute Delta High 2-4 Hz (V2/Hz) 28.6 % 25.6 % -2.2 %
Absolute Theta 4-8 Hz (V2/Hz) 11.3 % 27.5 % 8.3 %
Absolute Alpha 8-12 Hz (V2/Hz) 10.0 % 11.8 % 5.6  %
Absolute Beta 12-30 Hz (V2/Hz) 10.0 % 11.8 % 5.6 %
Absolute Total Power (V2/Hz) 6.2 % 12.5 % 17.7 %
SEF 95% (0.5-30 Hz) Hz -0.7 % -1.4 % -1.8 %
SEF 95% (2-20 Hz) Hz -1.1 % 0 % -1.1 %
Table 68: A summary showing how the cases median EEG band power median values differed from
the controls in terms of relative difference percentage. A positive indicates that the cases value is
greater than the control equivalent.
Examining the data shows that cases values are higher than controls for all but quiet
sleep absolute delta high power and for both SEF 95% ranges. This would indicate that
cases have more energetic EEG over the frequency bands measured. In the three delta
bands, levels are considerably greater indicating that delta activity has been modified by
exposure.  Delta power is  composed of high amplitude,  slow wave voltages (SWS –
slow wave sleep), often related to cellular regeneration and in the infant dominates the
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neonatal EEG (Scher et al., 1994).  This difference might suggest that the mechanisms
involved in delta activity and sleep regulation are affected by exposure although the
neural underpinnings SWS delta activity remain uncertain (Knyazev, 2012). 
The higher frequency bands (theta, alpha and beta) were also been affected showing
more activity in the cases. This would indicate that in the exposed infants, faster EEG
activity is present at times when lower levels in these frequency bands would be more
normal. These higher frequencies may explain why there is a higher level of arousal
during periods when a infant should be in settled sleep, and would in part explain why
drug exposed neonates are less likely to have settled to sleep. 
9.2 ECG Discussion
The analysis of the ECG data can be divided into three categories, conventional analysis
of the ECG in both the time and frequency domains, and analysis and measurement of
parasympathetic activity using estimates of cardiac vagal tone. 
9.2.1 Time Domain Analysis
Examining the data, it is apparent that for nearly all the ECG time domain variables that
describe heart rate variability (SDNN, mean HR standard deviation, RMSSD, SD1 &
SD2),  the  cases  have  higher  median  values.  However,  the  mean HR and mean RR
interval were not greatly affected. This indicates that average time between successive R
wave peaks (mean HR and RR interval) are poor indicators of the variation within the
heart rates for this study group, and describe only the basic mechanism for regulating
the rate. 
The main differences are summarised in Table 69.
Relative difference for each sleep state
ECG variable Active Indeterminate Quiet
Mean HR (bpm) -0.8 % -1.7 % 0.0 %
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Mean HR Standard Deviation (bpm) SDNN 40.9 % 28.9 % 26.1 %
Mean RR interval (ms) 2.0 % 1.0 % 0.0 %
RMSSD (ms) 21.7 % 29.2 % 29.5 %
Poincarè Plot – SD1 (ms) 23.1 % 29.2 % -14.5 %
Poincarè Plot – SD2 (ms) 42.6 % 28.4 % 18.3 %
Table 69: A summary showing how the cases median HRV values differed from the controls. A
positive value indicates that the cases value is greater than the controls.
When statistical testing was performed comparing the medians (using non parametric
tests) between the two groups, none of the comparisons showed statistically significant
differences (where p<=0.05). However this was more likely due to the small sample
sizes involved, and greater numbers may well elicit a statistically significant difference.
Note that even though the data was not normally distributed, and non-parametric tests
were used for the statistics where medians are more applicable, mean RR and mean HR
are standard ECG variables used across the literature. This means that a median value of
a group of mean HR is acceptable.
9.2.2 Frequency Domain Analysis
The summary analysis of the frequency domain results showed a similar picture to the
time domain in  that  nearly all  variables.  During AS and IS,  the VLF band showed
82.3% and 78.7%  increases amongst the cases compared with the controls. Although no
neonatal data could be found indicating the significance of these raised VLF values, in
an  adult  population,  Bigger  et  al.,  (1992) showed that  increased  VLF was  strongly
associated with sudden arrhythmic death syndrome (SADS).
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Relative difference for each sleep state
ECG variable Active Indeterminate Quiet
Very Low Frequency (VLF) ms2/Hz 82.3 % 78.7 % -9.6 %
Low Frequency (LF) ms2/Hz 24.1 % 15.0 % 19.6 %
High Frequency (HF) ms2/Hz 30.5 % 46.2 % 38.7 %
LF/HF -76.9 % 29.7 % -21.1 %
Table 70: A summary showing how the cases median HRV  values differed from the controls.
Positive values indicate that the cases values was greater than the controls.
Only during QS was this pattern of higher medians not reproduced for VLF, although
there was only a 9% increase in the controls compared with the cases. This is not all that
surprising as QS is characterised by slower more rhythmic breathing, little movement
and  no  REM activity.  Consequently  a  more  regular  and  consistent  HR is  expected
during QS, so there would be less variability during this phase.
As with the time domain analysis, the results showed no statistical difference (where
p<=0.05) between the groups,  although VLF showed the most  significant difference
(p=0.057)  between  cases  and controls.  This  matches  the  high  percentage  difference
observed for VLF during AS and IS.
9.3 CVT Discussion
Of all the parameters examined the one that showed the greatest difference in medians
was  cardiac  vagal  tone.  The  median  CVT for  each  sleep  state  were  higher  in  the
exposed group when compared with the control group. This was statistically significant
(p-value =0.002 for AS and 0.033 for IS).  Again QS was shown not be significantly
different,  and  as  stated  before,  this  sleep  state  is  the  deepest  where  physiological
variability is at a minimum.
As CVT was considered the most promising variable as a predictive test,  a receiver
operator characteristic (ROC) curve, shown in Figure 86 using varying levels of CVT
from 2 – 6 was prepared. The AUROC was 0.83 or 83% indicating that CVT was shown
to be a good indicator of prior exposure, although the sample was small.
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One of the aims of this work was to develop an electrophysiological method that could
identify differences between groups. CVT showed the strongest difference between the
groups. 
Overall,  the  ECG results  often  showed  the  exposed  group  to  have  higher  or  more
‘energetic’ values. However, ECG is the product of autonomic nervous system activity,
containing indicators of the level of activity from a number of different systems. The
electrophysiological test that showed the most significant difference was that of cardiac
vagal tone, an indicator of parasympathetic activity alone. This would suggest that the
PNS  is  affected  most,  and  therefore  is  the  most  important  factor  in  assessing  the
exposed infants.
Before more patient focused treatment of NAS can be developed, a more objective test
indicating the level of withdrawal that the infant is undergoing is needed. CVT could be
a useful tool in assessing how successful treatment for NAS is using existing drugs such
as Oromorph.
9.3.1 The Relationship Between CVT and VLF
Although CVT and VLF power were derived using different methods, CVT from a time
domain analysis, and VLF from a frequency analysis, they are both powerful indicators
of parasympathetic nervous system activity, and are consequently related. It strengthens
the  observation  that  parasympathetic  activity  in  the  cases  is  modified  in  that  two
different parameters, derived using different methods, show similar results.
9.3.2 Physiological Explanation for the Results
A plausible explanation for the differences between the exposed cases and the controls
is that the level of nerve fibre myelination differs between the two groups. This would
consequently  have  an  effect  on both  the  development  of  the  brain  and the  nervous
system. In a study examining how vagal nerve fibres develop in the first year of life,
Pereyra et al., (1992) found that the number of myelinated fibres increased by a third,
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whilst the number of unmyelinated fibres changed only slightly. This showed that the
vagal nerve is not fully developed at the time of birth. Consequently any factor, such as
irregular  myelination,  affecting  the  growth of  the  vagal  nerve  could  well  affect  the
neuro-development of the infant.
In a study looking at the effects of methadone on the development of the early stages of
myelination,  Vestal-Laborde  et  al.,  (2014) found  that early  myelination  in  the
developing  rat  brain  was  altered  by  perinatal  exposure  to  therapeutic  doses  of
methadone.   They  conclude  that  “while  the  long-term effects  of  these  observations
remain  unknown,  accelerated  or  increased  myelination  could  disrupt  the  complex
sequence  of  synchronized  events  leading  to  normal  connectivity  in  the  developing
brain.”
Not only has methadone been implicated in abnormal myelination development,  the
same group also found that buprenorphine had a similar effect  (Eschenroeder et  al.,
2012). Like methadone, it  is  also an opioid,  but is  a partial  antagonist  compared to
methadone which is a full antagonist. This means that buprenorphine does not active mu
receptors to the same extent as methadone and thus its effectiveness reaches a ceiling at
a lower dose. It is often more suited to drug addicts who have used lower doses of
opioids, and in pregnant women has been shown to produce less severe NAS compared
with methadone (Jones et al., 2005). 
However, in a study on the pups of pregnant rats,  Sanchez et al., (2008) showed that
exposure to buprenorphine caused myelination to be altered in the exposed group. On
examination of the pups, corpus callosum, the exposed group had a “significant increase
in  the  calibre  of  the  mylinated  axons”,  although  the  measured  axons  showed  a
disproportionately thinner myelin sheath, suggesting an alteration to myelination. This
reduction in the myelinated sheath would affect  the resistance of the coating of the
axon,  and thus  affect  its  conductivity.  Such a  reduction  could  cause  'leaky  circuits'
where current leaks from poorly insulated axons, thus affecting the signal propagation
to the vagal nerve. 
This would be seen electrophysiologically in a number of ways. If conductivity along
nerve  fibres  such as  the  vagus  nerve  were  affected,  then  neuronal  firing  would  be
irregular and inconsistent. This lack of regularity could be an explanation for why the
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results of this work showed higher electrophysiological values for nearly all of the EEG,
ECG and CVT parameters investigated. This would also explain why the CVT results
had a far greater spread or variability within the exposed group. 
From a clinical  perspective,  this  may be related to why the exposed infants have a
higher  risk  of  developing  SUDI.  The  vagus  nerve  is  an  important  component  in
respiratory control, and it has been long thought that cardio/respiratory factors underline
the cause of SUDI.  Sachis et al., (1981) found that the number of myelinated vagus
fibres (axon and myelin) in SUDI victims were 'strikingly lower',  although they did
point out that it was unknown if this was a cause or effect of the SUDI. Further work by
Becker et al., (1993) showed that there was delayed maturation of the vagus nerve in
infants that succumb to SUDI. They examined the vagus nerves of 30 SUDI victims
under  post  mortem,  and  found  that  in  SUDI  infants,  “more  small  and  fewer  large
myelinated fibres were found than in controls, suggesting that the vagus nerve in SUDI
is relatively immature.” This explanation would appear to link with Porges polyvagal
theory  as  disinhibition  of  the  dorsal  vagal  complex  can  lead  to  lethal  apnoea  and
bradycardia in mammals (Porges, 2001). 
Overall this study has shown that the EEG, ECG and CVT have all been altered by in
utero exposure to  methadone and other  illicit  drugs.   Of these measurements,  CVT
proved the most promising as a prognostic tool, as by using a non invasive test such as
ECG coupled with a method of identifying sleep state, CVT could be a useful clinical
biomarker  for  identifying  which  infants  would  require  further  treatment  for  NAS.
Although not a predictive test for NAS, it is still a useful method that could be used to
measure the effectiveness of future treatments and has the potential to aid in developing
patient specific management regimens.
The longer term effects of impaired parasympathetic regulation in the neonate can only
be surmised, but having a tool to show which infants are already at risk would be useful
in their clinical management.
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9.4 Conclusions
This body of work has shown that electrophysiology has a role to play in the monitoring
of drug-exposed infants. It has highlighted that in a group of neonates all exposed to
methadone, erratic parasympathetic function in the form of high and variable CVT is
present, even during periods of settled sleep. 
Concerning the original aims of the study (section 1.6), the first two hypothesis related
to finding differences between the two groups using EEG or ECG were not proven
using statistical testing, although the EEG data suggested that both delta wave activity
had been modified and higher frequency activity was present in the exposed group. In
relation to the ECG and HRV analysis, again no statistically significant measurement
was found. However, VLF as an indicator of autonomic function could be a direction for
future work. 
The third hypothesis was proven to be correct in that CVT could be used to measure
autonomic  nervous  function  and,  in  the  case  of  the  exposed group,  was  a  tool  for
measuring  dysfunction.
Finally the fourth hypothesis  that at least one of these electro-physiological tests could
be used to predict the onset of NAS withdrawal was not proven, but VLF and especially
CVT has  been  shown  to  be  useful  in  identifying  drug  exposure,  and  may  be  key
components  in  understanding  which  neonates  might  be  pre-disposed  to  NAS
withdrawal.
Future Work
This study has shown that CVT, when measured during periods of recognisable sleep, is
useful in identifying drug exposure non-invasively in the neonate. A development of this
would be to estimate CVT prenatally by using the mothers' ECG and separating the
QRS component of the unborn child. From this, an estimate of foetal CVT could be
established. This would be useful in developing a better understanding of the effects of
drugs  on  the  unborn  infant,  especially  in  understanding  the  relationship  between
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maternal drug dose and potential NAS withdrawal.
At present, methadone is the primary treatment for opioid addiction, but if alternatives
were  investigated,  such  as  Naltrexone,  using  CVT  as  an  indicator  of  autonomic
dysfunction would be a novel way of comparing the treatments. 
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